OUR RESEARCH

SCHOOL OF CHINESE MEDICINE

2010 - 2015

香港浸會大學
HONG KONG BAPTIST UNIVERSITY

School of 中醫藥學院
Chinese Medicine

OUR RESEARCH

SCHOOL OF CHINESE MEDICINE

2010 - 2015

Professor Roland T CHIN

In the past six decades since its founding, HKBU has remained steadfast in upholding the whole person education ethos while exploring new research frontiers and pioneering academic programmes. This spirit to innovate has led to success and recognition for HKBU. In the area of higher education in Chinese medicine, the University was the first in the city to offer Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science double-degree programme and Bachelor of Pharmacy (Hons) in Chinese Medicine programme.

Established in 1999, the School of Chinese Medicine (SCM) has attained remarkable achievements in Chinese medicine education, research, knowledge transfer and the provision of healthcare, and its research achievements have been particularly notable in recent years. Riding on the University's strategy of fostering interdisciplinary research, the experts and researchers of SCM have been conducting innovative research on the traditional discipline of Chinese medicine with the aim of discovering new knowledge and creating new technologies to benefit society.

I am pleased to say that these endeavours have led to very encouraging results. Based on the research attainments of SCM from 2010-11 through 2014-15 that are recorded in this brochure, I have every confidence that SCM will continue to scale new heights in research and bring lasting impact to society.

Professor Roland T CHIN

President and Vice-Chancellor
Hong Kong Baptist University

Professor Rick WONG

The first of its kind in offering Chinese medicine degree programmes in Hong Kong, the School of Chinese Medicine (SCM) of the Hong Kong Baptist University has grown by leaps and bounds. Since its establishment in 1999, the School has been providing quality education and engaging in cutting-edge research to benefit public health. It has become a strong school of Chinese medicine on all fronts and has been recognised as a leader in Chinese medicine research in Hong Kong.

SCM has achieved outstanding results at the Research Assessment Exercise 2014 conducted by the University Grants Committee. The majority of its research activities have attained a status of international standing or international excellence. It is gratifying to note that SCM has outperformed other local institutions in its world leading research activities.

In recent years, the School has been successful in winning a large number of major external research grants. The funding bodies include the National Natural Science Foundation of China; the Science, Technology and Innovation Commission of Shenzhen; the Croucher Foundation; the General Research Fund of the Research Grants Council; the Innovation and Technology Commission; the Health and Medical Research Fund; and the Hong Kong Scholars Programme. Moreover, the School has also established a prominent presence in the international research arena in the areas of biomedical sciences and Chinese medicine. We have been publishing an increasing number of papers in high impact journals, and the number of patent applications filed and patents granted are also on the rise.

The University fosters interdisciplinary research and promotes the internationalization of its research efforts. SCM has been paying tremendous efforts and successful in the integration of Chinese medicine into the public medical and healthcare framework in Hong Kong. I have full confidence that SCM will play a crucial role in the research on the theme of Health, and deliver research outputs with far-reaching impacts on public health.

Professor Rick WONG

Vice-President (Research & Development) and Dean of Graduate School
Hong Kong Baptist University

Professor LU Aiping

Chinese medicine has a long, celebrated history and is a unique field of life science which originated in China. Due to the great breadth and profundity of its theories and proven efficacy, Chinese medicine has become a new focus of attention for scientists all over the world. Committed to both inheritance and innovation in Chinese medicine, SCM makes full use of modern technologies to conduct innovative research on standardisation of Chinese medicine and integration of Chinese medicine and western medicine, and contributes to the internationalisation of Chinese medicine.

To consolidate our strengths for innovative research on Chinese medicine, SCM has in recent years devoted resources to establish seven research centres to focus on multi-disciplinary and integrative research on four major areas: (1) basic research on systems biology of Chinese medicine syndrome diagnosis; (2) translational medicine in bone and joint diseases; (3) authentication and testing of Chinese medicines; and (4) mechanism, clinical trial and discovery of Chinese medicine in treating cancer, inflammation diseases, functional and organic gastroenterology diseases as well as neurodegenerative diseases.

In order to turn research into outcomes and impacts which benefit society, the School has been proactive in seeking collaborations with enterprises and research institutes and set up in 2015 the "University□Enterprise Synergy Innovation Platform" for R&D and new drug discovery.

As a result of our hard work in research over the years, we have reaped encouraging results and we are proud to present them in this brochure so that universities and research institutes in Hong Kong and other places can better understand our research endeavours and strengths. We look forward to working with scientists and institutions engaged or interested in Chinese medicine research from all around the globe to make greater contribution to Chinese medicine research.

Professor LU Aiping

Dean of School of Chinese Medicine
Hong Kong Baptist University

AUTOPHAGY
2016, VOL. 12, NO. 8, 1372–1389
http://dx.doi.org/10.1080/15548627.2016.1179404

Taylor & Francis
Taylor & Francis Group

RESEARCH PAPER

A novel curcumin analog binds to and activates TFEB *in vitro* and *in vivo* independent of MTOR inhibition

Ju-Xian Song[a,b], Yue-Ru Sun[c], Ivana Peluso[d], Yu Zeng[a,b], Xing Yu[a,b], Jia-Hong Lu[e], Zheng Xu[c], Ming-Zhong Wang[a], Liang-Feng Liu[a,b], Ying-Yu Huang[a,b], Lei-Lei Chen[a,b], Siva Sundara Kumar Durairajan[a,b], Hong-Jie Zhang[a,b], Bo Zhou[f], Hong-Qi Zhang[a], Aiping Lu[a], Andrea Ballabio[d], Diego L. Medina[d], Zhihong Guo[c], and Min Li[a,b]

[a]School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China; [b]Mr. & Mrs. Ko Chi Ming Center for Parkinson Disease Research (CPDR), Hong Kong Baptist University, Kowloon Tong, Hong Kong, China; [c]Department of Chemistry, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China; [d]Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy; [e]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China; [f]State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu, China

ABSTRACT

Autophagy dysfunction is a common feature in neurodegenerative disorders characterized by accumulation of toxic protein aggregates. Increasing evidence has demonstrated that activation of TFEB (transcription factor EB), a master regulator of autophagy and lysosomal biogenesis, can ameliorate neurotoxicity and rescue neurodegeneration in animal models. Currently known TFEB activators are mainly inhibitors of MTOR (mechanistic target of rapamycin [serine/threonine kinase]), which, as a master regulator of cell growth and metabolism, is involved in a wide range of biological functions. Thus, the identification of TFEB modulators acting without inhibiting the MTOR pathway would be preferred and probably less deleterious to cells. In this study, a synthesized curcumin derivative termed C1 is identified as a novel MTOR-independent activator of TFEB. Compound C1 specifically binds to TFEB at the N terminus and promotes TFEB nuclear translocation without inhibiting MTOR activity. By activating TFEB, C1 enhances autophagy and lysosome biogenesis *in vitro* and *in vivo*. Collectively, compound C1 is an orally effective activator of TFEB and is a potential therapeutic agent for the treatment of neurodegenerative diseases.

ARTICLE HISTORY
Received 5 October 2015
Revised 7 April 2016
Accepted 11 April 2016

KEYWORDS
autophagy; curcumin analogs; lysosomal biogenesis; mechanistic target of rapamycin; transcription factor EB

Introduction

Macroautophagy (herein referred to as autophagy) is a highly conserved cellular process for the bulk degradation of long-lived proteins and organelles mediated by lysosomes. Defects in the autophagy-lysosome pathway (ALP) have been linked to a variety of human diseases[1,2] including neurodegenerative disorders caused by toxic, aggregate-prone proteins.[3,4] Recently, TFEB (transcription factor EB) was identified as a master regulator of autophagy and lysosomal biogenesis.[5-7] Starvation, lysosomal stress or inhibition of the mechanistic target of rapamycin (serine/threonine kinase) complex 1 (MTORC1) activates TFEB by promoting its translocation to the nucleus,[8-10] where it binds to the CLEAR (coordinated lysosomal expression and regulation) elements and activates genes involved in autophagy and lysosomal biogenesis.[5,6] TFEB overexpression or small molecules capable of stimulating the expression and/or nuclear translocation of endogenous TFEB, has been shown to promote clearance of pathologic lysosomal substrates in lysosomal storage disorders (LSDs)[11-13] and to be neuroprotective by promoting the clearance of toxic protein aggregates in cell and animal models of neurodegenerative disorders such as Parkinson disease (PD),[14] Alzheimer disease (AD)[15-17] and Huntington disease (HD).[18]

Curcumin is a natural polyphenolic compound derived from the herbal medicine turmeric (*Curcuma longa* Linn.), which is nontoxic and possesses diverse pharmacologic effects.[19] It is well documented that curcumin enhances autophagy via inhibiting the phosphoinositide 3-kinase-AKT-MTOR signaling pathway.[20,21] However, the poor absorption and low bioavailability of curcumin curtails its clinical application.[19,22] To improve the bioavailability and potency, a number of derivatives of curcumin have been chemically synthesized.[23,24] Among these derivatives, monocarbonyl analogs of curcumin without the β-diketone moiety have exhibited enhanced stability, improved pharmacokinetic profiles and better *in vitro* and *in vivo* activities.[25-28]

By screening a series of synthetic monocarbonyl analogs of curcumin, an analog termed C1 was identified as a potent TFEB activator. Unlike currently known TFEB activators, C1 activates TFEB by directly binding to TFEB and promotes its entry into the nucleus, without affecting TFEB phosphorylation or inhibiting the activities of MTOR and MAPK1/ERK2

CONTACT Min Li limin@hkbu.edu.hk Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China; Diego Medina medina@tigem.it Telethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy; Zhihong Guo chguo@ust.hk The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/kaup.

Supplemental data for this article can be accessed on the publisher's website.

Extracted from

Song, Ju-Xian et al. A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition, *Autophagy* **12:8**, 1372-1389, DOI:10.1080/15548627.2016.1179404 (2016).

nature COMMUNICATIONS

ARTICLE

Received 18 Jun 2015 | Accepted 28 Jan 2016 | Published 7 Mar 2016

DOI: 10.1038/ncomms10872 OPEN

Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation

Defang Li[1,2,3,4,5,*], Jin Liu[1,2,3,4,*], Baosheng Guo[1,2,3,4,5,6], Chao Liang[1,2,3,4,7,8], Lei Dang[1,2,3,4], Cheng Lu[2,9], Xiaojuan He[1,9], Hilda Yeuk-Siu Cheung[1,6], Liang Xu[1], Changwei Lu[1], Bing He[1,2,3,4], Biao Liu[1,2,3,4,6], Atik Badshah Shaikh[1,2,3,4], Fangfei Li[1,2,3,4], Luyao Wang[1,2,3,4], Zhijun Yang[1,2,3,4,6], Doris Wai-Ting Au[10], Songlin Peng[1,11], Zongkang Zhang[12], Bao-Ting Zhang[12], Xiaohua Pan[1,13], Airong Qian[8,14], Peng Shang[8,14], Lianbo Xiao[1,15], Baohong Jiang[16], Chris Kong-Chu Wong[17], Jiake Xu[18], Zhaoxiang Bian[1,2,3], Zicai Liang[4], De-an Guo[16], Hailong Zhu[1,2,3,4], Weihong Tan[7], Aiping Lu[1,2,3,4,5,6,7,8,9,15] & Ge Zhang[1,2,3,4,5,6,7,8,15]

Emerging evidence indicates that osteoclasts direct osteoblastic bone formation. MicroRNAs (miRNAs) have a crucial role in regulating osteoclast and osteoblast function. However, whether miRNAs mediate osteoclast-directed osteoblastic bone formation is mostly unknown. Here, we show that increased osteoclastic miR-214-3p associates with both elevated serum exosomal miR-214-3p and reduced bone formation in elderly women with fractures and in ovariectomized (OVX) mice. Osteoclast-specific *miR-214-3p* knock-in mice have elevated serum exosomal miR-214-3p and reduced bone formation that is rescued by osteoclast-targeted antagomir-214-3p treatment. We further demonstrate that osteoclast-derived exosomal miR-214-3p is transferred to osteoblasts to inhibit osteoblast activity *in vitro* and reduce bone formation *in vivo*. Moreover, osteoclast-targeted miR-214-3p inhibition promotes bone formation in ageing OVX mice. Collectively, our results suggest that osteoclast-derived exosomal miR-214-3p transfers to osteoblasts to inhibit bone formation. Inhibition of miR-214-3p in osteoclasts may be a strategy for treating skeletal disorders involving a reduction in bone formation.

[1] Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China. [2] Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China. [3] Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518057, China. [4] Research Group of Bone and Joint Diseases, HKBU Institute of Science and Technology, Haimen 226100, China. [5] Academician Chen Xinzi Workroom for Advancing Translational Medicine in Bone and Joint Diseases, Kunshan RNAi Institute, Kunshan Industrial Technology Research Institute, Kunshan, Jiangsu 215300, China. [6] Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, Hong Kong Baptist University, Hong Kong SAR 999077, China. [7] Hong Kong Baptist University Branch of State Key Laboratory of Chemo/Biosensing and Chemometrics of Hunan University, Hong Kong 999077, China. [8] Hong Kong Baptist University-Northwestern Polytechnical University Joint Research Centre for Translational Medicine on Musculoskeletal Health in Space, Shenzhen 518057, China. [9] Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. [10] Department of Biology and Chemistry, City University of Hong Kong, Hong Kong SAR 999077, China. [11] Department of Spine Surgery, Shenzhen People's Hospital, Ji Nan University Second College of Medicine, Shenzhen 518020, China. [12] School of Chinese Medicine, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR 999077, China. [13] Department of Orthopaedics and Traumatology, Bao'an Hospital Affiliated to Southern Medical University and Shenzhen 8th People Hospital, Shenzhen 518100, China. [14] Key Laboratory for Space Bioscience and Biotechnology, Institute of Special Environmental Biophysics, School of Life Science, Northwestern Polytechnical University, Xi'an 710072, China. [15] Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Shanghai 200052, China. [16] Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. [17] Department of Biology, Hong Kong Baptist University, Hong Kong SAR 999077, China. [18] Molecular Laboratory, School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Western Australia 6907, Australia. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.L. (email: aipinglu@hkbu.edu.hk) or to G.Z. (email: zhangge@hkbu.edu.hk).

Extracted from

Li, Defang *et al*. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. *Nat. Commun*. **7**, DOI: 10.1038/ncomms10872 (2016).

TECHNICAL REPORTS

nature medicine

Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference–based bone anabolic strategy

Chao Liang[1–8,22], Baosheng Guo[1,2,4–8,22], Heng Wu[1,4–7,22], Ningsheng Shao[9], Defang Li[1,4–8], Jin Liu[1,4–8], Lei Dang[1,4–8], Cheng Wang[1,10], Hui Li[9], Shaohua Li[9], Wing Ki Lau[1], Yu Cao[3], Zhijun Yang[1,4–7], Cheng Lu[1,2,4–8], Xiaojuan He[1,2,4–7], D W T Au[11], Xiaohua Pan[1], Bao-Ting Zhang[12], Changwei Lu[1], Hongqi Zhang[1], Kinman Yue[1], Airong Qian[8,13], Peng Shang[8,13], Jiake Xu[14], Lianbo Xiao[1,15], Zhaoxiang Bian[1,4–7], Weihong Tan[1,7,16–21], Zicai Liang[4], Fuchu He[3], Lingqiang Zhang[3], Aiping Lu[1,2,4–8,15] & Ge Zhang[1,2,4–8,13,15]

Currently, major concerns about the safety and efficacy of RNA interference (RNAi)-based bone anabolic strategies still exist because of the lack of direct osteoblast-specific delivery systems for osteogenic siRNAs. Here we screened the aptamer CH6 by cell-SELEX, specifically targeting both rat and human osteoblasts, and then we developed CH6 aptamer–functionalized lipid nanoparticles (LNPs) encapsulating osteogenic pleckstrin homology domain-containing family O member 1 (*Plekho1*) siRNA (CH6-LNPs-siRNA). Our results showed that CH6 facilitated *in vitro* osteoblast-selective uptake of *Plekho1* siRNA, mainly via macropinocytosis, and boosted *in vivo* osteoblast-specific *Plekho1* gene silencing, which promoted bone formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties in both osteopenic and healthy rodents. These results indicate that osteoblast-specific aptamer-functionalized LNPs could act as a new RNAi-based bone anabolic strategy, advancing the targeted delivery selectivity of osteogenic siRNAs from the tissue level to the cellular level.

Metabolic skeletal disorders associated with impaired bone formation (for example, osteoporosis) remain major clinical challenges. RNA interference (RNAi)-based approaches aimed at promoting osteoblastic bone formation may hold therapeutic potential[1,2]. However, a major bottleneck for translating RNAi-based approaches into clinical application is the lack of osteoblast-specific osteogenic siRNA delivery systems[3].

Plekho1 (also known as casein kinase-2 interacting protein-1 (CKIP-1)) has been identified as an intracellular negative regulator of bone formation that does not affect bone resorption[4]. Previously we developed a targeting system involving dioleoyl trimethylammonium propane (DOTAP)-based cationic liposomes attached to six repetitive sequences of aspartate, serine and serine ($(AspSerSer)_6$), which had good affinity for the physiochemical features of the bone-formation surface when compared to the bone-resorption surface. By using this system, osteogenic *Plekho1* siRNA was specifically delivered to the bone-formation surface to promote bone formation[5]. However, as the system was not specific to osteoblasts at the cellular level, other non-osteoblasts near the bone-formation surface, including endothelial cells and lymphocytes, may also be targeted, which arouses concerns about efficacy and potential toxic side effects[5–7]. In addition, other potential concerns, including mononuclear phagocyte system (MPS)-induced dose reduction[8,9], inefficient nanoparticle extravasation

[1]Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. [2]Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China. [3]State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, China. [4]Academician Chen Xinzi Workroom for Advancing Translational Medicine in Bone & Joint Diseases, Kunshan RNAi Institute, Kunshan Industrial Technology Research Institute, Kunshan, Jiangsu, China. [5]Institute of Integrated Bioinfomedicine & Translational Science, Hong Kong Baptist University Shenzhen Research Institute and Continuing Education, Shenzhen, China. [6]Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, Hong Kong Baptist University Shenzhen Research Institute and Continuing Education, Shenzhen, China. [7]Hong Kong Baptist University Branch of State Key Laboratory of Chemo/Biosensing and Chemometrics of Hunan University, Hong Kong, China. [8]Hong Kong Baptist University–Northwestern Polytechnical University Joint Research Centre for Translational Medicine on Musculoskeletal Health in Space, Shenzhen, China. [9]Department of Biochemistry and Molecular Biology, Beijing Institute of Basic Medical Science, Beijing, China. [10]Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China. [11]Department of Biology and Chemistry, City University of Hong Kong, Hong Kong SAR, China. [12]School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. [13]Key Laboratory for Space Bioscience and Biotechnology, Institute of Special Environmental Biophysics, School of Life Science, Northwestern Polytechnical University, Xi'an, China. [14]Molecular Laboratory, School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Australia. [15]Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Shanghai, China. [16]Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China. [17]College of Biology, Hunan University, Changsha, China. [18]Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, China. [19]Department of Chemistry, University of Florida, Gainesville, Florida, USA. [20]Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, USA. [21]Center for Research at Bio/Nano Interface, Shands Cancer Center, University of Florida, Gainesville, Florida, USA. [22]These authors contributed equally to this work. Correspondence should be addressed to G.Z. (zhangge@hkbu.edu.hk), A.L. (aipinglu@hkbu.edu.hk) or L.Z. (zhanglq@nic.bmi.ac.cn).

Received 6 February 2014; accepted 2 December 2014; published online 9 February 2015; doi:10.1038/nm.3791

Extracted from

Liang, Chao *et al.* Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. *Nature Medicine* **21(3)**, 288-294, DOI:10.1038/nm.3791 (2015).

nature COMMUNICATIONS

ARTICLE

Received 25 Mar 2014 | Accepted 17 Apr 2014 | Published 22 May 2014

DOI: 10.1038/ncomms4920

NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity

Jiahong Lu[1,2,*], Liqiang He[1,*], Christian Behrends[3], Masatake Araki[4], Kimi Araki[5], Qing Jun Wang[6], Joseph M. Catanzaro[7], Scott L. Friedman[8], Wei-Xing Zong[7], M. Isabel Fiel[9], Min Li[2] & Zhenyu Yue[1]

The Beclin 1-Vps34 complex, the core component of the class III phosphatidylinositol-3 kinase (PI3K-III), binds Atg14L or UVRAG to control different steps of autophagy. However, the mechanism underlying the control of PI3K-III activity remains elusive. Here we report the identification of NRBF2 as a component in the specific PI3K-III complex and a modulator of PI3K-III activity. Through its microtubule interaction and trafficking (MIT) domain, NRBF2 binds Atg14L directly and enhances Atg14L-linked Vps34 kinase activity and autophagy induction. NRBF2-deficient cells exhibit enhanced vulnerability to endoplasmic reticulum (ER) stress that is reversed by re-introducing exogenous NRBF2. NRBF2-deficient mice develop focal liver necrosis and ductular reaction, accompanied by impaired Atg14L-linked Vps34 activity and autophagy, although the mice show no increased mortality. Our data reveal a key role for NRBF2 in the assembly of the specific Atg14L-Beclin 1-Vps34-Vps15 complex for autophagy induction. Thus, NRBF2 modulates autophagy via regulation of PI3K-III and prevents ER stress-mediated cytotoxicity and liver injury.

[1] Department of Neurology and Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [2] School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. [3] Institute of Biochemistry II, Goethe University School of Medicine, Frankfurt, Germany. [4] Division of Bioinformatics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. [5] Division of Developmental Genetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan. [6] Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. [7] Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, New York, USA. [8] Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [9] Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to Z.Y. (email: zhenyu.yue@mssm.edu).

Extracted from

Lu, Jiahong *et al*. NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity. *Nat. Commun.* **5**, DOI: 10.1038/ncomms4920 (2014).

Autophagy 10:1, 144–154; January 2014; © 2014 Landes Bioscience

HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression

A process modulated by the natural autophagy inducer corynoxine B

Ju-Xian Song,[1] Jia-Hong Lu,[1,2] Liang-Feng Liu,[1] Lei-Lei Chen,[1] Siva Sundara Kumar Durairajan,[1] Zhenyu Yue,[2] Hong-Qi Zhang,[1,*] and Min Li[1,*]

[1]School of Chinese Medicine; Hong Kong Baptist University; Kowloon Tong; Hong Kong; [2]Departments of Neurology and Neuroscience; Friedman Brain Institute; Icahn School of Medicine at Mount Sinai; New York, NY USA

Keywords: Parkinson disease, SNCA, autophagy, HMGB1, corynoxine B

Abbreviations: ALP, autophagy-lysosomal pathway; BECN1, Beclin 1, autophagy related; CMA, chaperone-mediated autophagy; Cory B, corynoxine B; CQ, chloroquine; Dox, doxycycline; EBSS, Earle's balanced salt solution; FBS, fetal bovine serum; HA, hemagglutinin; HMGB1, high mobility group box 1; LC3, microtubule-associated protein 1 light chain 3; PD, Parkinson disease; Rap, rapamycin; SNCA, synuclein, alpha (non A4 component of amyloid precursor); UPS, ubiquitin-proteasome system; WM, wortmannin; WT, wild type

SNCA/α-synuclein and its rare mutations are considered as the culprit proteins in Parkinson disease (PD). Wild-type (WT) SNCA has been shown to impair macroautophagy in mammalian cells and in transgenic mice. In this study, we monitored the dynamic changes in autophagy process and confirmed that overexpression of both WT and SNCA^{A53T} inhibits autophagy in PC12 cells in a time-dependent manner. Furthermore, we showed that SNCA binds to both cytosolic and nuclear high mobility group box 1 (HMGB1), impairs the cytosolic translocation of HMGB1, blocks HMGB1-BECN1 binding, and strengthens BECN1-BCL2 binding. Deregulation of these molecular events by SNCA overexpression leads to autophagy inhibition. Overexpression of BECN1 restores autophagy and promotes the clearance of SNCA. siRNA knockdown of *Hmgb1* inhibits basal autophagy and abolishes the inhibitory effect of SNCA on autophagy while overexpression of HMGB1 restores autophagy. Corynoxine B, a natural autophagy inducer, restores the deficient cytosolic translocation of HMGB1 and autophagy in cells overexpressing SNCA, which may be attributed to its ability to block SNCA-HMGB1 interaction. Based on these findings, we propose that SNCA-induced impairment of autophagy occurs, in part, through HMGB1, which may provide a potential therapeutic target for PD.

Introduction

Parkinson disease is characterized by the formation of SNCA-containing inclusions termed Lewy bodies and the degeneration of dopaminergic neurons in the midbrain.[1] Protein degradation pathways remove damaged or abnormally modified proteins in neurons, and thus play central roles in maintaining proper neuronal function.[1] Current literature provides evidence that the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP) are primary mechanisms for the degradation of wild-type SNCA and its mutant variants (A53T and A30P).[1-3] It is generally accepted that under normal conditions unmodified soluble SNCA is recognized by the UPS and chaperone-mediated autophagy (CMA) and subsequently degraded. However, for the more insoluble oligomeric and aggregated SNCA, macroautophagy is the only mechanism for their clearance.[4,5]

The initiation of macroautophagy (here referred to as autophagy) is regulated by multiple signaling pathways involving 2 macromolecular complexes: the MTOR -ULK1-ATG13-RB1CC1-C12orf44/ATG101 complex (the latter gene product, C12orf44, is also known as RGD1359310 in the rat and 9430023L20Rik in mice), and the BECN1-PIK3C3 (ortholog of yeast Vps34) complex.[6] BECN1 plays an essential role in autophagy initiation by interacting with various cofactors,[7] one of which is high mobility group box 1.[8] Autophagic stimuli trigger HMGB1 translocation from the nucleus into the cytosol, where it binds to BECN1 and results in dissociation of BECN1-BCL2, and subsequent induction of autophagy.[8] Autophagy is very important for preventing the accumulation of

*Correspondence to: Hong-Qi Zhang; Email: hqzhang@hkbu.edu.hk; Min Li; Email: limin@hkbu.edu.hk
Submitted: 02/01/2013; Revised: 10/03/2013; Accepted: 10/08/2013
http://dx.doi.org/10.4161/auto.26751

Extracted from

Song, Ju-Xian *et al*. HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer Corynoxine B. *Autophagy* **10:1**, 144-154, DOI:10.4161/auto.26751 (2014).

ARTICLES

nature medicine

miR-214 targets *ATF4* to inhibit bone formation

Xiaogang Wang[1,6], Baosheng Guo[2,3,6], Qi Li[1], Jiang Peng[4], Zhijun Yang[2], Aiyuan Wang[4], Dong Li[5], Zhibo Hou[3], Ke Lv[1], Guanghan Kan[1], Hongqing Cao[1], Heng Wu[2,3], Jinping Song[1], Xiaohua Pan[3], Qiao Sun[1], Shukuan Ling[1], Yuheng Li[1], Mu Zhu[1], Pengfei Zhang[1], Songlin Peng[3], Xiaoqing Xie[3], Tao Tang[2], An Hong[3], Zhaoxiang Bian[2], Yanqiang Bai[1], Aiping Lu[2], Yinghui Li[1], Fuchu He[5], Ge Zhang[2,3] & Yingxian Li[1]

Emerging evidence indicates that microRNAs (miRNAs) have important roles in regulating osteogenic differentiation and bone formation. Thus far, no study has established the pathophysiological role for miRNAs identified in human osteoporotic bone specimens. Here we found that elevated miR-214 levels correlated with a lower degree of bone formation in bone specimens from aged patients with fractures. We also found that osteoblast-specific manipulation of miR-214 levels by miR-214 antagomir treatment in miR-214 transgenic, ovariectomized, or hindlimb-unloaded mice revealed an inhibitory role of miR-214 in regulating bone formation. Further, *in vitro* osteoblast activity and matrix mineralization were promoted by antagomir-214 and decreased by agomir-214, and miR-214 directly targeted *ATF4* to inhibit osteoblast activity. These data suggest that miR-214 has a crucial role in suppressing bone formation and that miR-214 inhibition in osteoblasts may be a potential anabolic strategy for ameliorating osteoporosis.

Bone remodeling is delicately regulated by both the number and activity of osteoblasts and osteoclasts[1–3]. Osteoblast lineage commitment, proliferation and differentiation are controlled by a well-defined genetic program[2,4–7]. miRNAs are noncoding, ~22-nucleotide RNAs that are involved in the regulation of sophisticated gene expression to coordinate a broad spectrum of biological processes[8–11]. Multiple miRNAs have been identified to regulate the complex process of osteogenic differentiation and osteoblastic bone formation[12–22]. Cell-type–specific deletion of Dicer, which is required for miRNA biogenesis, in committed osteoprogenitors results in lethality at embryonic day 14.5. The mutant embryos have a deformed cartilaginous skeleton and a lack of bone formation. Targeted deletion of Dicer in mature osteoblasts leads initially to delayed perinatal bone formation, with a subsequent increase in postnatal bone acquisition[23,24]. Several miRNAs are involved in the regulation of osteoblast-specific gene expression and bone morphogenic protein 2 (BMP-2)-induced osteogenesis *in vitro*[17,18]. However, most of these miRNAs have only been identified *in vitro*, and their functional roles in the pathophysiological mechanisms responsible for reduced bone formation in skeletal disorders remain to be established before they can be targeted in the clinical setting.

In this study we screened for the expression of miRNAs in bone specimens from aged patients with fractures and identified that miR-214 was negatively correlated with bone formation. We show that miR-214 participates in the inhibition of osteoblast differentiation and osteoblastic bone formation in skeletal disorders. We identified *ATF4*, a gene encoding one of the main transcription factors required for osteoblast function[25], as a direct target of miR-214. Our findings further demonstrate that therapeutic inhibition of miR-214 in osteoblasts may lead to derepression of *Atf4* expression, which coincides with the promotion of osteoblastic bone formation in both ovariectomized (OVX) and hindlimb-unloaded mice, and suggest a role for miR-214 in the pathophysiological process leading to reduced bone formation in skeletal disorders.

RESULTS

High miR-214 expression correlates with reduced bone formation

To search for the miRNAs preferentially expressed in human bone tissues that have been previously shown to be involved in osteogenic differentiation, bone development and bone formation[17,18,26], we assessed the expression of those miRNAs in femurs from nine adult individuals by real-time PCR. We identified 33 enriched miRNAs in our analysis (**Supplementary Fig. 1a**). To examine the expression pattern of these miRNAs in different ages, we collected bone specimens from 40 aged individuals with fractures in two clinical settings (**Supplementary Table 1**). In those samples, the expression of miR-23b, miR-30a, miR-130a, miR-140* and miR-214 varied with age (**Fig. 1a**,**b**): the expression of miR-214 was higher in the samples from the more aged individuals. The expression of miR-214, but not the other miRNAs examined in our analysis, was negatively correlated with the expression of the bone formation marker genes *BGLAP* (osteocalcin) and *ALP* (alkaline phosphatase) in aged women and men (**Fig. 1c**,**d** and **Supplementary Fig. 1b**).

[1]State Key Laboratory of Space Medicine Fundamentals and Application, China Astronaut Research and Training Center, Beijing, China. [2]Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. [3]National Engineering Research Center of Genetic Medicine (Guangzhou), Department of Orthopedics in Second Hospital of Medical College (Shenzhen), Jinan University, China. [4]Institute of Orthopedics, General Hospital of Chinese People's Liberation Army, Beijing, China. [5]State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, China. [6]These authors contributed equally to this work. Correspondence should be addressed to Y.L. (yingxianli@yahoo.cn) or G.Z. (zhangge@hkbu.edu.hk).

Received 14 May; accepted 12 November; published online 9 December 2012; doi:10.1038/nm.3026

Extracted from

Wang, Xiaogang *et al.* miR-214 targets *ATF4* to inhibit bone formation. *Nature Medicine* **19:1**, 93-100, DOI:10.1038/nm.3026 (2013).

TECHNICAL REPORTS

nature medicine

A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy

Ge Zhang[1,13], Baosheng Guo[1,13], Heng Wu[1,13], Tao Tang[1,13], Bao-Ting Zhang[1,2,13], Lizhen Zheng[1], Yixin He[1], Zhijun Yang[3], Xiaohua Pan[4], Heelum Chow[5], Kinwah To[5], Yaping Li[6], Dahu Li[7], Xinluan Wang[1], Yixiang Wang[8], Kwongman Lee[9], Zhibo Hou[10], Nan Dong[11], Gang Li[1], Kwoksui Leung[1], Leungkim Hung[1], Fuchu He[7], Lingqiang Zhang[7] & Ling Qin[1,12]

Metabolic skeletal disorders associated with impaired bone formation are a major clinical challenge. One approach to treat these defects is to silence bone-formation–inhibitory genes by small interference RNAs (siRNAs) in osteogenic-lineage cells that occupy the niche surrounding the bone-formation surfaces. We developed a targeting system involving dioleoyl trimethylammonium propane (DOTAP)-based cationic liposomes attached to six repetitive sequences of aspartate, serine, serine ($(AspSerSer)_6$) for delivering siRNAs specifically to bone-formation surfaces. Using this system, we encapsulated an osteogenic siRNA that targets casein kinase-2 interacting protein-1 (encoded by *Plekho1*, also known as *Plekho1*). *In vivo* systemic delivery of *Plekho1* siRNA in rats using our system resulted in the selective enrichment of the siRNAs in osteogenic cells and the subsequent depletion of *Plekho1*. A bioimaging analysis further showed that this approach markedly promoted bone formation, enhanced the bone micro-architecture and increased the bone mass in both healthy and osteoporotic rats. These results indicate $(AspSerSer)_6$-liposome as a promising targeted delivery system for RNA interference–based bone anabolic therapy.

Impaired bone formation occurs in several varieties of dysfunctional bone homeostasis. To date, intermittent injection of recombinant human parathyroid hormone (iPTH) is the only bone anabolic agent clinically approved for stimulating bone formation in severe osteoporosis[1,2]. However, iPTH treatment is limited to a 2-y period because of increasing bone resorption over bone formation and a potential risk of developing osteosarcoma in patients receiving iPTH treatment[3–5]. This limitation has provided an incentive to search for new, safe bone anabolic drugs that do not activate bone resorption.

RNA interference (RNAi), a natural cellular process that regulates gene expression through a highly precise mechanism of sequence-directed gene silencing, could theoretically be used to target any disease-associated pathogenic gene of interest[6]. Accordingly, RNAi-based therapies targeting those genes that have been identified to negatively regulate bone formation without modulating bone resorption could facilitate translational therapy for treating diseases marked by impaired bone formation[7]. However, there is a major concern that the large therapeutic doses of systemically administered siRNA that would be needed to stimulate sufficient bone formation may carry a high risk for adverse effects in nonskeletal tissues[8]. This concern leaves the field with a great challenge when considering the use of these treatments[6]. Thus, development of a specific delivery system for RNAi-based therapies that addresses this issue is highly desirable.

The niche surrounding the bone-formation surfaces is predominantly occupied by osteogenic-lineage cells at various stages of differentiation[3]. All of these cells could be potential targets of pro-osteogenic siRNAs. A practical strategy, then, is to develop a generalized siRNA delivery system that selectively targets bone-formation surfaces to facilitate the delivery of therapeutic siRNAs to the majority of the osteogenic-lineage cells. Such a delivery system would probably allow for a highly targeted dose of therapeutic siRNA to be delivered to the bone while avoiding possible negative side effects to nonskeletal tissues, thus increasing the efficacy and safety of RNAi-based bone anabolic therapy.

To date, two types of stable bone-targeting molecules, bisphosphonates and oligopeptides, have been used to target bone after they have been coupled to nonspecific bone therapeutic agents[9].

[1]Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China. [2]School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, China. [3]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China. [4]Department of Orthopedics, Second Hospital of Medical College of Ji Nan University, Shenzhen People's Hospital, Shenzhen, China. [5]School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China. [6]Center of Drug Delivery System, Shanghai Institute of Materia Medica, Shanghai, Chinese Academy of Sciences, Shanghai, China. [7]State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, China. [8]Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, China. [9]Lee Hysan Clinical Research Laboratory, The Chinese University of Hong Kong, Hong Kong, China. [10]Biomedical Research and Development Center, Guangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Jinan University, Guangzhou, China. [11]Institute of Molecular Biology, Nan Kai University, Tianjin, China. [12]Translational Medicine Research & Development Center, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Shenzhen, China. [13]These authors contributed equally to this work. Correspondence should be addressed to L.Q. (lingqin@cuhk.edu.hk), L.Zhang (zhanglq@nic.bmi.ac.cn) or G.Z. (zhangge@ort.cuhk.edu.hk).

Received 18 April 2011; accepted 13 June 2011; published online 29 January 2012; doi:10.1038/nm.2617

Extracted from

Zhang, Ge *et al*. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. *Nature Medicine* **18:2**, 307-314, DOI:10.1038/nm.2617 (2012).

Autophagy 8:1, 98–108; January 2012; © 2012 Landes Bioscience

Isorhynchophylline, a natural alkaloid, promotes the degradation of α-synuclein in neuronal cells via inducing autophagy

Jia-Hong Lu,[1] Jie-Qiong Tan,[2] Siva Sundara Kumar Durairajan,[1] Liang-Feng Liu,[1] Zhuo-Hua Zhang,[2] Long Ma,[2] Han-Ming Shen,[3] H.Y. Edwin Chan[4,*] and Min Li[1,*]

[1]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong; [2]State Key Laboratory of Medical Genetics, Central South University, China; [3]Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; [4]School of Life Sciences, The Chinese University of Hong Kong, Hong Kong

Keywords: isorhynchophylline, Parkinson disease, protein aggregates, alpha-synuclein, oligomers, autophagy, neuron

Abbreviations: 3-MA, 3-methylamphetamine; α-syn, alpha-synuclein; CQ, chloroquine; DA, dopaminergic; GFP, enhanced green fluorescent protein; IsoRhy, isorhynchophylline; (MAP)LC3, microtubule-associated protein 1 light chain 3; mTOR, mammalian target of rapamycin; PD, Parkinson disease; Tf-LC3, tandem fluorescent LC3; BiFC, bimolecular fluorescence complementation

Accumulation of α-synuclein (α-syn) in the brain is a pathogenic feature and also a causative factor of Parkinson disease. Isorhynchophylline (IsoRhy) is a major tetracyclic oxindole alkaloid isolated from the Chinese herbal medicine *Uncaria rhynchophylla* (Miq.)Jacks (Gouteng in Chinese), which has been used for the treatment of neurological diseases in East Asia for centuries. Here we report a novel function of IsoRhy as a neuronal autophagy inducer. IsoRhy induced autophagy in different neuronal cell lines, including N2a, SH-SY5Y and PC12 cells, and also in primary cortical neurons. Furthermore, IsoRhy induced autophagy in the fat bodies of Drosophila. IsoRhy promoted clearance of wild-type, A53T and A30P α-syn monomers, α-syn oligomers and α-syn/synphilin-1 aggresomes in neuronal cells via the autophagy-lysosome pathway. More importantly, IsoRhy was able to decrease the expression levels of wild-type and A53T α-syn protein in differentiated human dopaminergic neurons. Notably, IsoRhy-induced autophagy was independent of the mTOR pathway but dependent on the function of Beclin 1. Taken together, data from this study raise the possibility that oxindole alkaloid derivatives may serve as a means to stimulate autophagy in neuronal cells, thereby exerting preventive and therapeutic values against neurodegenerative diseases such as Parkinson disease by reducing pathogenic protein aggregates in neurons.

Introduction

Parkinson disease (PD) is the most common motor neurodegenerative disease. It is characterized by the accumulation of Lewy bodies in the substantial nigra dopaminergic neurons. α-syn is a major component of Lewy bodies, and its aggregation has been linked to the pathogenesis of PD. Overexpression of α-syn due to duplication or triplication of the α-*syn* gene locus leads to the familial form of PD.[1-4] Point mutations (A53T, A30P) that increase the aggregation propensity of α-syn results in familial early onset PD.[5-7] Overexpression of wild-type (WT) and mutant α-syn in transgenic mice as well as transgenic flies caused progressive locomotor defects with dopaminergic neuron loss and intracytoplasmic inclusions.[8-12] These findings suggest that α-syn aggregation could be a therapeutic target for the treatment of PD and other synucleinopathies.

The major degradation systems for cytosolic proteins in the central nervous system are the ubiquitin-proteasome system and the autophagy pathway.[13] Macroautophagy, here referred to as autophagy, is a 'self-eating' cellular machinery used to degrade and recycle long-lived proteins and organelles to maintain cellular homeostasis.[14] It has been well established that α-syn aggregates, as well as other aggregation-prone proteins including tau and mutant huntingtin, rely to a great extent on macroautophagy for clearance since they cannot go through the narrow core of proteasomes for degradation.[15] Suppression of neurodegeneration by treatment with the chemical autophagy inducer rapamycin inspired researchers to identify compounds that promote autophagy in neurons.[16] Recent screening for such molecules in yeast and mammalian cells has identified small molecules that activate autophagy.[17,18] These compounds have been shown to induce autophagy and clearance of aggregation-prone proteins such as mutant huntingtin and α-syn in mammalian cells.

IsoRhy is a tetracyclic oxindole alkaloid isolated from the Chinese herbal medicine *Uncaria rhynchophylla* (Miq.) Jacks (Gouteng in Chinese), which is routinely used in traditional

*Correspondence to: Min Li and H.Y. Edwin Chan; Email: limin@hkbu.edu.hk and hyechan@cuhk.edu.hk
Submitted: 07/26/11; Revised: 10/03/11; Accepted: 10/05/11
http://dx.doi.org/10.4161/auto.8.1.18313

Extracted from

Lu, Jia-Hong *et al*. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. *Autophagy* **8:1**, 98-108, DOI: 10.4161/auto.8.1.18313 (2012). (Erratum in *Autophagy* **8:5**, 864-866; 2012)

Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research (CCIR)

Director:

Professor Lu Aiping

http://ccir.hkbu.edu.hk/

In 2009, the School established CCIR to investigate the causes of and novel therapeutic strategies for cancer and inflammatory diseases by integrating Chinese medicine and modern scientific technology, with the aim of making breakthroughs in research and contributing to health and well-being.

The Centre's efforts are currently focused on the following three major areas:

I. Basic science research, focusing on:

i. Molecular cancer biology and carcinogenesis of colorectal cancer, ovarian cancer, melanoma and liver cancer;
ii. Metastatic cancer biology of the aforementioned cancers; and
iii. Chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases.

II. Translational science/medicine research, devoted to treating cancer and inflammatory diseases by means of:

i. Chinese medicine;
ii. Targeted therapies, including among others immunotherapy; and
iii. Development of different drug delivery methods.

III. Clinical research, focusing on:

i. The design of clinical trials to evaluate the therapeutic efficacy of Chinese pharmaceutical products;
ii. The carrying out of epidemiological and clinical studies to evaluate the therapeutic efficacy of herbal medicines alone or in combination with chemotherapy and radiotherapy; and
iii. The establishment of a tissue sample library for the common cancerous and inflammatory diseases in Hong Kong.

Institute for Advancing Translational Medicine in Bone and Joint Diseases (TMBJ)

Director:

Professor Lu Aiping

Associate Director:

Dr. Zhang Ge

http://tmbj.hkbu.edu.hk/

TMBJ was established in September 2012 to create a collaboration platform for scientists of the School to work in synergy with those of the Faculty of Science to efficiently and effectively translate basic scientific findings into clinical applications that would benefit patients suffering from bone and joint diseases. With its rich academic resources comprising both expertise and infrastructure, TMBJ collaborates with the industry to conduct cutting-edge research leading to the development of innovative biological reagents, therapeutic agents, bio-imaging modalities and advanced biomaterials for the diagnosis, prevention and treatment of bone and joint diseases for clinical trials and commercialisation.

TMBJ aims to bring scientific knowledge and research findings "from the bench to the bedside", and improve the quality of life for patients suffering from bone and joint diseases all over the world.



Hong Kong Chinese Medicine Clinical Study Centre (CMCS)

Director:
Professor Bian Zhaoxiang

Associate Director:
Professor Lu Aiping

http://cmcs.hkbu.edu.hk/

Established in June 2014, CMCS is the only centre which focuses on Chinese medicine clinical trial in Hong Kong. The mission of CMCS is to create a dynamic centre that enables its academic faculty to develop, demonstrate and implement innovative models of clinical research in integrative and Chinese medicine in Hong Kong, mainland China and all over the world.

Currently, CMCS focuses on two main research directions:

- To provide multidisciplinary health professions a synergistic collaboration platform to perform high-quality Chinese Medicine Clinical trials across a wide range of therapeutic areas, and to integrate pharmacological, biological & clinical research;
- To develop 2-4 new drugs for gastrointestinal, orthopedics, metabolism, oncology and dementia based on efficacy-driven Chinese Medicine discovery platform.

The scope of our research centre includes:

- Clinical trial design and implementation
- Standardisation strategies for TCM
- New drug discovery and screening
- Clinical practice guidelines development

Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR)

Director:
Professor Li Min

Associate Director:
Professor Bian Zhaoxiang

http://cpdr.hkbu.edu.hk/

Established in October 2014, CPDR is a centre for translational and clinical research in Parkinson's disease and other neurodegenerative diseases which aims to develop new drugs for preventing and treating neurodegenerative diseases including Parkinson's disease using Chinese medicines.

CPDR adopts Chinese medicine perspectives and findings from long-standing clinical practice as the fundamental basis for pharmacological studies of neurodegenerative diseases, including Parkinson's disease and their etiology and pathogenesis. It endeavours to discover more effective and non-toxic or less toxic drugs through integrating the application of molecular/cell biology and pharmacology techniques to benefit patients suffering from Parkinson's disease and other neurodegenerative diseases. Through collaborations with top global and national/world-class institutes in China and the world, CPDR aims to become an excellent platform to integrate Western and Chinese medicine and transform basic research into clinical applications, and serve as an innovative research and development base for training professionals.

Consun Chinese Medicines Research Centre for Renal Diseases (CCRD)

Director:
Dr. Yu Zhiling

http://ccrd.hkbu.edu.hk/

Established in February 2015, CCRD aims to boost research and development of Chinese medicines for the prevention and treatment of renal diseases, and ultimately benefit patients suffering from different kinds of renal and related diseases.

In addition to serving as a platform for innovative research on and development of preventative and therapeutic approaches for renal diseases, CCRD is committed to the nurturing of researchers and professionals, and dissemination and transfer of knowledge of new preventive and therapeutic approaches for renal diseases. •

Research Centre for Standardisation of Chinese Medicines (CSCM)

Director:
Professor Zhao Zhongzhen

Associate Director:
Professor Chen Hubiao

http://cscm.hkbu.edu.hk/

Established in March 2015, CSCM aims to develop innovative QC of and standardisation methods for Chinese medicines, promote the standardisation of Chinese medicines, formulate standards using developed methods through collaboration with governments, and provide services to industries using standardized methods.

The researchers of CSCM provide expertise in scientific elucidation of macroscopic identification of commonly used Chinese materia medica, focus on the standardisation of processed Chinese materia medica and processing methods, conduct comparative studies of chemistry and bioactivities of multi-sourced medicines, investigate into the active ingredients of Chinese medicines, and contribute to the studies of innovative methods for quality analysis of Chinese medicine decoction and polysaccharide-rich Chinese medicines. CSCM is committed to contributing to the standardisation and globalisation of Chinese medicines.

Institute of Integrated Bioinformedicine and Translational Science (IBTS)

Director:
Professor Lu Aiping

Associate Director:
Dr. Zhang Ge

http://ibts.hkbu.edu.hk/

IBTS, established in 2015, is committed to the promotion of precision medicine and translational medicine to enhance health management for the people in Hong Kong, mainland China and all over the world.

It seeks to establish a collaborative platform to facilitate multidisciplinary research to achieve better healthcare. Through integrating the academic, clinical and industrial resources, IBTS aims to build a partnership network for collecting and managing clinical, biological and environmental big data, which enable the researchers to develop models, networks, and approaches for providing predictive, preventive and personalised healthcare services.



SHENZHEN TSUMURA MEDICINE CO LTD

2015 Industrial Collaboration

HKBU received a donation of HK$5 million in 2015 from SHENZHEN TSUMURA MEDICINE CO LTD for the establishment of the "HKBU-SHENZHEN TSUMURA MEDICINE CO LTD Pharmacognosy Laboratory" to formulate standards for grading the quality of Chinese materia medica and Chinese medicinal decoction pieces as well as standards for the shapes of Chinese medicinal decoction pieces with a view to spurring research on the standardisation of Chinese materia medica. •

Beijing Tide Pharmaceutical Company Limited

2015 Industrial Collaboration

SCM and the Beijing Tide Pharmaceutical Company Limited (Tide) signed two cooperation framework agreements in 2015, setting the groundwork for collaborations in drug discovery to treat chronic inflammatory diseases, autoimmune diseases, malignant tumours, and bone and joint diseases as well as the development of new drug delivery systems, and consolidation in using healthcare data related to chronic diseases, refractory diseases and malignant tumours to foster public health and wellness. •

Infinitus (China) Company Limited

2015 Industrial Collaboration

SCM obtained a sponsorship of HK$3 million from Infinitus (China) Company Limited in 2015 for conducting a demonstration study on the modernisation of Chinese health care products with a view to promoting the modernisation, standardisation and internationalisation of Chinese health care products. •

University-Enterprise Synergy Innovation Platform

2015 Industrial Collaboration

In order to turn research into outcomes and impacts which benefit society, the School has entered into collaboration agreements with eight enterprises and research institutes and set up the "University-Enterprise Synergy Innovation Platform" in 2015 to optimise the use of talents and resources of SCM and the partner organisations to conduct innovative and integrated research in Chinese medicine and build a world-class, multi-disciplinary platform for R&D and new drug discovery. •

Zhangzhou Pien Tze Huang Pharmaceutical Company Limited

2015 Industrial Collaboration

HKBU signed an agreement with Zhangzhou Pien Tze Huang Pharmaceutical Company Limited in 2015 to establish “Zhangzhou Pien Tze Huang Pharmaceutical Company Limited—Hong Kong Baptist University Innovative Research Platform for Chinese Medicines”. By integrating their technologies and cooperation networks, the two parties aim at conducting innovative research on Chinese medicines and building a modern, multi-disciplinary centre for innovative research into Chinese medicines. •

Consun Pharmaceutical Group Limited

2015 Industrial Collaboration

SCM received a donation of HK$5 million from the Consun Pharmaceutical Group Limited for the establishment of the "Consun Chinese Medicines Research Centre for Renal Diseases" to foster research and development of Chinese medicine for the prevention and treatment of renal diseases. An agreement signing-cum- cheque presentation ceremony was held in 2015. •

Yunnan University of Nationalities

2014 Academic Collaboration

In 2014, HKBU and Yunnan University of Nationalities entered into an agreement to establish the "Yunnan University of Nationalities and Hong Kong Baptist University Joint Laboratory of Traditional Natural Drug Development" with the aim of conducting joint projects in, among others, drug discovery, research on the development of traditional compound medicine, functional food and health products processed with plants and medicines of the Yunnan nationalities.



Northwestern Polytechnical University

2014 Academic Collaboration

HKBU signed a strategic cooperation agreement with Northwestern Polytechnical University in 2014 and opened the "Hong Kong Baptist University and Northwestern Polytechnical University Joint Research Centre for Space Life Science in Musculoskeletal System". A collaborative project entitled "The effects of microgravity on the function of the cells in bone tissue" was approved by the China Manned Space Engineering Office to be conducted on "Tianzhou-1", China's first cargo ship in space scheduled to be launched in 2016.

Guizhou Yibai Pharmarceutical Company Limited

2014 Industrial Collaboration

HKBU and Guizhou Yibai Pharmaceutical Co. Ltd. signed a cooperation agreement in 2014 to establish the "Hong Kong Baptist University—Guizhou Yibai Joint Research Platform for Translational Medicine and Drug Discovery". Housed in and managed by SCM, the platform aims to develop new combinational target-specific drugs. •



Junlan Electronic (HK) Limited

2014 Industrial Collaboration

With a donation of HK$2.7 million from the Junlan Electronic (HK) Limited to be realised in phases, SCM has established the "HKBU R&D Platform for Mobile Healthcare Management System", which aims to develop mobile healthcare management systems to foster health and wellness. A cheque presentation ceremony was held in 2014 to express gratitude to the company for its strong support. •

Qingfeng Pharmaceutical Group

2014 Industrial Collaboration

The Qingfeng Pharmaceutical Group has made a donation of HK$900,000 earmarked for innovative drug discovery in Chinese medicine. The Group has also commissioned SCM to conduct a five-year research project on “Aptamer modified Paclitaxel for tumor treatment”, and provides the School with a project fund of HK$2.7 million. An agreement signing-cum-cheque presentation ceremony was held in 2014. •

PuraPharm International (HK) Limited

2014 Industrial Collaboration

SCM was supported by PuraPharm International (HK) Limited in 2014 to apply for the Innovation and Technology Fund for the research project of “Ren Shu Chang Le Granule” for treating Diarrhea-predominant Irritable Bowel Syndrome. Jointly conducted by SCM and the Chinese University of Hong Kong, the project has obtained the approval from China Food and Drug Administration to conduct clinical trials. •

Eu Yan Sang (HK) Limited

2014 Industrial Collaboration

SCM received in 2014 a sponsorship of HK$1 million from Eu Yan Sang (HK) Limited for conducting a research project entitled “Standardization on the Nomenclatures of Chinese Medicinal Materials and Decoction Pieces Sold in Hong Kong”. The project has also obtained a funding of HK416,000 from the Innovation and Technology Fund. •

Hunan University

2013 Academic Collaboration

The University entered into an agreement with Hunan University in 2013 to set up “Hong Kong Baptist University Branch of State Key Laboratory of Chemo/ Biosensing and Chemometrics (CBC State Key Lab) of Hunan University”, which is the Hong Kong branch of the CBC State Key Lab. The two institutions work together at the HKBU Branch to conduct research in molecular, biomedical and translational sciences, especially in the fields of systems biology and drug discovery in Chinese medicine. •

China Academy of Chinese Medical Sciences

2013 Academic Collaboration

SCM entered into collaboration with the China Academy of Chinese Medicinal Sciences in setting up "China Academy of Chinese Medical Sciences — Hong Kong Baptist University Centre for Translational Medical Research in Integrative Chinese and Western Medicine" in 2013. In addition to embarking on research on translational medicine, the research centre contributes to nurturing translational medicine talents. •

Jinan University

2013 Academic Collaboration

The University entered into collaboration with Jinan University in 2013 to establish the "Jinan University and Hong Kong Baptist University Joint Laboratory of Innovative Drug Development". Professor Lu Aiping was appointed to lead its research work. Besides the Joint Laboratory, a Hong Kong branch laboratory was set up under TMBJ. •

Kunshan Technology Research Institute Small Nucleic Acid Biotechnology Research Institute

2013 Industrial Collaboration

SCM established the "Academician Chan Sun Chi Workroom for Advancing Translational Medicine in Bone and Joint Disease" in collaboration with Kunshan Technology Research Institute Small Nucleic Acid Biotechnology Research Institute in 2013. With an annual funding of RMB 1 million provided by the Institute, Professor Lu Aiping leads a research team in conducting research on RNAi-related technologies in the biomedical field as well as new drug discovery related to bone and joint diseases. •

Livzon Pharmaceutical Group Inc.

2012 Industrial Collaborations

Since 2012, SCM has been collaborating with Livzon Pharmaceutical Group Inc. in establishing a Hong Kong branch of the National Engineering Research Centre for Modernisation of Traditional Chinese Medicine to conduct combinational drug research, drug development of TCM and research on resources of western herb. The Hong Kong branch conducts inter-disciplinary research and international cooperation in the field of chronic diseases such as cancer, inflammation, bone and joint diseases and neurodegenerative diseases to promote the modernisation of TCM. •

List of International Collaborations

Name	Institute	Regional District	Country
Doug ALTMAN	Oxford University	Oxford	UK
Seung Joon BAEK	College of Veterinary Medicine, University of Tennessee	Knoxville	USA
Andrea BALLABIO	Telethon Institute of Genetics and Medicine	Naples	Italy
Jeffrey A. BANAS	University of Iowa	Iowa	USA
Rudolf BAUER	Institute of Pharmaceutical Sciences, University of Graz	Graz	Austria
Kelvin CHAN	University of Sydney	Sydney	Australia
Shilin CHEN	Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences	Beijing	China
Duan CHEN	Faculty of Medicine, Norwegian University of Science and Technology	Trondheim	Norway
Hongli CHEN	Lanzhou University	Lanzhou	China
An-wen CHEN	University of Toronto	Toronto	Canada
Gong CHEN	Penn State University	Pennsylvania	USA
Omar Mukhtar EL-AGNAF	United Arab Emirates University	Al Ain	United Arab Emirates
Baomin FAN	Yunan Minzu University	Kunming	China
Antonella FORLINO	Unit of Biochemistry, University of Pavia	Pavia	Italy
Scott G. FRANZBLAU	University of Illinois at Chicago	Chicago	USA
Michael FROHMAN	Center for Developmental Genetics and Department of Pharmacology, State University of New York at Stony Brook	New York	USA
Dong HAN	National Center for Nanoscience and Nanotechnology	Beijing	China
Zhendan HE	Shenzhen University	Shenzhen	China
Rikard HOLMDAHI	Karolinska Institute	Stockholm	Sweden
Yingjie HU	Tropical Medicine Institute, Guangzhou University of Chinese Medicine	Guangzhou	China
Zhaofeng HUANG	Sun Yat-sen University	Guangzhou	China
Zhi-Bing HUANG	State Key Laboratory of Food Science and Technology, Sino-Germany Joint Research Institute, Nanchang University	Nanchang	China
Wen-Hua HUANG	Limin Pharmaceutical Factory, Livzon Group	Zhuhai	China
Robert JASTER	University of Rostock	Rostock	Germany
Guang JI	Shanghai University of Traditional Chinese Medicine	Shanghai	China
Wei JIA	University of Hawaii Cancer Center	Hawaii	USA
Zhi-Hong JIANG	State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology	Macao	China
Kathi J KEMPER	Ohio State University	Ohio	USA
William L. KLEIN	Northwestern University	Chicago	USA
Seong-Gyu KO	Kyung Hee University	Seoul	South Korea
Jost LANGHORST	University of Duisburg-Essen	North Rhine-Westphalia	Germany
Myeong Soo LEE	Korea Institute of Oriental Medicine	Daejeon	South Korea
Chung-Hang LEUNG	State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau	Macao	China
Shao LI	Bioinformatics Division, TNLIST, Tsinghua University	Beijing	China
Youping LI	Sichuan University	Chengdu	China
Zicai LIANG	Laboratory of Nucleic Acid Technology, Institute of Molecular Medicine, Peking University	Beijing	China
Fu-Long LIAO	Institute of Chinese Materia Medica, China Academy of Chinese Medicine	Beijing	China
Chao-Zhan LIN	Institute of Clinical Pharmacology, Guangzhou University of Traditional Chinese Medicine	Guangzhou	China
Wen-Lan LIU	Second People's Hospital of Shenzhen	Shenzhen	China
Jianping LIU	Beijing University of Chinese Medicine	Beijing	China
Baoyan LIU	China Academy of Chinese Medicinal Science	Beijing	China
Fengbin LIU	Guangzhou University of Traditional Chinese Medicine	Guangzhou	China
Long MA	State Key Laboratory of Medical Genetics, Xiangya School of Medicine, Central South University	Changsha	China
Kei MARUYAMA	Saitama Medical University	Saitama	Japan
Diego Luis MEDINA	Telethon Institute of Genetics and Medicine	Naples	Italy
David MOHER	University of Ottawa	Ottawa	Canada
Shao-Ping NIE	State Key Laboratory of Food Science and Technology, Sino-Germany Joint Research Institute, Nanchang University	Nanchang	China
Li-Feng PAN	Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences	Shanghai	China
Lutai PAN	Guiyang College of Traditional Chinese Medicine	Guiyang	China
Jian-Xin PU	State Key Lab of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences	Kunming	China
Hongyan QIN	Lanzhou University	Lanzhou	China
Lijun RONG	University of Illinois at Chicago	Chicago	USA
David C. RUBINSZTEIN	Cambridge University for Medical Research	Cambridge	UK
Sven SCHRÖDER	HanseMerkur Center for TCM at the University Medical Center Hamburg	Hamburg	Germany
Sanjib SENAPATI	Indian Institute of Technology Madras	Chennai	India
Yibin SHAN	DE Shaw Research	New York	USA
Hongcai SHANG	Beijing University of Chinese Medicine	Beijing	China
Han-Ming SHEN	Yong Loo Lin School of Medicine, National University of Singapore	Queenstown	Singapore
Han-Dong SUN	State Key Lab of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences	Kunming	China
Weihong TAN	Center for Research at the Bio/Nano Interface, UF Health Cancer Center, University of Florida	Florida	USA
Ghee TAN	University of Hawaii at Hilo	Hawaii	USA
Xudong TANG	China Academy of Chinese Medicinal Science	Beijing	China
Peng-Fei TU	Peking University	Beijing	China
Jan VAN DER GREEF	Leiden Academic Centre for Drug Research, Analytical BioSciences, Leiden University	Leiden	Netherlands
Hongying WANG	State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College	Beijing	China
Hongqi WANG	Guangzhou University of Traditional Chinese Medicine	Guangzhou	China
Wei WEI	Beijing University of Chinese Medicine	Beijing	China
Xi-Yang WU	Jinan University	Guangzhou	China
Lianbo XIAO	Guanghua Integrated Chinese and Western Medicine Hospital	Shanghai	China
Jiake XU	School of Pathology and Laboratory Medicine, University of Western Australia	Nedlands	Australia
Guowang XU	Dalian Institute of Chemical Physics, Chinese Academy of Sciences	Dalian	China
Gang XU	State Key Lab of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences	Kunming	China
Hongxi XU	Shanghai University of Traditional Chinese Medicine	Shanghai	China
Yu XUE	Huazhong University of Science and Technology	Wuhan	China
Zhen-Yu YUE	Icahn School of Medicine at Mount Sinai	New York	USA
Lingqiang ZHANG	State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine	Beijing	China
Weidong ZHANG	Modern Research Center for Traditional Chinese Medicine, Second Military Medical University of China	Shanghai	China
Bo ZHOU	State Key Laboratory of Applied Organic Chemistry, Lanzhou University	Lanzhou	China
Hong ZHOU	ANZAC Research Institute, University of Sydney	Sydney	Australia
Hua ZHOU	State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology	Macao	China
Lixin ZHU	University of New York at Buffalo	New York	USA

Map of International Collaborations


ARCTIC OCEAN
Trondheim
NORWAY
Stockholm
UNITED KINGDOM
Hamburg
Rostock
Cambridge
Oxford
Leiden
North Rhine-Westphalia
NETHERLANDS
GERMANY
AUSTRIA
Graz
Pavia
ITALY
Naples
Beijing
Dalian
Seoul
Daejeon
SOUTH KOREA
JAPAN
Saitama
Lanzhou
CHINA
Wuhan
Shanghai
Chengdu
Changsha
Nanchang
Guiyang
Kunming
Guangzhou
Shenzhen
Zhuhai
Macao
NORTH PACIFIC OCEAN
UNITED ARAB EMIRATES
Al Ain
INDIA
Chennai
SINGAPORE
Queenstown
INDIAN OCEAN
AUSTRALIA
Nedlands
Sydney

Number of Major External Competitive Research Grants Awarded



Total Amount of Major External Competitive Research Grants Awarded



Notes

SZSTI: Funding schemes under Science, Technology and Innovation Commission of Shenzhen; **NSFC/RGC:** National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme; **NSFC:** Funding schemes under National Natural Science Foundation of China; **ITF:** Innovation and Technology Fund; **HMRF:** Health and Medical Research Fund; **GRF:** General Research Fund; **GDNSF:** Funding schemes under Guangdong Province Natural Science Foundation

Number of Local Major Competitive Research Grants Awarded to Schools of Chinese Medicine in Hong Kong



Total Amount of Local Major Competitive Research Grants Awarded to Schools of Chinese Medicine in Hong Kong



Notes

1. Local Major Competitive Research Grants include: **GRF** (General Research Fund); **HMRF** (Health and Medical Research Fund); **ITF** (Innovation and Technology Fund) and **NSFC/RGC**: National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme.
2. Information is acquired from the websites of corresponding funding agencies (with "Chinese Medicine" as the keyword in the search of funded projects).
3. The figures are not meant to be complete or exhaustive.

Number of Patents Filed



Number of Patents Granted



Notes

Jurisdiction of Patents: **US** (United States of America); **Taiwan; IP** (International Procedures); **HK** (Hong Kong); **EP** (European) and **CN** (China)

Number of Papers and Books Published



SCI[1] Papers Published in Prestigious International Journals[2] (2011-2015) by Schools of Chinese Medicine in Hong Kong

	Number of SCI Papers	Number of Academic Staff	Normalized Ratio
HKBU	10	16	0.63
University A	0	5	0.00
University B	0	10	0.00

Bone & Joint Diseases Related (B&J) SCI[1] Papers Published in World's Top Academic Journals[3] (2011-2015) by HKBU SCM – Benchmark to Western Medicine

	Number of SCI Papers	Number of B&J Academic Staff	Normalized Ratio
HKBU - School of Chinese Medicine	4	2	2.00
University A - Department of Orthopaedics and Traumatology	0	8	0.00
University B - Department of Orthopaedics and Traumatology	0	5	0.00

Notes

1. SCI refers to Science Citation Index.
2. Prestigious International Journals include: a. *Autophagy*, b. *Nature Communications*, c. *Nature Medicine* and d. *Sciences*.
3. World's Top Academic Journals include: a. *Nature Communications*, b. *Nature Medicine* and c. *Sciences*.
4. The figures are not meant to be complete or exhaustive.

Major Conferences

2015

Cross-strait Four-region Chinese Medicine (Hong Kong) Forum

Workshop on Academic Thinking and Clinical Experiences of National TCM Masters and Famous Veteran Doctors of TCM

2015

Academic Seminar on Chinese Medicine Clinical Practice Guidelines for Hong Kong

2014

2014 International Summit on Innovative Drug Discovery

2014

First *Gao Fang* Festival

Compendium of Materia Medica Cultural Project Launch Ceremony and Cross-strait Four-region Chinese Medicine Forum

2014

Second Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine Award Presentation Ceremony-cum-Award Winner's Lecture

2013

2013 International Summit on Innovative Drug Discovery

2013

Forum on Chinese Medicine Clinical Teaching

2012

Compendium of Materia Medica Cultural Project Launch Ceremony and Cross-strait Four-region Chinese Medicine Forum

2012

4th Annual Meeting of Global University Network of Traditional Medicine

First Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine Award Presentation Ceremony-cum-Award Winner's Lecture

2011

Forum on “Systems Biology in Cancer Research”

2010

9th Meeting of the Consortium for Globalization of Chinese Medicine

Guest Speakers

Name	Affliation	Topic
2015		
AI Jun	Guangxi University of Chinese Medicine, China	The theory of mechanism of stagnated heat of warm disease to the treatment of various disease
CHAE Younbyoung	Acupuncture and Meridian Science Research Center Kyung Hee University, South Korea	Brain responses to acupuncture stimulation: from the perspective of cognitive neuroscience
CHANG Fangrong	Kaohsiung Medical University, Taiwan	Natural medicines and TCM quality
CHANG Yuanshiun	China Medical University, Taiwan	Status and future development of traditional Chinese Medicine in Taiwan
CHAO Enxiang*	China-Japan Friendship Hospital, China	Treatment of wind-cough
CHAO Enxiang*	China-Japan Friendship Hospital, China	My insight of ancient and modern TCM doctor training ways
CHE Chun-Tao	University of Illinois at Chicago, U.S.A.	A Tale of Two Herbs: Paeonia lactiflora and Ligustrum lucidum
CHEN Hongxia	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	TCM differential treatment for common dysfunction of stroke
CHEN Luonan	Chinese Academy of Sciences, China	Detecting "un-occurred" disease state by dynamical network biomarkers – Precision Medicine by Big-Data
CHEN Dazhi	American Association of Acupuncture and Oriental Medicine. U.S.A.	Mechanism investigation and clinical application of acupuncture
CHEN Dacan	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	TCM treatment and research of atopic dermatitis
CHEN Zhifang	Taipei Chinese Medical Association, Taiwan	Clinical application of QingShang JuanTong decoction
CHI Yonggui Robin	Nanyang Technological University, Singapore	Carbene Catalyst-Enabled New Activation Modes and Rapid Access to Functional Molecules
CHU Chic-Chang	Cornell University, U.S.A.	Nature-Inspired Design of a New Family of Biodegradable Pseudo-Protein-Based Biomaterials: Their Biological Property and Biomedical Applications
GAO Sihua	Beijing University of Chinese Medicine, China	The strategies of integrated traditional Chinese and Western medicine in preventing and treating type 2 diabetes mellitus
HE Zhendan	Shenzhen University Health Science Center, China	Study on the chemical constituents and pharmacological effects of Kudingcha (Llicis Latifoliae Folium)
HOLMDAHL Rikard	Karolinska Institutet, Sweden	Autoimmunity to Cartilage Predicting and Regulating Rheumatoid Arthritis
HUANG Bin	Beijing University of Chinese Medicine, China	Prescription as derived from his book <<Si Sheng Xin Yuan>>
HUANG Hui	State Administration of Traditional Chinese Medicine, China	Development of modern Chinese Medicine Model
HUANG Jianling	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	Chinese medicine treatment for sterility
JIANG Zhihong	Macao University of Science and Technology, Macau	The acid sugar chain of Immunoglobulin in saliva as the biomarkers of leukemia and rheumatoid arthritis
KENNELLY Edward	City University of New York, U.S.A.	Adulterated Botanical Supplements in the United States Market
KO Seong-Gyu	Kyung Hee University, South Korea	Molecular targeted Cancer Therapy: Herbal Drug Development and Translational Study
LAM Ronald	Chinese Medicine Division of the Department of Health, HKSAR	The future development of Hong Kong Chinese Materia Medica Standards and Testing

* National TCM Master

Name	Affliation	Topic
LEE Inseon	University of Tübingen, Germany	Acupuncture and Functional dyspepsia
LIU Baoyan	China Academy of Chinese Medical Sciences, China	Challenge and opportunity of TCM syndrome differentiation and treatment in Age of Big Data
LIU Baoyan	China Academy of Chinese Medical Sciences, China	The development present stituation and future of the Chinese Medicine in mainland China
LIU Minru*	Tung Wah Hospital -- The University of Hong Kong Clinical Centre, HKSAR	Several major issues surrounding the development of Chinese Medicine
LONG Chunlin	Minzu University of China, China	Studies on Medicine-Food Plants Collected by Ethnic People in Yunnan Tropics
LU Yubo	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	Features and countermeasures of the management of Chinese Medicine hospital
SCHRÖDER Sven	University Medical Center Hamburg-Eppendorf, Germany	Neuroprotective Effects of Coptidis rhizome chinensis Franch.(Huang Lian)
SUN Guangrong*	Beijing University of Chinese Medicine, China	Strategic cooperation and development of traditional Chinese Medicine
SUO Zucai	The Ohio State University, U.S.A.	Watching DNA polymerases incorporate drug molecules and bypass an oxidative lesion
VERPOORTE Robert	Leiden University, Netherlands	Synergy: easier to say than to prove
WANG Qi*	Beijing University of Chinese Medicine, China	Three questions that TCM clinical research faced and their answers
WANG Qi*	Beijing University of Chinese Medicine, China	Clinical application of the "bianti, bianbing. bianzheng" diagnosis model
WANG Yitao	The University of Macau, Macau	The thinking and exploration on the innovation driven development of traditional Chinese Medicine
WEN Jianmin	Wangjing Hospital of the China Academy of Chinese Medical Sciences, China	The treatment strategy of traditional Chinese Medicine on osteoarthritis
WONG Wing Tak Jack	Weill Cornell Medical College of Cornell University, U.S.A.	Discovery of Novel Determinants of Endothelial Lineage: Insights from Chimeric Heterokaryons
WU Qifu	Southern Medical University, China	The clinical application and research progress of anti-rheumatic traditional Chinese Medicine
XU Hongxi	Shanghai University of Traditional Chinese Medicine, China	R&D outcomes and internationalization advance in TCM
XUAN Guowei	Guangzhou University of Chinese Medicine, China	Treating skin diseases from the perspective of du
XUE Yu	Life Science and Technology Huazhong University of Science and Technology, China	Computational Analysis of the Phosphoproteomic Data
YANG Shilin	National Engineering Research Center for Manufacturing Technology of TCM Solid Preparation, China Jiangxi University of Traditional Chinese Medicine, China	The research and development of total pulchinenosides (TPs) as a new anti-schistosoma drug
YE Min	Peking University, China	Chemical Analysis and Pharmacokinetics of Chinese Herbal Medicines
YU Zhimin	China Academy of Traditional Chinese Medicine, China	Toxicity of TCM and “to cure ills with poison”
YUAN Chun-Su	University of Chicago, U.S.A.	New Drug Development in the US and Tang Center for Herbal Medicine Research at University of Chicago
YUE Jianbo	City University of Hong Kong, HKSAR	Autophagy Regulation by Oxidative Stress, Ca2+ and Small Chemicals
ZHANG Hongchun	China-Japan Friendship Hospital, China	Treatment for chronic obstructive pulmonary disease
ZHANG Shengsheng	Capital Medical University, China	Treatment of chronic gastritis

* National TCM Master

Name	Affliation	Topic
ZHANG Yun	Chinese Academy of Engineering, China Shandong University, China	Vulnerable Plaque: State of the Art
ZHONG Qing	University of Texas Southwestern Medical Center, U.S.A.	Biochemical Dissection and Reconstitution of Mammalian Autophagy
ZHU Hui Xin	Institute of Chinese Academy of Traditional Chinese Medicine, China	The study of anti-cancer and pharmacological mechanisms of ESC
2014		
BAUER Rudolf	Universitaet Graz, Austria	European monographs about herbal medicines
CAO Hui	National Engineering and Research Center on the Modernization of Traditional Chinese Medicine, China	National Engineering and Research Center on the Moderization of Traditional Chinese Medicine (NERC-MTCM): Introduction and Proposal Submission
CHAN Kelvin	The University of Sydney and NICM, Australia University of Western Sydney, Australia	Global regulation and standardisation of Chinese medicines including some aspects in Australia
CHANG Yung-Hsien	China Medical University, Taiwan	Memorial <<Compendium of Materia Medica>> Li Shizhen, Chinese medicine culture construction project
CHEN Gong	Pennsylvania State University, U.S.A.	In vivo reprogramming for brain repair
CHEN Rixing	The Affiliated Hospital of the Jiangxi University of Chinese Medicine, China	Investigation for the effects of heat-sensitive moxibustion therapy on osteoarthritis in knee joints based on large-scale randomized controlled multi-center clinical trial
CHEN Dacan	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	TCM treatment of atopic dermatitis
CUI Meng	Institute of information on Traditional Chinese Medicine, China	Advances in information on Traditional Chinese Medicine in key areas
DAI Hui	Peking University Health Science Center, China	The molecular mechanisms and biology significance of polysaccharide recognition by the immune system
DIAO Jiajie	Stanford University, U.S.A.	Investigation in membrane fusion during autophagy by single molecular
DING Wenxing	University of Kansas Medical Center, U.S.A.	The double-edged Sword of Autophagy and Nrf2 in Cancer
GAO Hengjun	Tongji University, China	Clinical Translational Research, Discipline Development and Bio-bank
GAO Shangde	China Medical University, Taiwan	Prevention and treatment of autoimmune diseases by Chinese Medicine
GODA Yukihiro	National Institute of Health Sciences, Japan	Introduction of qNMR to the Japanese Pharmacopoeia (JP) for specification of marker compounds used for standardization of herbal medicines
GRAHAM James	University of Illinois at Chicago, U.S.A.	The NAPRALERT® Database: (Still) Outstanding in the Field of Natural Products
GUO De-an	Chinese Academy of Sciences, China	Strategy to elaborate TCM quality monographs and global harmonization
HAN Ji-Sheng	Chinese Academy of Sciences, China Peking Univeristy Health Science Centre, China	Translational Medicine of Acupuncture Research
HUANG Yi-Tsau	National Research Institute of Chinese Medicine, Taiwan	Prevention and treatment of chronic liver disease using TCM
JIANG Zhihong	Macau University of Science and Technology, Macau	The use of HPLC-Q-TOF MS and LC-MS/MS on sphingolipid genomic analysis and its application in the study of cellular neurotoxicity
KO Seong-Gyu	Kyung Hee University, South Korea	Education System for Traditional Medicine of Kyung Hee University and Research for Tailored Traditional Medicine in Korea
KO Richard	Herbal Synergy, U.S.A.	Overview of U.S. approach to standardization of Traditional Chinese Medicines
LAO Lixing	The University of Hong Kong, HKSAR	Evidence-based medicine acupuncture

* National TCM Master

Name	Affliation	Topic
LI Jiansheng	Henan University of Traditional Chinese Medicine, China	Clinical study of TCM for the treatment of chronic obstructive pulmonary disease
LI Zhenji	World Federation of Chinese Medicine Societies, China State Administration of Traditional Chinese Medicine, China	Strategic thinking of Chinese medicine theory and project implementation under the 973 Programme
LI Qizhong	Shanghai University of Traditional Chinese Medicine, China	Humanistic perspective and clinical applications of Gao Fang
LIN Zhixiu	The Chinese University of Hong Kong, HKSAR	Acupuncture clinical training
LIU Tonghua	Beijing University of Chinese Medicine, China	TCM prevention and treatment of diabetes
MEI Quanxi	Hospital of Traditional Chinese Medicine of Zhongshan, China	The historical uses and modern applications of Artemisiae Argyi Folium
MOHER David	University of Ottawa, Canada	Scientific writing and publishing: challenges and opportunities for academic institutions
MOHER David	University of Ottawa, Canada	Establishing a hospital based technology assessment unit
NG Bacon	Hospital Authority, HKSAR	Specialty development of healthcare personnel in Hong Kong
QIAN Zhongzhi	Chinese Pharmacopoeia Commission, China	Overview of National Drug Standards
RONG Lijun	University of Illinois at Chicago, U.S.A.	Identification of Entry Inhibitors of Influenza Viruses, Arenaviruses and Filoviruses
SHEN Hong	The First Affiliated Hospital of the Nanjing University of Chinese Medicine, China	An overview on clinical application of Gao Fang
SHEN Han-Ming	National University of Singapore, Singapore	A Force for Survival: Involvement of Autophagy in Stress-Mediated Cell Death
SHEN Yuandong	Shanghai Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, China	Standardization on Traditional Chinese Medicine in the field of ISO (International Organization for Standardization)
SUO Zucai	The Ohio State University, U.S.A.	Structural, Kinetic, and Dynamic Studies of DNA Polymerases
TSUTANI Kiichiro	The University of Tokyo, Japan	Evidence-based Activities on Kampo and Integrative Medicine in Japan: EKAT, KCONSORT and eJIM
UNSCHULD Paul U.	Charité-Medical University Berlin, Germany	The Translation of Historial Chinese Illness Terminology into Western Languages
WANG Mei	Leiden University, Netherlands	A systems pharmacology view on Dioscorea nipponica used in modern Chinese medicine: the first tHMP product registered in Europe and produced in China
WANG Fuchun	Changchun University of Chinese Medicine, China	Acupuncture techniques and their operation
WANG Yitao	University of Macau, Macau	Quality of Chinese Medicine and development of international products
Wu Che-yuen Justin	The Chinese University of Hong Kong, HKSAR	Development of specialty training in western medicine
WU Pui Kei	Medical College of Wisconsin, U.S.A.	A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase
WU Shun-Hua	State Intellectual Property Office, China	Patent protection in the field of drugs
XIAO Hongbin	China Academy of Chinese Medical Sciences, China	Preparing reference substances for herb medicine by pilot-scale - High performance column chromatography techniques
XIAO Tiqiao	Shanghai Synchrotron Radiation Facility, China Shanghai Institute of Applied Physics, China Chinese Academy of Sciences, China	X-ray imaging at Shanghai Synchrotron Radiation Facility
XU Fengqin	Xi Yuan Hospital of the China Academy of Chinese Medical Sciences, China	1. Gao Fang treatment for senile cardiovascular disease 2. Gao Fang and health care

* National TCM Master

Name	Affliation	Topic
XU Jiake	The University of Western Australia, Australia	From Nobel Prize-winning discovery to the mechanism of vesicle transport in osteoclasts
YANG Zhimin	Guangdong Provincial Hospital of Traditional Chinese Medicine, China	The theoretical study about spleen and stomach in the application of Gao Fang
YANG Ling	Chinese Academy of Sciences, China	New methodology of TCM pharmacokinetics - early ADME properties and their systemic integration
YU Shishan	China Academy of Chinese Medical Sciences, China	Study on bioactive compounds with novel structures from toxic plants in China
ZENG Jianguo	Hunan Agricultural University, China National Chinese Herbs (Hunan) Technology Center, China National Research Center of Engineering Technology for Utilization of Functional Ingredients from Botanicals, China	Lecture series on new TCM Medicines-Comprehensive utilization and development of medicinal resources macleaya cordata
ZHANG Shengsheng	Beijing Hospital of Traditional Chinese Medicine, China	A multicenter, randomized, double-blind, placebo-controlled trial of modified Liujunzi decoction in the treatment of functional dyspepsia and spleen Qi stagnation
ZHAO Liping	Shanghai Jiao Tong University, China	Can We Follow Koch's Postulates for Hunting Down Human Obesity Bugs in Gut Microbiota?
ZHEN Jin-Sheng	China Academy of Chinese Medicinal Sciences, China	《Compendium of Materia Medica》study: the past, present and future
ZHU Lixin	State University of New York at Buffalo, U.S.A.	Gut microbiome as an emerging target of TCM for the management of liver diseases
2013		
CHEN Kaixian	Shanghai University of Traditional Chinese Medicine, China	Status and Role of Chinese Medicine in Contemporary Society
CHEN Kaixian	Shanghai University of Traditional Chinese Medicine, China	Development of translational medicine and the integration of Chinese and western medicine
CHURILOV Leonid P.	St. Petersburg State University, Russia	Typical pathological processes, pathological reactions, their correlation to syndromes, symptoms and diseases General etiology and general pathogenesis, doctrines of monocausalism, conditionalism and constitutionalism, their synthesis in modern Pathophysiology
FAN Tai Ping	University of Cambridge, United Kingdom	Advances in Angiogenesis Research - a Chinese Medicine Perspective
FAN Baomin	Yunnan Minzu University, China	Study of catalyzed reactions of norbornene derivatives with terminal alkynes
GAO Ying	Dongzhimen Hospital of Beijing University of Chinese Medicine, China	Experience and guideline of TCM Diagnosis and treatment of cerebral infarction
GUO Dean	Chinese Academy of Sciences, China	Quality-oriented Research of Traditional Chinese Medicine
LI Jiren*	The First Affiliated Hospital of Wannan Medical College, China	Treating arthralgia and flaccidity syndromes
LIU Yanjiao	Guang'anmen Hospital, China Academy of Chinese Medical Sciences, China	Diagnosis, treatment and evaluation of insomnia
LU Guangxin*	China Academy of Chinese Medical Sciences, China	Health regimen and treating disease according to its origin (Video)
MA Long	Central South University, China	Genetic analyses of essential splicing factor genes in C. elegans
ROSARIO Joana	National Institute of Health, U.S.A.	From Scientist to Entrepreneur Drug Development-Science, Regulation and Financing
SHI Zhaohong	Hubei University of Chinese Medicine, China	From the Yang-Resolving Theory to the study of welsh onion on fatty liver prevention

* National TCM Master

Name	Affliation	Topic
TAN Weihong	State Key Laboratory of Chemo/Biosensing and Chemometrics of Hunan University, China University of Florida, U.S.A.	The cornerstone of molecular medicine: molecular tools
TANG Xudon	China Academy of Chinese Medical Sciences, China	Understanding the concept of standardization and the development of TCM treatment guidelines for chronic gastritis
WANG Changen	Fund Committee of National Natural Science Foundation of China (NSFC), China	TCM basic research supported by the "National Natural Science Foundation of China"
XIONG Jibo	Hunan University of Chinese Medicine, China	The use of the classical TCM theory for treating complicated diseases
ZHU Liangchun*	Nantong Hospital of Traditional Chinese Medicine, China	Mastering the superiority and soul of TCM for the treatment of complicated diseases (Video)

* National TCM Master

Cellular & Molecular Biology Lab

The lab provides techniques, equipment and protocols to investigate musculoskeletal disorders at cellular and molecular levels.

The laboratory can realize recognizing, analyzing and manipulating cells as well as biomolecular with efficiency, sensitiveness and high throughput. So far, the lab has established the following techniques:

Cell Techniques

It includes cell separation, cell culture, cell fusion, cell activity analysis, cell immunophenotyping analysis, cell circle analysis and so on.

Nucleic Acid Techniques

It includes DNA / RNA extraction, gene splicing, gene transduction, gene transfection, gene clone, gene expression, nucleic acid aptamer screening and so on.

Protein Macromolecular Techniques

It includes protein extraction, protein purification, protein separation, protein quantitative / qualitative analysis, protein-protein interaction analysis, nucleic acid aptamer-protein analysis interaction and so on. •



Histopathology & Bio-imaging Lab

The lab provides techniques, equipment and protocols for bio-imaging and non-destructive 3-D imaging evaluation as well as histopathological examination and histomorphometric analysis for musculoskeletal research and for developing innovative drugs in bone and joint diseases. So far, the lab has established the following techniques.

Biophotonic-based Fluorescence Imaging Techniques

Lumina XR Series III could sensitively image bioluminescent / fluorescent reporters and differentially evaluate their distribution in various organs within the same animal. It is employed to examine drug delivery by in vivo bio-imaging analysis.

Histopathological Examination & Histomorphometric Analysis & Gene Expression Analysis in specific cells

Non-decalcified histological processing for bone tissue and static / dynamic bone histomorphometric analysis could be performed in the lab. Techniques of wide special stains for bone and cartilage, such as the VonKossa, tartrate-resistant acid phosphatase (TRAP), alkaline phosphatase, Gömöritrichrome, safranin O and toluidine blue stains are provided in the lab. Further, laser-captured micro-dissection in combination with Q-PCR analysis for gene expression in specific cells is also established in the lab. •







Synthesis & Pharmaceutics & Chemical Analysis Lab

The lab focuses on improving human health by safely and effectively translating new drug into clinical trials using synthetic technology, targeted nano-pharmaceutical technology and quality analysis.

Drug Synthesis

Synthesizing conjugates of certain nucleic acid aptamers (possessing high specificity and affinity to specificity cell type) and natural products to develop smart drug molecules with both cell-selectivity and intracellular bioactivity for achieving efficacy and safety.

Drug Delivery

Linking certain nucleic acid aptamers (possessing high specificity and affinity to specificity cell type) with lipid- / polymer-based cargo system to develop targeted delivery system for translating the molecular understandings toward RNA interference-based therapeutics in bone and joint diseases.

Drug Analysis

Providing expert analysis in all facets of pharmaceutical analysis (including stability, related substances, impurities and active assays, etc.) to establish specification for active pharmaceutic ingredient (API) and formulation according to the instructions provided by FDA or CFDA. •



Bioinformatics & Drug Design Lab

The lab provides an integrated bioinformatics analysis and drug design platform focusing on the following five aspects: constructing an comprehensive and large biomedical data warehouse; data mining techniques for extraction of useful results from large amounts of biological data; undertaking assay of omics, including proteomics and metabolomics; dealing with methods for storing, retrieving and analyzing biological data, such as nucleic acid and protein sequences, structures, functions, pathways and genetic interactions; computer-aided drug design (CADD) technology from the availability of bioinformatics applications.







Biomedical Database

Biomedical data warehouse is constructed by collecting and integrating databases of different biomedical domains. By now, these biomedical databases including SinoMed, PubMed, OMIM, GO, NCI pathway interaction database, MeSH, PubChem, TCMDB, PDB, ChEMBL, PharmaGKB, TTD, DrugBank, UniProt, UMLS and KEGG.

Data Mining

Based on the biomedical database, typical text mining tasks include text categorization, text clustering, concept / entity extraction, sentiment analysis and document summarization are performed to derive high-quality information from these texts.

Assay of Proteomics & Metabolomics

The lab provides a comprehensive analysis platform for protein and metabolite. Two widely used and powerful methods, including Gas chromatography (GC) and High performance liquid chromatography (HPLC) are used for separation in the lab. Furthermore, Mass spectrometry (MS) is applied to identify and to quantify metabolites after separation by GC, HPLC. Also several statistical programs are available for analysis of MS data.

(Continued)

(Continued)

Bioinformatics Analysis

By applying computationally intensive techniques, we develop new algorithms and statistics with which to assess relationships among members of large data sets, to increase the understanding of biological processes. Also commercial software, such as ingenuity pathway analysis (IPA) is often used for casual network analysis, comparison analysis, upstream regulator analysis, mechanistic networks and pathway analysis.

Computer-Aided Drug Design

With understanding the structure of small molecules, proteins and nucleic acids, we apply computer-aided drug design (CADD) technology to discover or design active compounds to cure the diseases. To further understand the mechanism of effects of drug / drug combination on biological network, we also develop structure-based technology to identify targets of compounds from drug / drug combination. •

Experimental Animal Centre

The centre is located at the ground floor of Jockey Club School of Chinese Medicine Building. It is committed to ensuring the humane care and use of all animals associated with its research and teaching programs. It currently equips 6 laboratory animal breeding rooms that offer independent air condition system with high efficiency air filter and full air exchange rate, and that are in compliance with the international standards and regulations for breeding environment and laboratory room of murine. It provides services and resources needed by investigators to accomplish the animal research of bone-related disease and assist in providing training in laboratory animal care and use to technical personnel, students and faculty. •

AWARDS

Faculty Staff Awards Obtained

Awarded Staff	Title of the Award / Honours	Awarding Body	Nature of Award / Honours
2014 - 2015			
LU Aiping	Award for Outstanding Contribution to Standardisation in China (First Chinese Medicine researcher to win the individual award)	The General Administration of Quality Supervision, Inspection and Quarantine of the PRC and the Standardisation Administration of the PRC	National
LU Aiping	2014 Award for Promoting Standardisation	China Association for Standardisation (CAS)	National
ZHAO Zhongzhen	Award for his outstanding achievement and contribution to Chinese materia medica research	Hong Kong Chinese Medicine Industry Association	Local
ZHANG Ge	Chinese Medical Science and Technology Award (Second Class) - Investigation of regulatory echanism of ubiquitin ligases and their application in the treatment of osteoporosis	Chinese Medical Association	National
KWAN Hiu Yee	Travel Award	Asia Oceania Association for the Study of Obesity	Regional
LI Defang	Young Investigator Award - Osteoclast-derived exosomal miR-214 inhibits osteoblastic bone formation	American Society for Bone and Mineral Research (ASBMR)	Regional
SONG Juxian	Best Poster Award - A synthesised curcumin derivative activates TFEB to promote autophagy and lysosome biogenesis, and protect neurons independent of mTOR inhibition	Institute of Biophysics, Chinese Academy of Sciences	International
2013 - 2014			
ZHAO Zhongzhen	Medal of Honour	Hong Kong Special Administrative Region	Local
BIAN Zhaoxiang	Science and Technology Award (1st Class)	China Association for Traditional Chinese Medicine	Regional
BIAN Zhaoxiang	Research Award (2nd Class)	The 4th Internal conference of integrated digestive disease, World Association of Chinese Medicine	International
LI Min	Best Poster Award - “NRBF2, a novel Beclin1-PI3K-III complex component, regulates autophagy and prevents ER stress-induced toxicity”	European Molecular Biological Organisation (EMBO) International Conference	International
ZHANG Ge	Beijing Science and Technology Award (First Prize) - “Investigation of molecular function, regulatory mechanism and disease correlation of ubiquitin ligases”	The People's Government of Beijing Municipality, China	National
ZHANG Ge	National Science and Technology Progress Award under the 2013 Higher Education Outstanding Scientific Research Output Awards (Science and Technology) (Second Class) - “Modernisation Research and Application of Anti-osteoporosis TCM Drugs”	Ministry of Education, China	National
LIANG Zhitao	Advanced individual of national science and technology project of Shenzhen Virtual University Park 2013	The Science, Technology and Innovation Commission of Shenzhen	Regional
TSANG Siu Wai	Research Award (2nd Class)	World Association of Chinese Medicine	International

Awarded Staff	Title of the Award / Honours	Awarding Body	Nature of Award / Honours
2012 - 2013			
BIAN Zhaoxiang	Top Ten Research Papers - Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation	China Medicinal Plants Association	National
2011 - 2012			
ZHAO Zhongzhen	"Three one-hundred" Award - co-edited a book named "Illustrated Chinese Materia Medica"	General Administration of Press and Publication of China	Regional
CHEN Hubiao	"Three one-hundred" Award - co-edited a book named "Illustrated Chinese Materia Medica"	General Administration of Press and Publication of China	Regional
YANG Zhijun	Team Award for Innovation	Osteoporosis Committee of the China Gerontological Society	Regional
School of Chinese Medicine	2012 ALA Presidential Citations for Innovative International Library Projects Award - Chinese Medicine Digital Project	American Library Association (ALA)	International
ZHANG Ge	Chinese Medical Science and Technology Award (Second Class) - Investigation of regulatory echanism of ubiquitin ligases and their application in the treatment of osteoporosis	Chinese Medical Association	National
LI Min	Municipal Science and Technology Project Award of Shenzhen Virtual University Park	Economy, Trade and Information Commission of Shenzhen Municipality	Regional
2010 - 2011			
ZHAO Zhongzhen	Outstanding Publications Award - co-edited a book series named Encyclopedia on Contemporary Medicinal Plants (simplified Chinese version)	National government of the People's Republic of China	National

Research Postgraduate Student Awards Obtained

Awarded Student	Programme	Title of the Award / Honours	Title of Journal paper	Organisation	Place of Conference
2015					
CHEN Leilei	PhD	Best Poster Award	A synthesised curcumin derivative activates TFEB to promote autophagy and lysosome biogenesis, and protect neurons independent of mTOR inhibition	7th International Symposium on Autophagy, Institute of Biophysics, Chinese Academy of Sciences	Huangshan, China
GADAU Marcus	PhD	Dragon Culture TCM Scholarship	Study of acupuncture treatment for lateral elbow pain in an international collaborative setting	Dragon Culture Charity Fund Limited	Hong Kong
LIANG Chao	PhD	Webster Jee Young Investigator Award	Aptamer-Functionalised delivery system for osteogenic siRNAs to achieve osteoblast-specific RNA interference for bone anabolic therapy	International Chinese Musculoskeletal Research Society-Orthopaedic Research Society	Las Vegas, USA
LIANG Chao	PhD	Clinical and Translational Medicine Best Thesis Award	Discovery of Small Molecules to Promote BMP Signaling and Bone Formation	Scientific Committee of SAS-CTM and China International Medical Foundation	Hangzhou, China
LIANG Chao	PhD	ASBMR Young Investigator Award	To attend the ECTS PhD Training Course European Calcified Tissue Society (ECTS) PhD Training Course	American Society for Bone and Mineral Research (ASBMR)	Tuscany, Italy
LIANG Chao	PhD	Dragon Culture TCM Scholarship	Aptamer-functionalised lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy	Dragon Culture Charity Fund Limited	Hong Kong
LIU Liangfeng	PhD	Best Poster Award	A synthesised curcumin derivative activates TFEB to promote autophagy and lysosome biogenesis, and protect neurons independent of mTOR inhibition	Institute of Biophysics, Chinese Academy of Sciences	Huangshan, China
LIU Jin	PhD	Young Investigator Award	A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts	The Second Xiangya Hospital of Central South University	Changsha, China
LIU Jin	PhD	Young Investigator Travel Grant	Osteoclastic miR-214 targets PTEN to increase bone resorption	American Society for Bone and Mineral Research (ASBMR)	Seattle, Washington, USA
ZHAO Ling	PhD	Second prize for best conference paper	Metabolic Signatures of Human Functional Constipation	Specialty Committee of Gastroenterology of the World Federation of Chinese Medicine Societies	Shanghai, China

Awarded Student	Programme	Title of the Award / Honours	Title of Journal paper	Organisation	Place of Conference
2014					
DU Bin	PhD	Travel Grants	An insight into anti-inflammatory effects of fungal beta-glucans	13th Meeting of the Consortium for Globalisation of Chinese Medicine	Beijing, China
LIANG Chao	PhD	2014 Young Investigator Travel Grant	Aptamer-Functionalised Lipid Nanoparticles (LNPs) Targeting Osteoblasts as a Novel RNA Interference-Based Bone Anabolic Strategy	American Society for Bone and Mineral Research	Texas, USA
LIANG Chao	PhD	Clinical and Translational Medicine Best Thesis Awards	Aptamer-Functionalised Lipid Nanoparticles (LNPs) Targeting Osteoblasts as a Novel RNA Interference-Based Bone Anabolic Strategy	Scientific Committee of SAS-CTM and China International Medical Foundation	Beijing, China
SU Tao	PhD	Best Student Research Paper Award	An ethanolic extract of Pinelliae Rhizoma inhibits proliferation and induces apoptosis through suppressing PI3K/AKT/mTOR signaling and ROS-mediated MAPKs activation in liver cancer cells	Advances in Cancer Medical Research	Singapore
XU Jun	PhD	Travel Grants	A novel and rapid HPGPC-based strategy for quality control of saccharide-dominant herbal materials: Dendrobium officinale, a case study	13th Meeting of the Consortium for Globalisation of Chinese Medicine	Beijing, China
DANG Lei	Mphil	2014 Young Investigator Travel Grant	Mechanistic and Therapeutic insights into skeletal biology learned from the study of rare bone diseases	American Society for Bone and Mineral Research (ASBMR)	Texas, USA
2013					
LIU Biao	PhD	Oral Presentation Award 3rd Prize (Postgraduate Research Symposium on Regenerative Medicine)	Toward Targeted Therapy in Advanced Pancreatic Cancer: A Smart Triptolide-Nucleolin Aptamer Conjugate	2013th Academic Exchanges Conference between Guangdong province	Guangzhou, China
LIU Jin	PhD	Oral Presentation Award 2nd Prize (Postgraduate Research Symposium on Regenerative Medicine)	Does age-related increase in CKIP-1 within mesenchymal stem cells associate with age-related impairment in fracture repair ?	Postgraduate Research Symposium on Regenerative Medicine Ministry of Education (MOE) Key Laboratory for Regenerative Medicine, Guangdong-Hong Kong-Macau Synergistic Innovation Center for Tissue Repair and Regeneration	Guangzhou, China

FACULTY STAFF

Faculty Staff

Professor LU Aiping

Dean, School of Chinese Medicine
Dr. Kennedy Y.H. Wong Endowed Chair of Chinese Medicine
Director, Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer & Inflammation Research
Director, Institute for Advancing Translational Medicine in Bone & Joint Diseases
Director, Institute of Integrated Bioinformedicine & Translational Science
Associate Director, Hong Kong Chinese Medicine Clinical Study Centre

Field of expertise

Chinese medicine
Clinical pharmacology
Arthritis and related new drug discovery

Email : aipinglu@hkbu.edu.hk



Professor ZHAO Zhongzhen

Associate Dean, School of Chinese Medicine
Chair Professor, Teaching and Research Division
Director, Research Centre for Standardisation of Chinese Medicines

Field of expertise

Chinese materia medica
Chinese medicinal identification
Traditional medicines in the world

Email : zzzhao@hkbu.edu.hk

Professor BIAN Zhaoxiang

Associate Vice-President, HKBU
Director and Chair Professor, Clinical Division
Director, Hong Kong Chinese Medicine Clinical Study Centre
Associate Director, Institute of Creativity
Associate Director, Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research

Field of expertise

Basic and clinical research of gastrointestinal disease with Chinese medicine

Email : bzxiang@hkbu.edu.hk

Professor LI Min

Director and Professor, Teaching and Research Division
Programme Director, Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science programme
Associate Director, Clinical Division
Director, Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research

Field of expertise

Internal medicine of Chinese medicine
Pharmacology of Chinese medicine
Neurodegenerative diseases
Cardio-cerebrovascular diseases

Email : limin@hkbu.edu.hk

Professor CHEN Hubiao

Professor, Teaching and Research Division
Programme Director, Bachelor of Pharmacy (Hons) in Chinese Medicine programme
Associate Director, Research Centre for Standardisation of Chinese Medicines

Field of expertise

Medicinal botany
Resource science of Chinese medicinal materials

Email : hbchen@hkbu.edu.hk

Professor ZHANG Hongqi

Professor, Teaching and Research Division

Field of expertise

Physiology
Neuroscience
Pathology

Email : hqzhang@hkbu.edu.hk



Dr. ZHANG Ge

Associate Director and Associate Professor, Teaching and Research Division
Director, Technology Development Division
Associate Director, Institute for Advancing Translational Medicine in Bone & Joint Diseases
Associate Director, Institute of Bioinformedicine & Translational Science

Field of expertise

Basic science and clinical translational medicine in orthopedics and traumatology

Email : zhangge@hkbu.edu.hk



Dr. YUE Kin Man, Kevin

Associate Director and Associate Professor, Teaching and Research Division

Field of expertise

Biochemistry
Diabetes

Email : kkmyue@hkbu.edu.hk



Dr. YU Zhiling

Associate Professor, Teaching and Research Division
Associate Director, Technology Development Division
Director, Consun Chinese Medicines Research Centre for Renal Diseases

Field of expertise

Pharmacology of Chinese medicine

Email : zlyu@hkbu.edu.hk



Dr. HAN Quanbin, Simon

Associate Professor, Teaching and Research Division

Field of expertise

Natural product chemistry
Chemical analysis of Chinese herbal medicines
Application of high-speed counter-current chromatography

Email : simonhan@hkbu.edu.hk

Dr. KO Ka Shun, Joshua

Associate Professor, Teaching and Research Division

Field of expertise

Pharmacology
Toxicology
Chemotherapy
Gastroenterology

Email : jksko@hkbu.edu.hk

Dr. YANG Zhijun

Associate Professor, Teaching and Research Division

Field of expertise

Pharmaceutical formulation in Chinese materia medica
Drug delivery system

Email : yzhijun@hkbu.edu.hk

Dr. ZHANG Hongjie

Associate Professor, Teaching and Research Division

Field of expertise

Phytochemistry
Drug discovery from natural resources

Email : zhanghj@hkbu.edu.hk

Dr. ZHANG Shiping

Associate Professor, Teaching and Research Division

Field of expertise

Acupuncture
Neuroscience

Email : spzhang@hkbu.edu.hk

Dr. KWAN Hiu Yee

Assistant Professor, Teaching and Research Division

Field of expertise

Therapeutic mechanisms of Chinese herbal medicines in nonalcoholic fatty liver disease and obesity

Email : hykwan@hkbu.edu.hk

Dr. XU Min

Assistant Professor, Teaching and Research Division

Field of expertise

Internal medicine of Chinese medicine
Neurology

Email : xumin@hkbu.edu.hk

Dr. ZHU Hailong

Assistant Professor, Teaching and Research Division

Field of expertise

Bioinformatics
Computational biology
Systems biology
Big data analytics

Email : hlzhu@hkbu.edu.hk



Dr. JIANG Ming

Principal Lecturer, Teaching and Research Division

Field of expertise

Traditional Chinese medicine classics
Clinical internal Chinese medicine

Email : mjiang@hkbu.edu.hk



Dr. TU Feng

Principal Lecturer, Teaching and Research Division

Field of expertise

Orthopaedics and Traumatology of CM and *Tui Na*

Email : tufeng@hkbu.edu.hk



Dr. XU Gang

Principal Lecturer, Teaching and Research Division

Field of expertise

Digestive surgery
Diabetes

Email : gangxu@hkbu.edu.hk

Dr. DAI Zhaoyu

Senior Lecturer, Teaching and Research Division

Field of expertise

Internal medicine of Chinese medicine
Psycho-physical medicine of Chinese medicine
Traditional Chinese medicine classics

Email : daizhaoyu@hkbu.edu.hk

Dr. ZHANG Qingling

Senior Lecturer, Teaching and Research Division

Field of expertise

Traditional Chinese medicine classics
Clinical internal Chinese medicine

Email : qlzhang@hkbu.edu.hk

Dr. GUO Ping

Lecturer I, Teaching and Research Division

Field of expertise

Chinese materia medica
Authentication of Chinese medicinals

Email : s193231@hkbu.edu.hk

Dr. LI Hong

Lecturer I, Teaching and Research Division

Field of expertise

Acupuncture
Pain and gastrointestinal diseases

Email : lihong@hkbu.edu.hk

Dr. AU-YEUNG Kathy Ka Wai

Research Assistant Professor, Teaching and Research Division

Field of expertise

Investigating the anti-carcinogenic effects of herbal medicinal compounds in both colon cancer and pancreatic cancer

Email : aykathy@hkbu.edu.hk

Dr. DURAIRAJAN Siva Sundara Kumar

Research Assistant Professor, Teaching and Research Division

Field of expertise

Neurodegenerative diseases
Molecular pharmacology
Pharmacology of Chinese medicine

Email : dsskumar@hkbu.edu.hk



Dr. GUO Baosheng

Research Assistant Professor, Teaching and Research Division

Field of expertise

Bone biomechanics
Bone bio-imaging
Bone biology
Muscle atrophy

Email : borisguo@hkbu.edu.hk



Dr. HE Xiaojuan

Research Assistant Professor, Teaching and Research Division

Field of expertise

Immunotherapy of tumor and immune related diseases
Immunopharmacological study on herbal medicines
New drug (herbal product) research and development

Email : hexiaojuan@hkbu.edu.hk



Dr. LI Defang

Research Assistant Professor, Teaching and Research Division

Field of expertise

Anti-tumor and anti-inflammation of Chinese herbal compound, cardiovascular diseases, intervention treatment of Compounds of Chinese Herbs, regulation of miRNA in osteoporosis

Email : lidefang@hkbu.edu.hk

Dr. SONG Juxian

Research Assistant Professor, Teaching and Research Division

Field of expertise

Neurodegenerative diseases
Pharmacology of Chinese medicine
Regulation of autophagy and lysosomal biogenesis

Email : s189721@hkbu.edu.hk

Dr. TSANG Siu Wai

Research Assistant Professor, Teaching and Research Division

Field of expertise

Pathophysiology of pancreatitis, diabetes, different types of cancers, stress-associated colonic hypersensitivity

Email : tsang@hkbu.edu.hk



Dr. TSE Kai Wing Anfernee

Research Assistant Professor, Teaching and Research Division

Field of expertise

Discovery of novel anti-cancer and anti-inflammatory agents from Chinese medicine and food sources
Development of new drug combination strategies of targeted therapies for cancers
Food/drug safety: the role of Ribosome Inactivating Protein from natural products in inflammation

Email : anfernee@hkbu.edu.hk



Dr. YI Tao

Research Assistant Professor, Teaching and Research Division

Field of expertise

Identification and development of medicinal resource
Quality evaluation of TCM
Pharmacodynamic constituents and mechanism of TCM products

Email : yitao@hkbu.edu.hk

Dr. CHUI Chung Hin

Research Assistant Professor, Clinical Division

Field of expertise

Drug delivery and drug discovery in the treatment of cancer, haematological disorder, liver disorder and microbial infection

Email : chchui@hkbu.edu.hk

Dr. LIN Chengyuan

Research Assistant Professor, Clinical Division

Field of expertise

Physiological, cellular and molecular biological studies of gastrointestinal peptides/hormones

Mechanism study on Chinese medicine in the control of gastrointestinal disorders

Email : lincy@hkbu.edu.hk



Dr. ZHONG Li Dan

Research Assistant Professor, Clinical Division

Field of expertise

Chinese medicine clinical assessment and treatment of autoimmune diseases; gynaecology disorders and digestive diseases

Email : ldzhong@hkbu.edu.hk

APPENDICES

List of Major External Research Grants Awarded

Grant	Principle Investigator	Project Title	Project Period (Months)	Approved Amount
AY 2014 - 2015				
GRF/ECS	LI Min	Understanding the molecular mechanisms of Corynoxine B in promoting autophagy and neuroprotection: Targeting HMGB1-Beclin 1 interaction (Ref no: 12100914)	36	HK$564,833
	YANG Zhijun	Immunoliposome delivery triptolide to lung cancer enhanced by Carbonic Anhydrase IX Antibody (Ref no. 12102514)	24	HK$900,000
	ZHANG Ge	Aptamer-functionalized osteoblast-targeting delivery system for osteogenic siRNAs to achieve cell-specific RNA interference for bone anabolic therapy (Ref no: 12102914)	36	HK$1,035,000
	ZHANG Hongjie	Structural Modification and Biological Studies of the Antitumor Natural Products Miliusanes as Novel Cancer Therapeutic Agents (Ref no: 12103014)	36	HK$914,985
	HAN Quanbin	Bio-/chem-equivalence of polysaccharies of G. lucidum and G. sinense evaluated with a novel systematic approach (Ref no.: 22100014)	36	HK$473,589
HMRF	LI Min	Combined Use of Chinese Medicine Decoction (Tianma Gouteng Yin) and Sinemet for the Treatment of Parkinson's Desease: Preclinical Evaluation on Safety and Efficacy (Ref no.: 12132091)	24	HK$999,600
	KWAN Hui Yee	A study to reduce the toxicity of Xanthii Fructus (Ref no.: 12133831)	24	HK$596,600
ITF	DURAIRAJAN Siva Sundara Kumar	Structural Modification of Protopine Alkaloid from the Chinese Herbal medicine Yanhusuo for the Optimization of anti-Alzheimer's Disease Activity (Ref no: ITS/187/13)	18	HK$1,397,000
	DURAIRAJAN Siva Sundara Kumar	Structural Modification of Protopine Alkaloid from the Chinese Herbal Medicine Yanhusuo for the Optimization of anti-Alzheimer's Disease Activity (Ref no: InP/250/14)	18	HK$226,000
	LU Aiping	Toward Targeted Therapy in Advanced Pancreatic Cancer: A Smart Triptolide-Nucleolin Aptamer Conjugate (Ref no: UIM/256)	24	HK$1,170,000
	YU Zhiling	Study on the Processing Standards for Toxic Chinese Materia Medica (Ref no: InP/100/14)	12	HK$353,000
	YU Zhiling	Study on the Processing Standards for Toxic Chinese Materia Medica (Ref no: InP/094/14)	24	HK$353,000
	YU Zhiling	Study on the Processing Standards for Toxic Chinese Materia Medica (Ref no: GHP/030/13)	24	HK$2,380,000
	ZHAO Zhongzhen	Standardisation on the Nomenclatures of Chinese Medicinal Materials and Decoction Pieces Sold in Hong Kong (Ref no: InP/254/14)	14	HK$206,000
Croucher Foundation	LU Aiping	Toward cell-targeted therapeutics in osteosarcoma: A smart Triptolide-aptamer conjugat CAS-Croucher Funding Scheme for Joint Laboratories	36	HK$1,200,000
NSFC	GUAN Yifu	Design, diversity-oriented synthesis and anti-HIV activity evaluation of Litseane-like library	36	CNY 250,000
	GUO BaoSheng	Molecular Mechanism for Bone Formation Reduction During Aging: Functional Role of Plekho1 in Regulating BMP Signaling	36	CNY 230,000
	HAN Quanbin	Comparison of chemistry and bioactivities of Gannoderma polysaccharides	48	CNY 730,000
	TSANG Siu Wai	Eruberin A suppresses the activation of pancreatic stellate cells and chronic pancreatitis via down regulating sonic hedgehog signaling	36	CNY 230,000
	YU Hua	Feasibility of three species of Siegesbeckiae Herba as one herbal medicine : Chemical and biological evaluations	48	CNY 760,000

Notes

SZSTI: Funding schemes under Science, Technology and Innovation Commission of Shenzhen; **NSFC/RGC:** National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme; **NSFC:** Funding schemes under National Natural Science Foundation of China; **ITF:** Innovation and Technology Fund; **HMRF:** Health and Medical Research Fund; **GRF:** General Research Fund; **ECS**: Early Career Scheme; **GDNSF:** Funding schemes under Guangdong Province Natural Science Foundation

Grant	Principle Investigator	Project Title	Project Period (Months)	Approved Amount
SZSTI	BIAN Zhaoxiang	Investigation of the active components of Ma Zi Ren Wan in treating constipation	24	CNY 330,000
	GUO BaoSheng	Role of Plekho1 in Regulating BMP Signaling for Bone Formation Reduction During Aging	24	CNY 300,000
	LI Min	Study on the Neuroprotection of Corynoxine in Parkinson's disease and the Phosphoprotein Regulatory Network of Corynoxine-induced Neuronal Autophagy	24	CNY 500,000
	YU Zhiling	Investigation of the molecular mechanisms for the anti-coloractal cancer effects of Ampelopsis Radix	24	CNY 300,000
	ZHANG Ge	The molecular mechanism of aged-related bone loss during osteoporosis: osteoclastic miR-214 regulates the activity of osteoblasts	36	CNY 300,000
GDNSF	YI Tao	Development a targeted separation platform using functionalized magnetic nanoparticles for discovery of anti-inflammatory components from Xuelianhua	36	CNY 100,000
AY 2013 - 2014				
GRF	KWAN Hiu Yee	Antiobesity Effect of Cinnamon (Ref no: 260613)	24	HKD 504,065
	LU Aiping	Understanding the molecular mechanism in failure of osteoblast-mediated repair for articular bone erosion during progressive rheumatoid arthritis: Role of casein kinase-2 interacting protein-1 in controlling osteoblast function (Ref no: 261113)	24	HKD 606,223
	HSIAO Wendy	ERIC-PCR and pyrosequencing analysis of the impact of Gynostemma saponins on gut microflora compositions and the host disease status in Apcmin/+ mice (Ref no:260413)	24	HKD 770,769
HMRF	DURAIRAJAN Siva Sundara Kumar	An in vivo investigation of the therapeutic effects of modified Huang-Lian-Jie-Du-Tang and its combination with a Western drug memantine in Alzheimer's disease (Ref no: 11122511)	24	HKD 904,000
	HAN Quanbin	The clinical potential of Astragalus polysaccharide in cancer therapy via synergism with antitumor drugs (Ref no: 11122531)	24	HKD 994,800
	TSE Kai Wing	Evaluation and Characterization of the Inflammatory Properties of Ribosome Inactivating Protein Momorcharin derived from Momordica charantia (bitter melon) (Ref no: 11122441)	27	HKD 825,600
	YU Zhiling	Evaluation of the chronic toxicity of a commonly used Chinese medicinal herb Siegesbeckiae Herba (Ref no: 11122521)	24	HKD 850,000
ITF	LI Min	Chemical Modification of Oxindole Alkaloids from the Chinese Herbal Medicine Gouteng for the Optimization of anti-Parkinson's Disease Activity (Ref no: ITS/274/12)	22	HKD 1,000,000
	LI Min	Chemical Modification of Oxindole Alkaloids from the Chinese Herbal Medicine Gouteng for the Optimization of anti-Parkinson's Disease Activity (Ref no: InP/322/13)	13	HKD 197,000
	ZHAO Zhongzhen	Standardization on the Nomenclatures of Chinese Medicinal Materials and Decoction Pieces Sold in Hong Kong (Ref no: ITS/185/13FX)	18	HKD 416,000
	ZHAO Zhongzhen	Standardization on the Nomenclatures of Chinese Medicinal Materials and Decoction Pieces Sold in Hong Kong (Ref no: InP/083/14)	16	HKD 237,000
	ZHAO Zhongzhen	Heritage and Innovation of Chinese Medicine (Ref no: GSP/021/14)	8.5	HKD 653,000
	ZHAO Zhongzhen	Exhibition at InnoCarnival 2013: "Marching Towards Modern Chinese Medicine: Conservation of Rare Chinese Medicines Resources and Exhibition of Modern Chinese Medicine (Ref no: GSP/018/13)	7.5	HKD 644,000

Notes

SZSTI: Funding schemes under Science, Technology and Innovation Commission of Shenzhen; **NSFC/RGC:** National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme; **NSFC:** Funding schemes under National Natural Science Foundation of China; **ITF:** Innovation and Technology Fund; **HMRF:** Health and Medical Research Fund; **GRF:** General Research Fund; **ECS**: Early Career Scheme; **GDNSF:** Funding schemes under Guangdong Province Natural Science Foundation

Grant	Principle Investigator	Project Title	Project Period (Months)	Approved Amount
Hospital Authority	LU Aiping & BIAN Zhaoxiang	The Development of Chinese Medicine Clinical Practice Guidelines in Hong Kong	24	HKD 444,320
Ministry of Science and Technology of the People's Republic of China	LU Aiping	Research and development of aptamer-triptolide conjugate for treatment of rheumatoid arthritis	36	CNY 1,500,000
NSFC	LIANG Zhitao	Scientific elucidation of macroscopic identification of Bupleuri Radix by profiling tissue-specific chemicals	36	CNY 230,000
	YU Shan	The effect of nuclear receptors LRH-1 on the castration antagonistic androgen synthesis in prostate tumor and its study as new therapeutic targets for prostate cancer	36	CNY 230,000
AY 2012 - 2013				
GRF	LEUNG Fung Ping	Theaflavins ameliorate endothelial dysfunction in estrogen deficiency through PPARδ activation (Ref no: 260712)	30	HKD 850,000
	TAI William	Functions of Dickkopf-3 (Dkk3) in ovarian carcinoma tumorigenesis and metastasis (Ref no: 261512)	30	HKD 920,000
	YU Zhiling	Evaluation of the anti-melanoma action of sesquiterpenes isolated from a traditional Chinese medicinal herb Atractylodis Macrocephalae Rhizoma (Ref no: 262512)	24	HKD 707,908
	ZHANG Ge	Toward a novel bone anabolic strategy for aged postmenopausal osteoporosis: Inhibiting miR-214 in osteogenic cells for promoting bone formation (Ref no: 478312)	36	HKD 1,098,250
	ZHANG Hongjie	Discovery of Aryl Naphthalide Lignans as Potential Anti-HIV Inhibitors from the Medicinal Plant Justicia gendarussa (Ref no: 262912)	36	HKD 1,268,250
	ZHAO Zhongzhen	Laser Microdissection Analysis: Linking morphology and biochemistry to assess the quality of Chinese medicinal materials (Ref no.: 263412)	24	HKD 843,720
NSFC/RGC	ZHANG Ge	Skeletal role of CK2-interating Protein-1 in Regulating Osteoblastic Bone Formation: Molecular Mechanism and Reversing Osteporosis (Ref no: N_HKBU435/12)	48	HKD 753,925
HMRF	BIAN Zhaoxiang	Chinese Herbal Medicine (MaZiREnWan) for functional constipation: a prospective, double-blinded, double-dummy, randomized, controlled study (Ref no: 9101501)	24	HKD 996,600
ITF	HSIAO Wendy	Living a Modern Healthy Life with Traditional Chinese Medicine (Ref no: GSP/012/12)	6	HKD 650,000
	YU Zhiling	Standardization of the Vinegar for Processing Chinese Materia Medica (Ref no: UIM/238)	24	HKD 1,294,000
	ZHANG Hongjie	In Vivo Evaluation of Antitumor Efficacy of Plant-Derived Novel Natural Products Miliusanes (Ref no: InP/249/12)	6	HKD 151,000
	ZHANG Hongjie	In Vivo Evaluation of Antitumor Efficacy of Plant-Derived Novel Natural Products Miliusanes (Ref no: InP/250/12)	18	HKD 245,000
	ZHANG Hongjie	In Vivo Evaluation of Antitumor Efficacy of Plant-Derived Novel Natural Products Miliusanes (Ref no: ITS/131/12)	18	HKD 965,000

Notes

SZSTI: Funding schemes under Science, Technology and Innovation Commission of Shenzhen; **NSFC/RGC:** National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme; **NSFC:** Funding schemes under National Natural Science Foundation of China; **ITF:** Innovation and Technology Fund; **HMRF:** Health and Medical Research Fund; **GRF:** General Research Fund; **ECS**: Early Career Scheme; **GDNSF:** Funding schemes under Guangdong Province Natural Science Foundation

Grant	Principle Investigator	Project Title	Project Period (Months)	Approved Amount
Hong Kong Jockey Club Charities Ltd.	YU Zhiling	Establishment of a Research & Development Laboratory for Testing Chinese Medicines	24	HKD 2,000,000
NSFC	ZHANG Ge	Study on molecular mechanism of bone formation reduction in aged women: Functional role of CKIP-1	48	CNY 700,000
SZSTI	YU Zhiling	Investigation of the anti-inflammatory effects and the underlying mechanism of action of a herbal formula comprising Rosae Multiflorae Fructus and Lonicerae Japonicae Flos	24	CNY 200,000
	ZHANG Ge	Study on molecular mechanism of bone formation reduction in aged women: Functional role of CKIP-1	48	CNY 500,000
	ZHANG Ge	Establishing the bridge for translating cell-specific RNA interference to bone anabolic therapy: An aptamer functionalized osteoblast-targeting delivery system for osteogenic siRNAs	24	CNY 300,000
AY 2011 - 2012				
GRF	CHEN Hubiao	Active Components Screening and Metabolism Study of Tibetan “Xuelianhua” (Saussurea laniceps) (Ref no: 260111)	24	HKD 653,060
	ZHANG Ge	Therapeutic RNAi targeting CKIP-1 to reverse severe postmenopausal osteoporosis (Ref no: 479111)	33	HKD 800,000
NSFC/RGC	LI Min	Functional Analysis of Corynoxine B in Promoting Autophagy and Protecting Neurons (Ref no: N_HKBU213/11)	36	HKD 914,066
HMRF	BIAN Zhaoxiang	Effects of combination of Berberine and 5-Aminosalicylate (5-ASA) against experimental ulcreative colitis and its potential mechanisms (Ref no: 10111971)	36	HKD 972,280
ITF	YU Zhiling	Pharmacological Studies for Developing Qian-wang-hong-bai-san as a Modern Therapeutic Agent against Skin Hyperpigmentary Disorders (Ref no: InP/093/12)	18	HKD 227,000
	YU Zhiling	Pharmacological Studies for Developing Qian-wang-hong-bai-san as a Modern Therapeutic Agent against Skin Hyperpigmentary Disorders (Ref no: InP/094/12)	16	HKD 264,000
	YU Zhiling	Pharmacological Studies for Developing Qian-wang-hong-bai-san as a Modern Therapeutic Agent against Skin Hyperpigmentary Disorders (Ref no: ITS/235/11)	18	HKD 604,000
	YU Zhiling	Platform Development for Quality Control Standards of Processed Chinese Materia Medica (Decoction Pieces) in the HK Market (Ref no: ITS/196/11FP)	12	HKD 2,444,000
AY 2010 - 2011				
GRF	BIAN Zhaoxiang	Nerve growth factor-mediated enteric neuronal plasticity contributes to neonatal maternal separation-induced visceral hyperalgesia in rats (Ref no: 260010)	24	HKD 800,000
	LIU Liang	Identification of novel small molecule binding sites of IkB kinase-beta (IKK-beta)as a new technical platform for anti-inflammatory and anti-cancer drug discovery (Ref no: 261010)	30	HKD 900,000
HMRF	LI Min	The effect of Chinese Herbal Medicine (JiaWeiLiuJunZiTang) on Non-motor Symptoms in Idiopathic Parkinson's Diseases (PD): A Randomized Controlled Trial (Ref no: 809111)	27	HKD 586,380
ITF	HSIAO Wendy	Traditional Chinese Medicine for Modern Life: Production of HKBU School of Chinese Medicine’s Booth for InnoCarnival 2011	4	HKD 650,000

Notes

SZSTI: Funding schemes under Science, Technology and Innovation Commission of Shenzhen; **NSFC/RGC:** National Natural Science Foundation of China (NSFC) / RGC Joint Research Scheme; **NSFC:** Funding schemes under National Natural Science Foundation of China; **ITF:** Innovation and Technology Fund; **HMRF:** Health and Medical Research Fund; **GRF:** General Research Fund; **ECS**: Early Career Scheme; **GDNSF:** Funding schemes under Guangdong Province Natural Science Foundation

List of Patents Granted

Name of Invention	Inventor(s)	Jurisdiction	Patent No.	Issue Date
2015				
Anti-Cancer Agents Synthesized Based on Miliusane Compounds	ZHANG Hongjie	United States	US 9,211,333	15 December 2015
Oxanorbornadiene Derivatives and Their Anticancer Activities	BIAN Zhaoxiang LIN Chengyuan FAN Baomin MU Huaixue ZHOU Yongyun ZENG Weimin LU Aiping CHAN Sun Chi Albert	United States	US 9,120,816	1 September 2015
A Chinese Medicinal Formulation For Treating Inflammatory Bowel Disease And The Preparation Thereof	BIAN Zhaoxiang TSANG Siu Wai IP Siu Po WU Che Yuen Justin LU Aiping CHAN Sun Chi Albert	United States	US 9,044,502	2 June 2015
Pharmaceutical Composition and Methods for Modulating Immune System, Preventing, Pretreating and/or Treating Cancers	HAN Quanbin	United States	US 9,005,676	14 April 2015
A Quality Control Marker and Its Use in Herbs Authentication	HAN Quanbin CHEN Hubiao XU Jun	United States	US 8,999,719 B2	7 April 2015
2014				
Asymmetric Synthesis of Norcantharidin Analogues by Alkynylation of Oxabenzonorbornadienes and Their Anticancer Activities	CHAN Sun Chi Albert FAN Baomin WANG Jun LIN Chengyuan HUANG Chao YANG Qingjing XU Jianbin BIAN Zhaoxiang LU Aiping HU Jun	United States	US 8,835,658 B2	16 September 2014
Novel Formulation of Dehydrated Lipid Vesicles for Controlled Release of Active Pharmaceutical Ingredient via Inhalation	YANG Zhijun HUANG Wenhua WONG Chi Sun ZHAO Zhongzhen	China	ZL 210952.0	16 April 2014
Method of Using Rhein for Treating Fibrotic Conditions and Tumors	BIAN Zhaoxiang TSANG Siu Wai LU Aiping XIAO Haitao QIN Hongyan CHAN Sun Chi Albert XU Hongxi CHEN Shilin YANG Dajian	United States	US 52,540B2	18 February 2014
2012				
Chemical Preparation of a New Ginsenoside Dihydroginsenoside Rg2 and its Application	JIANG Zhihong	China	ZL 0175442.X	1 November 2012
2011				
A Fish Feed Containing Traditional Chinese Herbs for the Prevention of Enteritis in Grass Carps	WONG Ming Hung CHOI Wai Ming MO Wing Yin BIAN Zhaoxiang MAK Nai Ki GUO Yicong WU Shengchun	Hong Kong	HK 1146782	7 August 2011

List of Patents Filed

Name of Invention	Inventor(s)	Jurisdiction	Application No.	Filing Date
2015				
Synthesis of Autophagy Inducing Compound and the Uses thereof	LI Min SONG Juxian LIU Liangfeng ZHANG Hongjie	United States	14/927,483	30 October 2015
Anticancer Miliusane Derivatives	ZHANG Hongjie	United States	14/927,485	30 October 2015
Controlled-release dosage form of subcutaneous injection for lowering blood glucose level	YANG Zhijun BIAN Zhaoxiang LU Aiping WONG Chi Kwan Blenda CHEN Xiaoyu	United States	14/783,433	9 October 2015
Long-Acting Controlled-Release Liposome Gel Composition	YANG Zhijun LU Aiping BIAN Zhaoxiang CHEN Xiaoyu WONG Chi Kwan Blenda	Hong Kong	15109333	23 September 2015
Herbal Formulation for skin care	YU Zhiling YU Hua	Taiwan	104127120	20 August 2015
Compound for Inhibiting Syk Activity	XU Hongxi LV Yue FU Wenwei CHEN Kaixian BIAN Zhaoxiang CHEN Shilin YANG Dajian LU Aiping CHAN Sun Chi Albert	United States	14/824,762	12 August 2015
Chinese medicinal formulation for treating inflammatory bowel disease and the preparation thereof	BIAN Zhaoxiang TSANG Siu Wai IP Siu Po WU Che Yuen Justin LU Aiping CHAN Sun Chi Albert	Hong Kong	15107247.9	29 July 2015
Lignans Isolated from Lasiaspinosa (L.) Thwait Suppressed Metastatic Oesophageal Carcinoma Cell Migration and Invasion in Vitro.	BIAN Zhaoxiang MU Huaixue LIN Chengyuan XU Hongxi YANG Dajian CHEN Shilin LU Aiping CHAN Sun Chi Albert	United States	62/183,726	23 June 2015
The Study on an Bioactivity Evaluation of Crude Extraction from Lasiaspinosa (L.) Thwait and Its main Compounds.	BIAN Zhaoxiang MU Huaixue LIN Chengyuan XU Hongxi YANG Dajian CHEN Shilin LU Aiping CHAN Sun Chi Albert	United States	62/183,728	23 June 2015
Bioactivity Evaluation of Crude Extraction from Lasia spinosa (L.) Thwait and Its main Compounds	BIAN Zhaoxiang MU Huaixue LIN Chengyuan WANG Jinjin YANG Zhijun LU Aiping CHAN Sun Chi Albert	United States	62/183,729	23 June 2015

Name of Invention	Inventor(s)	Jurisdiction	Application No.	Filing Date
Pb-Id for Treating Inflammation	BIAN Zhaoxiang MU Huaixue LIN Chengyuan HAN Quanbin LU Aiping HUANG Linfang CHEN Shilin YANG Dajian XU Hongxi CHAN Sun Chi Albert	United States	14/742,727	18 June 2015
Palladium/Silver Co-Catalyzed Tandem Reactions Synthesis of Phenylacetophenone Derivatives by Oxabenzonorbornadienes with Terminal Alkynes and Their Anti-Tumor or Anti-Cancer Activities	BIAN Zhaoxiang LIN Chengyuan MU Huaixue FAN Baomin ZHOU Yongyun CHEN Jingchao LU Aiping CHAN Sun Chi Albert	United States	14/743,209	18 June 2015
Method of Using Dihydro-resveratrol for Treating Acute Pancreatitis and Associated Pulmonary Injury	BIAN Zhaoxiang TSANG Sui Wai ZHANG HongJie LU Aiping CHAN Sun Chi Albert	United States	14/740,410	16 June 2015
Quality control marker and its use in herbs authentication	HAN Quanbin CHEN Hubiao XU Jun	Hong Kong	15104833.6	21 May 2015
Usage of Guttiferone K, A Natural Compound from Garcinia Yunnanensis Hu on Treating High Metastatic Cancer	XU Hongxi LAO Yuanzhi XI Zhichao TAN Hongsheng CHEN Kaixian BIAN Zhaoxiang YANG Dajian CHEN Shilin LU Aiping CHAN Sun Chi Albert	United States	14/701,529	1 May 2015
Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells	BIAN Zhaoxiang TSANG Siu Wai ZHANG Hongjie CHEN Yegao CHAN Sun Chi Albert LU Aiping XU Hongxi CHEN Shilin YANG Dajian	Hong Kong	15102549.5	12 March 2015
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	LI Min SONG Juxian ZEND Yu LIU Liangfeng	International Procedure	PCT/ CN2015/073764	6 March 2015
A mTOR-independent Activator of TFEB for Autophagy Enhancement and Uses thereof	LI Min SONG Juxian ZEND Yu LIU Liangfeng	United States	14/609,438	30 January 2015
Composition Comprising Rhizoma Coptidis, Cortex Pellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	LI Min DURAIRAJAN Siva Sundara Kumar LIU Liangfeng SONG Juxian CHEN Leilei	Hong Kong	15100686.2	21 January 2015
2014				
Anticancer Maytansinoids with Taiwano Fused Macrocyclic Rings	SOEJARTO Djaja Deol FONG H.S. Harry ZHANG Hongjie	International Procedure	PCT/ CN2014/092834	2 December 2014
Use of Herbal Saponins to Regulate Gut Microflora	HSIAO Wen Luan Wendy CHEN Lei	International Procedure	PCT/ CN2014/090255	4 November 2014

Name of Invention	Inventor(s)	Jurisdiction	Application No.	Filing Date
Controlled-release dosage form of subcutaneous injection for lowering blood glucose level	YANG Zhijun BIAN Zhaoxiang LU Aiping WONG Chi Kwan Blenda CHEN Xiaoyu	International Procedure	PCT/ CN2014/088958	20 October 2014
Aryl Naphthalide Lignans As anti-HIV Agents	RONG Lijun FONG H.S. Harry Zhang Hongjie SOEJARTO Djaja Doel RUMSCHLAG-BOOMS Emily	Hong Kong	14109999.6	7 October 2014
Herbal Formulation for skin care	YU Hua YU Zhiling	China	201410417672.2	22 August 2014
Anti-cervical Cancer Compound and Method of Use Thereof	LIN Chengyuan BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Kaixian CHEN Shilin LAO Yuanzhi LU Aiping YANG Dajian ZHANG Hong WANG Xiaoyu	United States	14/449,132	31 July 2014
Anti-Prostate Cancer Compound and Method of Use Thereof	LI Xin TAN Hongsheng BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Kaixian CHEN Shilin LAO Yuanzhi LU Aiping YANG Dajian ZHANG Hong WANG Xiaoyu	United States	14/333,524	17 July 2014
Quality Control Marker and Its Use in Herbs Authentication	XU Jun CHEN Hubiao HAN Quanbin	China	201410330544.4	11 July 2014
Composition Comprising Rhizoma Coptidis, Cortex Pellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	LI Min CHEN Leilei DURAIRAJAN Siva Sundara Kumar LIU Liangfeng SONG Juxian	China	201410265207.1	13 June 2014
Composition Comprising Rhizoma Coptidis, Cortex Pellodendri and Fructus Gardeniae and For Treating Neurodegenerative Diseases	LI Min DURAIRAJAN Siva Sundara Kumar LIU Liangfeng SONG Juxian CHEN Leilei	United States	14/303,622	13 June 2014
Use of Herbal Saponins to Regulate Gut Microflora	HSIAO Wen Luan Wendy CHEN Lei	United States	14/290,148	29 May 2014
Bioactive Fractions and Compounds from Polygonum Genus, Their Use in Anti-diarrhea and The Method of Preparation	BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Shilin LU Aiping XIAO Haitao YANG Dajian	Hong Kong	14104756.0	21 May 2014

Name of Invention	Inventor(s)	Jurisdiction	Application No.	Filing Date
Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells	BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Shilin TSANG Siu Wai CHEN Yegao LU Aiping YANG Dajian ZHANG Hongjie	China	201410210304.0	19 May 2014
A Chinese Medicinal Formulation for Treating Inflammatory Bowel Disease and the Preparation Thereof	BIAN Zhaoxiang CHAN Sun Chi Albert TSANG Siu Wai LU Aiping WU Che Yuen Justin IP Siu Po	China	201410173979.2	28 April 2014
Herbal Composition for Skin-Whitening and Anti-Skin-Aging, Method of Preparation and the Use thereof	YU Hua YU Zhiling	United States	14/191,470	27 February 2014
Controlled-release dosage form of subcutaneous injection for lowering blood glucose level	YANG Zhijun BIAN Zhaoxiang LU Aiping WONG Chi Kwan Blenda CHEN Xiaoyu	China	201410055853.5	19 February 2014
Melanogenesis Effect of Total Saponins of Gynostemma Pentaphyllum	HSIAO Wen Luan Wendy TSANG Ting Fung	United States	14/165,560	27 January 2014
Usage of Oblongifolin C, a Natural Compound from Garcinia yunnanensis Hu, on Treating Cancer as Metastatic Inhibitor and Autophagic Flux Inhibitor	TAN Hongsheng BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Kaixian CHEN Shilin LAO Yuanzhi LU Aiping YANG Dajian WANG Xiaoyu XU Naihan LIU Zhenyan	United States	14/151,792	9 January 2014
Usage of Sodium Houttuyfonate on Inhibiting Idiopathic Pulmonary Fibrosis and Bleomycin Induced Pulmonary Fibrosis	LIN Chengyuan SHEN Yunhui BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Kaixian CHEN Shilin LAO Yuanzhi LU Aiping YANG Dajian	United States	14/149,823	8 January 2014
2013				
New Triptolide Derivatives, Their Preparation Method and Uses	LU Jun LU Cheng LU Aiping LIU Biao WANG Cheng ZHANG Ge	International Procedure	PCT/ CN2013/001551	11 December 2013
New Triptolide Derivatives, Their Preparation Method and Uses	LU Jun LU Cheng LU Aiping LIU Biao WANG Cheng ZHANG Ge	China	201380002841.X	11 December 2013
Anti-cancer and Anti-obesity Cyclic Peptide Agents	ZHANG Hongjie	International Procedure	PCT/ CN2013/085301	16 October 2013
Anti-cancer and Anti-obesity Cyclic Peptide Agents	ZHANG Hongjie	Taiwan	102137118	15 October 2013

Name of Invention	Inventor(s)	Jurisdiction	Application No.	Filing Date
Bioactive Fractions and Compounds from Polygonum Genus, Their Use in Anti-diarrhea and The Method of Preparation	BIAN Zhaoxiang CHAN Sun Chi AlbertXU Hongxi CHEN Shilin LU Aiping XIAO Haitao YANG Dajian	China	201310240061.0	17 June 2013
Anti-cancer and Anti-obesity Cyclic Peptide Agents	ZHANG Hongjie	China	201380048848.5	16 June 2013
Anti-cancer and Anti-obesity Cyclic Peptide Agents	ZHANG Hongjie	European Procedure	13846540.6	16 June 2013
Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells	BIAN Zhaoxiang CHAN Sun Chi Albert XU Hongxi CHEN Shilin TSANG Siu Wai CHEN Yegao LU Aiping YANG Dajian ZHANG Hongjie	United States	13/899,713	22 May 2013
Anti-cancer and Anti-obesity Cyclic Peptide Agents	ZHANG Hongjie	United States	13/804,276	14 March 2013
Herbal Composition for Skin-Whitening and Anti-Skin-Aging, Method of Preparation and the Use thereof	YU Hua YU Zhiling	China	201310063194.5	28 February 2013
2012				
Autophagy Inducing Compound and the Uses thereof	LI Min LU Jiahong DURAIRAJAN Siva Sundara Kumar LIU Liangfeng SONG Juxian	China	201280014006.3	22 March 2012
Autophagy Inducing Compound and the Uses thereof	LI Min LU Jiahong DURAIRAJAN Siva Sundara Kumar LIU Liangfeng SONG Juxian	Hong Kong	14107306.8	22 March 2012
Aryl Naphthalide Lignans As anti-HIV Agents	RONG Lijun FONG H.S. Harry ZHANG Hongjie SOEJARTO Djaja Doel RUMSCHLAG-BOOMS Emily	China	201280048097.2	27 July 2012

List of Publications

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
2014-2015		
Research Paper		
A Chinese medicinal formulation ameliorates dextran sulfate sodium-induced experimental colitis by suppressing the activity of nuclear factor-kappaB signaling. *J Ethnopharmacol*. 2015 Mar 13;162:20-30.	TSANG SW, IP SP, WU JC, NG SC, YUNG KK, BIAN ZX	2.998
A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice. *Lipids Health Dis*. 2015 Aug 25;14(1):93.	CHU ZS, YU ZL, PAN SY, JIA ZH, WANG XY, ZHANG Y, ZHU PL, WANG XJ, KO KM	2.219
A comparative tissue-specific metabolite analysis and determination of protodioscin content in Asparagus species used in traditional Chinese medicine and Ayurveda by use of laser microdissection, UHPLC-QTOF/MS and LC-MS/MS. *Phytochem Anal*. 2014 Nov-Dec;25(6):514-28.	JAISWAL Y, LIANG Z, HO A, CHEN H, ZHAO Z	2.341
A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. *Biomaterials*. 2015 Jun;52:148-60.	LIU J, DANG L, LI D, LIANG C, HE X, WU H, QIAN A, YANG Z, AU DW, CHIANG MW, ZHANG BT, HAN Q, YUE KK, ZHANG H, LV C, PAN X, XU J, BIAN Z, SHANG P, TAN W, LIANG Z, GUO B, LU A, ZHANG G	8.557
A herbal formula comprising Rosae Multiflorae Fructus and Lonicerae Japonicae Flos inhibits the production of inflammatory mediators and the IRAK-1/TAK1 and TBK1/IRF3 pathways in RAW 264.7 and THP-1 cells. *J Ethnopharmacol*. 2015 Nov 4;174:195-9. Epub 2015 Aug 20. [Epub ahead of print]	CHENG BC, HUA YU, TAO SU, FU XQ, GUO H, TING LI, CAO HH, TSE KW, KWAN HY, YU ZL	2.998
A novel and rapid HPGPC-based strategy for quality control of saccharide-dominant herbal materials: Dendrobium officinale, a case study. *Anal Bioanal Chem*. 2014 Oct;406(25):6409-17.	XU J, LI SL, YUE RQ, KO CH, HU JM, LIU J, HO HM, YI T, ZHAO ZZ, ZHOU J, LEUNG PC, CHEN HB, HAN QB	3.436
A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition, *Autophagy*, [accepted]	SONG JX, SUN YR, PELUSO I, ZENG Y, YU X, LU JH, XU Z, WANG MZ, LIU LF, HUANG YY, CHEN LL, DURAIRAJAN SSK, ZHANG HJ, ZHOU B, ZHANG HQ, LU A, BALLABIO A, MEDINA DL, GUO Z, LI M	11.753
A ruthenium(II) complex as turn-on Cu(II) luminescent sensor based on oxidative cyclization mechanism and its application in vivo. *Sci Rep*. 2015 Feb 2;5:8172.	ZHANG Y, LIU Z, YANG K, ZHANG Y, XU Y, LI H, WANG C, LU A, SUN S	5.578
Activation of transient receptor potential vanilloid 3 channel suppresses adipogenesis. *Endocrinology*. 2015 Jun;156(6):2074-86.	CHEUNG SY, HUANG Y, KWAN HY, CHUNG HY, YAO X	4.503
Acupuncture for refractory epilepsy: role of thalamus. *Evid Based Complement Alternat Med*. 2014;2014:950631.	CHEN SP, WANG SB, RONG PJ, LIU JL, ZHANG HQ, ZHANG JL	1.880
Anti-fibrotic and anti-tumorigenic effects of rhein, a natural anthraquinone derivative, in mammalian stellate and carcinoma cells. *Phytother Res*. 2015 Mar;29(3):407-14.	TSANG SW, BIAN ZX	2.660
Anti-fibrotic effect of trans-resveratrol on pancreatic stellate cells. *Biomed Pharmacother*. 2015 Apr;71:91-7.	TSANG SW, ZHANG H, LIN Z, MU H, BIAN ZX	2.023
Anti-fibrotic effects of phenolic compounds on pancreatic stellate cells. *BMC Complement Altern Med*. 2015 Jul 30;15:259.	LIN Z, ZHENG LC, ZHANG HJ, TSANG SW, BIAN ZX	2.020
Anti-influenza virus effects of crude phenylethanoid glycosides isolated from ligustrum purpurascens via inducing endogenous interferon-γ. *J Ethnopharmacol*.2016 Feb 17;179:128-36. Epub 2015 Jul 17.[Epub ahead of print]	HU XP, SHAO MM, SONG X, WU XL, QI L, ZHENG K, FAN L, LIAO CH, LI CY, HE J, HU YJ, WU HQ, LI SH, ZHANG J, ZHANG FX, HE ZD	2.998
Apigenin Attenuates Atherogenesis through Inducing Macrophage Apoptosis via Inhibition of AKT Ser473 Phosphorylation and Downregulation of Plasminogen Activator Inhibitor-2. *Oxid Med Cell Longev*. 2015;2015:379538.	ZENG P, LIU B, WANG Q, FAN Q, DIAO JX, TANG J, FU XQ, SUN XG	3.516

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Application of microscopy technique and high performance liquid chromatography for quality assessment of Polygonum multiflorum Thunb. (Heshouwu). *Pharmacogn Mag*. 2014 Oct;10(40):415-21.	LIANG L, ZHAO Z, KANG T	1.256
Application of microscopy technique and high-performance liquid chromatography for quality assessment of the flower bud of Tussilago farfara L. (Kuandonghua). *Pharmacogn Mag*. 2015 Jul-Sep;11(43):594-600.	LI D, LIANG L, ZHANG J, KANG T	1.256
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. *NATURE MEDICINE*. 2015 Mar;21(3):288-94.	LIANG C, GUO B, WU H, SHAO N, LI D, LIU J, DANG L, WANG C, LI H, LI S, LAU WK, CAO Y, YANG Z, LU C, HE X, AU DW, PAN X, ZHANG BT, LU C, ZHANG H, YUE K, QIAN A, SHANG P, XU J, XIAO L, BIAN Z, TAN W, LIANG Z, HE F, ZHANG L, LU A, ZHANG G	28.223
Astragalus saponins modulates colon cancer development by regulating calpain-mediated glucose-regulated protein expression. *BMC Complement Altern Med*. 2014 Oct 15;14:401.	WANG Y, AU YEUNG KK, ZHANG X, KO JK	2.020
Autophagic effects of Chaihu (dried roots of Bupleurum Chinense DC or Bupleurum scorzoneraefolium WILD). *Chin Med*. 2014 Sep 11;9:21.	LAW BY, MO JF, WONG VK	1.490
Black tea protects against hypertension-associated endothelial dysfunction through alleviation of endoplasmic reticulum stress. *Sci Rep*. 2015 May 15;5:10340.	CHEANG SW, NGAI CY, TAM YY, TIAN XY, WONG WT, ZHANG Y, LAU CW, CHEN ZY, BIAN ZX, HUANG Y, LEUNG PF	5.578
Chemical differentiation and quality evaluation of commercial Asian and American ginsengs based on a UHPLC-QTOF/MS/MS metabolomics approach. *Phytochem Anal*. 2015 Mar-Apr;26(2):145-60.	CHEN Y, ZHAO Z, CHEN H, YI T, QIN M, LIANG Z	2.341
Chronic black tea extract consumption improves endothelial function in ovariectomized rats. *Eur J Nutr*. 2015 Aug 15. [Epub ahead of print]	LEUNG FP, YUNG LM, NGAI CY, CHEANG WS, TIAN XY, LAU CW, ZHANG Y, LIU J, CHEN ZY, BIAN ZX, YAO X, HUANG Y	3.467
Clinical observation on treating neurotoxic side effects from chemotherapy by acupuncture therapy plus the Tongbi decoction. *Clinical Journal of Chinese Medicine*.2014;6(34):36-37.	LIU YL	--
Combinational Treatment of Curcumin and Quercetin against Gastric Cancer MGC-803 Cells in Vitro. *Molecules*. 2015 Jun 22;20(6):11524-34.	ZHANG JY, LIN MT, ZHOU MJ, YI T, TANG YN, TANG SL, YANG ZJ, ZHAO ZZ, CHEN HB	2.416
Combined Salvianolic Acid B and Ginsenoside Rg1 Exerts Cardioprotection against Ischemia/Reperfusion Injury in Rats. *PLoS One*. 2015 Aug 17;10(8):e0135435.	DENG Y, YANG M, XU F, ZHANG Q, ZHAO Q, YU H, LI D, ZHANG G, LU A, CHO K, TENG F, WU P, WANG L, WU W, LIU X, GUO DA, JIANG B	3.234
Comparative analysis of EPA and DHA in fish oil nutritional capsules by GC-MS. *Lipids Health Dis*. 2014 Dec 13;13:190.	YI T, LI SM, FAN JY, FAN LL, ZHANG ZF, LUO P, ZHANG XJ, WANG JG, ZHU L, ZHAO ZZ, CHEN HB	2.219
Comparative researches on the pharmacodynamic effects between Radix Paeoniae Rubra and Radix Paeoniae Alba, *Hong Kong Journal of Traditional Chinese Medicine*, 2014;9(4)pp.49-53.	XU W, XU M, CHOW CI, CHOW Y, TIAN XY, LAN JY, XIA Q, LIN JL	--
Comparison of the methods for generating single-stranded DNA in SELEX. *Analyst*. 2015 May 21;140(10):3439-44.	LIANG C, LI D, ZHANG GX, LI H, SHAO N, LIANG Z, ZHANG L, LU A, ZHANG G	4.107
Comparisons of the chemical profiles, cytotoxicities and anti-inflammatory effects of raw and rice wine-processed Herba Siegesbeckiae. *J Ethnopharmacol*. 2014 Oct 28;156:365-9.	SU T, YU H, KWAN HY, MA XQ, CAO HH, CHENG CY, LEUNG AK, CHAN CL, LI WD, CAO H, FONG WF, YU ZL	2.998
Comprehensive quantitative analysis of Shuang-Huang-Lian oral liquid using UHPLC-Q-TOF-MS and HPLC-ELSD. *J Pharm Biomed Anal*. 2015 Jan;102:1-8.	ZHANG TB, YUE RQ, XU J, HO HM, MA DL, LEUNG CH, CHAU SL, ZHAO ZZ, CHEN HB, HAN QB	2.979
Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease. *Scientific Reports*. 2015 Sep 14;5:13888.	LUAN HM, LIU LF, TANG Z, ZHANG MW, CHUA KK, SONG JX, MOK CT, LI M, CAI ZW	5.578
CONSORT in China: past development and future direction. *Trials*. 2015 Jun 1;16:243.	SONG TJ, LENG HF, ZHONG LL, WU TX, BIAN ZX	1.731

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Constitutional Study of Parkinson's Disease Patients Based on Traditional Chinese Medicine Pattern Differentiation, *Integrative Medicine International*, 2015;1pp.170-175.	LI JJ, CHUA KK, LI M	--
Creative and innovative good practice in traditional Chinese medicine clinical studies: strategies for sustainable development. *J Ethnopharmacol* 2014 Sep 29;155(3):1625-8.	LU A, ZHANG C, VERPOORTE R, ROBINSON N, XU Q	2.998
Cyclooxygenase-2-dependent oxidative stress mediates palmitate-induced impairment of endothelium-dependent relaxations in mouse arteries. *Biochem Pharmacol*. 2014 Oct 15;91(4):474-82.	GAO Z, ZHANG H, LIU J, LAU CW, LIU P, CHEN ZY, LEE HK, TIPOE GL, HO HM, YAO X, HUANG Y	5.009
Deficiency of female sex hormones augments PGE2 and CGRP levels within midbrain periaqueductal gray. *J Neurol Sci*. 2014 Nov 15;346(1-2):107-11.	WANG D, ZHAO J, WANG J, LI J, YU S, GUO X	2.474
Dietary lipids and adipocytes: potential therapeutic targets in cancers. *J Nutr Biochem*. 2015 Apr;26(4):303-11.	KWAN HY, CHAO X, SU T, FU XQ, LIU B, TSE KW, FONG WF, YU ZL	3.794
Discovery of deoxyvasicinone derivatives as inhibitors of NEDD8-activating enzyme. *Methods*. 2015 Jan;71:71-6.	ZHONG HJ, LEUNG KH, LIN S, CHAN DS, HAN QB, CHAN SL, MA DL, LEUNG CH	3.645
Distribution of toxic alkaloids in tissues from three herbal medicine Aconitum species using laser micro-dissection, UHPLC-QTOF MS and LC-MS/MS techniques. *Phytochemistry*. 2014 Nov;107:155-74.	JAISWAL Y, LIANG Z, HO A, WONG L, YONG P, CHEN H, ZHAO Z	2.547
Diversified bioactivities of four types of naturally occurring quinochalcones. *Fitoterapia*. 2014 Dec;99:7-20.	ZHAO S, LU X, XIAO C, NING Z, ZENG H, DING X, ZHANG Y, LU C, LIU Y	2.345
Drug discovery in traditional Chinese medicine: From herbal *fufang* to combinatory drugs, *Science*, [accepted]	HE B, LU C, WANG ML, ZHENG G, CHEN G, JIANG M, HE XJ, BIAN ZX, ZHANG G, LU A	33.611
Effects of auricular stimulation in the cavum conchae on glucometabolism in patients with type 2 diabetes mellitus. *Complement Ther Med*. 2014 Oct;22(5):858-63.	JU Y, ZHANG H, CHEN M, CHI X, LAN W, ZHANG H, MO J, YUNG NY	1.545
Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice. *Drug Des Devel Ther*. 2015 Feb 17;9:923-35.	ZHU PL, PAN SY, ZHOU SF, ZHANG Y, WANG XY, SUN N, CHU ZS, YU ZL, KO KM	3.028
Enhanced evidence-based chinese medicine clinical practice guidelines in Hong Kong: a study protocol for three common diseases. *Evid Based Complement Alternat Med*. 2015;2015:482706.	SHI N, ZHONG LL, HAN X, ZIEA TC, NG B, BIAN Z, LU A	1.880
Eruberin A, a Natural Flavanol Glycoside, Exerts Anti-Fibrotic Action on Pancreatic Stellate Cells. *Cell Physiol Biochem*. 2015;36(6):2433-46.	TSANG SW, ZHANG HJ, CHEN YG, AU YEUNG KK, BIAN ZX	2.875
Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease, *Parkinsonism Relat Disord*,2015; 21(11):1371-2.	LUAN HM, LIU LF, TANG Z, MOK CT, LI M, CAI ZW	3.972
Expression profile of long noncoding RNAs in cartilage from knee osteoarthritis patients. *Osteoarthritis Cartilage*. 2015 Mar;23(3):423-32.	FU M, HUANG G, ZHANG Z, LIU J, ZHANG Z, HUANG Z, YU B, MENG F	4.165
Fingerprint analysis of processed Rhizoma Chuanxiong by high-performance liquid chromatography coupled with diode array detection. *Chin Med*. 2015 Feb 10;10:2.	FANG JY, ZHU L, YI T, ZHANG JY, YI L, LIANG ZT, XIA L, FENG JF, XU J, TANG YN, ZHAO ZZ, CHEN HB	1.490
Folding fan mode counter-current chromatography offers fast blind screening for drug discovery. Case study: finding anti-enterovirus 71 agents from Anemarrhena asphodeloides. *J Chromatogr A*. 2014 Nov 14;1368:116-24.	LIU M, TAO L, CHAU SL, WU R, ZHANG H, YANG Y, YANG D, BIAN Z, LU A, HAN Q, XU H	4.169
Gender-Related Differences in Outcomes on Acupuncture and Moxibustion Treatment Among Depression Patients. *J Altern Complement Med*. 2015 Nov;21(11):673-80. Epub 2015 Aug 20. [Epub ahead of print]	FAN L, GONG J, FU W, CHEN Z, XU N, LIU J, LU A, LI Z, WU T, OU A, XIE H	1.585
Genomics, proteomics and metabolomics in the assessment of herbal nephrotoxicity, *Hong Kong Chinese Medical Journal*, 2014;9(3)pp.75-77.	XU W, XU M, DA JX, XIA Q, CHOW YK, DING N, LAN JY	--

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Ginsenoside RB1 Inhibits Fibrillation and Toxicity of Alpha-synuclein and Disaggregates Preformed Fibrils. *Neurobiol Dis*. 2015 Feb;74:89-101.	ARDAH MT, PALEOLOGOU KE, LV G, MENON SA, ABUL KHAIR SB, LU JH, SAFIEH-GARABEDIAN B, AL-HAYANI AA, ELIEZER D, LI M, EL-AGNAF OM	5.078
Ginsenosides attenuate methylglyoxal-induced impairment of insulin signaling and subsequent apoptosis in primary astrocytes. *Neuropharmacology*. 2014 Oct;85:215-23.	CHU JM, LEE DK, WONG DP, WONG RN, YUNG KK, CHENG CH, YUE KM	5.106
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition), *Autophagy,* [accepted]	KLIONSKY DJ, (…), LI M, (…), LU JH, (…), SONG JX, (…), *et al.*	11.753
Heat shock 70-kDa protein 5 (Hspa5) is essential for pronephros formation by mediating retinoic acid signaling. *J Biol Chem*. 2015 Jan 2;290(1):577-89.	SHI W, XU G, WANG C, SPERBER SM, CHEN Y, ZHOU Q, DENG Y, ZHAO H	4.573
Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome. *Acta Pharmacol Sin*. 2015 Jun;36(6):708-15.	WANG FY, SU M, ZHENG YQ, WANG XG, KANG N, CHEN T, ZHU EL, BIAN ZX, TANG XD	2.912
Histochemical evaluation of alkaloids in rhizome of Coptis chinensis using laser microdissection and liquid chromatography/mass spectrometry. *Drug Test Anal*. 2015 Jun;7(6):519-30.	YI L, LIANG ZT, PENG Y, GUO P, WONG LL, WAN XJ, HO HM, YI T, ZHAO ZZ	2.506
Hypothesis driven screening of Chinese herbs for promoting neuroprotection, *Science (Special issue: The Art and Science of Traditional Medicine" Part3: The Global Impact of Traditional Medicine)*, 2015; P69-71.	FRIEDEMANN T, LI M, FEI J, SCHUMACHER U, SONG JX, SCHRÖDER S	33.611
Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. *Biopharm Drug Dispos*. 2015 Nov;36(8):529-51. Epub 2015 Aug 11. [Epub ahead of print]	FONG SY, ZHANG Y, WONG YC, ZHOU L, HAN Q, ZUO Z	2.340
Identification of Chinese herbal medicines by fluorescence microscopy: fluorescent characteristics of medicinal bark. *J Microsc*. 2014 Oct;256(1):6-22.	HUANG X, LIANG Z, CHEN H, ZHAO Z, LI P	2.331
Improving clinical practice guideline development in integration of traditional Chinese medicine and Western medicine. *Chin J Integr Med*. 2015 Mar;21(3):163-5.	LU AP, CHEN KJ	1.217
Incretin action on bone: An added benefit? *J Diabetes Investig*. 2015 May;6(3):267-8.	MA RC, XU G	1.825
Individualized Traditional Chinese Medicine Treatment of Acute Stroke, *Science* (Special Issue: Translational Medicine at Capital Medical University: Investigating Major Chronic Disease). 2015 July 17; P68-71.	CHEN L, SONG JX, LUO YM, LI M, GAO L	33.611
Inhibition of autophagy ameliorates atherogenic inflammation by augmenting apigenin-induced macrophage apoptosis.*Int Immunopharmacol*. 2015 Jul;27(1):24-31.	WANG Q, ZENG P, LIU Y, WEN G, FU X, SUN X	2.472
Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. *Exp Dermatol*. 2014 Nov;23(11):855-7.	FU XQ, CHOU GX, KWAN HY, TSE KW, ZHAO LH, YUEN TK, CAO HH, YU H, CHAO XJ, SU T, CHENG BC, SUN XG, YU ZL	3.762
Insights from systems pharmacology into cardiovascular drug discovery and therapy. *BMC Syst Biol*. 2014 Dec 24;8:141.	LI P, FU Y, RU J, HUANG C, DU J, ZHENG C, CHEN X, LI P, LU A, YANG L, WANG Y	2.435
Integrative network analysis: bridging the gap between Western medicine and traditional Chinese medicine.*J Integr Med*. 2015 May;13(3):133-5.(The predecessor of JIM is the Journal of Chinese Integrative Medicine (JCIM, www.jcimjournal.com)	HE B, ZHANG G, LU AP	--
Large-scale exploration and analysis of drug combinations. *Bioinformatics*. 2015 Jun 15;31(12):2007-16.	LI P, HUANG C, FU Y, WANG J, WU Z, RU J, ZHENG C, GUO Z, CHEN X, ZHOU W, ZHANG W, LI Y, CHEN J, LU A, WANG Y	4.981
LC-MS-based Urinary Metabolite Signatures in Idiopathic Parkinson's Disease. *J. Proteome Res*. 2015 Jan 2;14(1):467-78.	LUAN HM, LIU LF, MENG N, TANG Z, CHUA KK, CHEN LL, SONG JX, MOK V, XIE LX, LI M, CAI ZW	4.245

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Lifestyle Changes through Chinese Medicine Education on Health Maintenance and Food Therapy among College Students. *International Journal of Development Research (IJDR)*. 2015; 5(6):4762-4767.	NIE S, CHONG K, THADANI RD, LI M	0.471
Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers. *Sci Rep*. 2015 Mar 13;5:9114.	KWAN HY, NIU X, DAI W, TONG T, CHAO X, SU T, CHAN CL, LEE KC, FU X, YI H, YU H, LI T, TSE KW, FONG WF, PAN SY, LU A, YU ZL	5.578
Localization of ginsenosides in the rhizome and root of Panax ginseng by laser microdissection and liquid chromatography-quadrupole/ time of flight-mass spectrometry. *J Pharm Biomed Anal*. 2015 Feb;105:121-33.	LIANG Z, CHEN Y, XU L, QIN M, YI T, CHEN H, ZHAO Z	2.979
Metabolite profiling of tissues of Acorus calamus and Acorus tatarinowii rhizomes by using LMD, UHPLC-QTOF MS, and GC-MS. *Planta Med*. 2015 Mar;81(4):333-41.	JAISWAL Y, LIANG Z, HO A, CHEN H, ZHAO Z	2.152
Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis. *Evid Based Complement Alternat Med*. 2015;2015:897914.	LI J, LIU Z, GUO M, XU K, JIANG M, LU A, GAO X	1.880
MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACH1. *J Cancer*. 2015 Jan 1;6(2):184-91.	ZHANG Q, YUAN Y, CUI J, XIAO T, JIANG D	3.271
Modulatory effects of adiponectin on the polarization of tumor-associated macrophages. *Int J Cancer*. 2015 Aug 15;137(4):848-58.	PENG J, TSANG JY, HO DH, ZHANG R, XIAO H, LI D, ZHU J, WANG F, BIAN Z, LUI VC, XU A, TAM PK, LAMB JR, XIA H, CHEN Y	5.085
Molecular network-based analysis of guizhi-shaoyao-zhimu decoction, a TCM herbal formula, for treatment of diabetic peripheral neuropathy. *Acta Pharmacol Sin*. 2015 Jun;36(6):716-23.	ZHAO N, LI J, LI L, NIU XY, JIANG M, HE XJ, BIAN ZX, ZHANG G, LU AP	2.912
Neuroprotective Activity of Coptisine from Coptis chinensis (Franch). *Evid Based Complement Alternat Med*. 2015;2015:827308.	EDEMANN T, SCHUMACHER U, TAO Y, LEUNG AK, SCHRÖDER S	1.880
Non-toxic agarose/gelatin-based microencapsulation system containing gallic acid for antifungal application. *Int J Mol Med*. 2015 Feb;35(2):503-10.	LAM PL, GAMBARI R, KOK SH, LAM KH, TANG JC, BIAN ZX, LEE KK, CHUI CH	2.088
Novel algorithm for simultaneous component detection and pseudo-molecular ion characterization in liquid chromatography-mass spectrometry. *Anal Chim Acta*. 2015 Jan 1;853:402-14.	ZHANG Y, WANG X, WO S, HO H, HAN Q, FAN X, ZUO Z	4.513
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation, *Nat. Commun*,[accepted]	LI DF, LIU J, GUO BS, LIANG C, DANG L, LU C, HE XJ, CHEUNG H YS, XU L, LU CW, HE B, LIU B, SHAIKH A B, LI FF, WANG LY, YANG ZJ, AU D WT, PENG SL, ZHANG ZK, ZHANG BT, PAN XH, QIAN AR, SHANG P, XIAO LB, JIANG BH, WONG C KC, XU JK, BIAN ZX, LIANG ZC, GUO DA, ZHU HL, TAN WH, LU A, ZHANG G	11.470
Palladium/Zinc Co-Catalyzed syn-Stereoselectively Asymmetric Ring-Opening Reaction of Oxabenzonorbornadienes with Phenols. *Chemistry*. 2015 Jun 15;21(25):9003-7.	LI S, XU J, FAN B, LU Z, ZENG C, BIAN Z, ZHOU Y, WANG J	5.731
Petroleum ether extractive of the hips of Rosa multiflora ameliorates collagen-induced arthritis in rats. *J Ethnopharmacol*. 2014 Nov 18;157:45-54.	WU J, LIU X, CHAN CO, MOK DK, CHAN SW, YU Z, CHEN S	2.998
Pharmacodynamic and pharmacological studies of Rehmannia glutinosa (Gaert.) *Libosch, Hong Kong Journal of Traditional Chinese Medicine*, 2015;10(2)pp.79-82.	XU W, LIN JL, XU M	--
Pharmacological studies on the anti-arthritic effect of Gui-Zhi-Shao-Yao-Zhi-Mu-Decoction, *Hong Kong Journal of Traditional Chinese Medicine*, 2015;10(1)pp.48-51.	XU W, XU M, ZHOU HH, LIU XQ	--
Prescription of Chinese Herbal Medicine in Pattern-Based Traditional Chinese Medicine Treatment for Depression: A Systematic Review. *Evid Based Complement Alternat Med*. 2015;2015:160189.	YEUNG WF, CHUNG KF, NG KY, YU YM, ZHANG SP, NG BF, ZIEA ET	1.880

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Proteomic Study of Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome in Rats. *Chem Res Toxicol*. 2015 Sep 21;28(9):1715-27.	LI YH, TAI WC, XUE JY, WONG WY, LU C, RUAN JQ, LI N, WAN TF, CHAN WY, HSIAO WL, LIN G	3.529
Protopine, A promising novel histone deacetylase 6 inhibitor reduces tauopathy inin vitro and in vivo. *Neurodegener*. Dis. 2015. 15(Suppl. 1), 352-1969-Page1579.	DURAIRAJAN SSK, LI M, MALAMPATTI S, ZHANG Y, HUANG Y, LIU LF, SONG JX, CHEN LL, ZENG Y, SENAPATI S	3.511
Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature. *Diagn Pathol*. 2015 Jul 16;10:106.	FU X, JIANG J, TIAN XY, LI Z	2.597
QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode. *Sci Rep*. 2015 Jul 2;5:11802.	CHEN YY, LI Q, PAN CS, YAN L, FAN JY, HE K, SUN K, LIU YY, CHEN QF, BAI Y, WANG CS, HE B, LU AP, HAN JY	5.578
Recent advances in research of natural and synthetic bioactive quinolines. *Future Med Chem*. 2015;7(7):947-67.	CHUNG PY, BIAN ZX, PUN HY, CHAN D, CHAN AS, CHUI CH, TANG JC, LAM KH	3.744
Regulatory effect of astragalus polysaccharides on intestinal intraepithelial γδT cells of tumor bearing mice. *Molecules*. 2014 Sep 23;19(9):15224-36.	SUN S, ZHENG K, ZHAO H, LU C, LIU B, YU C, ZHANG G, BIAN Z, LU A, HE X	2.416
Salvianolic acid A inhibits endothelial dysfunction and vascular remodeling in spontaneously hypertensive rats. *Life Sci*. 2016 Jan 1;144:86-93. Epub 2015 Jun 30. [Epub ahead of print]	TENG F, YIN Y, CUI Y, DENG Y, LI D, CHO K, ZHANG G, LU A, WU W, YANG M, LIU X, GUO DA, YIN J, JIANG B	2.702
Salvianolic acid A, a matrix metalloproteinase-9 inhibitor of Salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein E-deficient mice. *Phytomedicine*. 2014 Sep 15;21(10):1137-45.	ZHANG T, XU J, LI D, CHEN J, SHEN X, XU F, TENG F, DENG Y, MA H, ZHANG L, ZHANG G, ZHANG Z, WU W, LIU X, YANG M, JIANG B, GUO D	3.126
Saussurea involucrata: A review of the botany, phytochemistry and ethnopharmacology of a rare traditional herbal medicine. *J Ethnopharmacol*. 2015 Aug 22;172:44-60.	CHIK WI, ZHU L, FAN LL, YI T, ZHU GY, GOU XJ, TANG YN, XU J, YEUNG WP, ZHAO ZZ, YU ZL, CHEN HB	2.998
Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. *Drug Des Devel Ther*. 2015 Apr 9;9:2001-27.	ZHANG Y, ZHOU ZW, JIN H, HU C, HE ZX, YU ZL, KO KM, YANG T, ZHANG X, PAN SY, ZHOU SF	3.028
Spexin Enhances Bowel Movement through Activating L-type Voltage-dependent Calcium Channel via Galanin Receptor 2 in Mice. *Sci Rep*. 2015 Jul 10;5:12095.	LIN CY, ZHANG M, HUANG T, YANG LL, FU HB, ZHAO L, ZHONG LL, MU HX, SHI XK, LEUNG CF, FAN BM, JIANG M, LU AP, ZHU LX, BIAN ZX	5.578
Src inhibitor reduces permeability without disturbing vascularization and prevents bone destruction in steroid-associated osteonecrotic lesions in rabbits. *Sci Rep*. 2015 Mar 9;5:8856.	HE YX, LIU J, GUO B, WANG YX, PAN X, LI D, TANG T, CHEN Y, PENG S, BIAN Z, LIANG Z, ZHANG BT, LU A, ZHANG G	5.578
Statistical analysis of Chinese herbal medicines commonly used in Hong Kong Chinese medicine clinics., *Hong Kong Chinese Medicinal Journal*, 2014; 9(3):43-47.	TZE SC, ZHAO Z, CHEN H	--
Subcutaneous adipocytes promote melanoma cell growth by activating the Akt signaling pathway: role of palmitic acid. *J Biol Chem*. 2014 Oct 31;289(44):30525-37.	KWAN HY, FU X, LIU B, CHAO X, CHAN CL, CAO H, SU T, TSE KW, FONG WF, YU ZL	4.573
Sulfur dioxide residue in sulfur-fumigated edible herbs: The fewer, the safer? *Food Chem*. 2016 Feb 1;192:119-24. Epub 2015 Jul 3. [Epub ahead of print]	DUAN SM, XU J, BAI YJ, DING Y, KONG M, LIU HH, LI XY, ZHANG QS, CHEN HB, LIU LF, LI SL	3.391
Sustainable Utilization of TCM Resources. *Evid Based Complement Alternat Med*. 2015;2015:613836.	CHEN S, WANG Y, ZHAO Z, LEON CJ, HENRY RJ	1.880
TCM Zheng Classification and Clinical Trials 2014. *Evid Based Complement Alternat Med*. 2015;2015:538989.	LU A, XUE C, BIAN Z, CHO WC	1.880
The Anti-cancer and Anti-obesity Effects of Mediterranean Diet. *Crit Rev Food Sci Nutr*. 2015 Apr 1:0. [Epub ahead of print]	KWAN HY, CHAO X, SU T, FU X, TSE KW, FONG WF, YU ZL	5.176
The Crosstalk of Pathways Involved in Immune Response Maybe the Shared Molecular Basis of Rheumatoid Arthritis and Type 2 Diabetes. *PLoS One*. 2015 Aug 7;10(8):e0134990.	NIU X, LU C, XIAO C, GE N, JIANG M, LI L, BIAN Y, XU G, BIAN Z, ZHANG G, LU A	3.234
The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial. *Trials*. 2015 Apr 30;16:199.	CHUA KK, WONG A, KWAN PW, SONG JX, CHEN LL, CHAN AL, LU JH, MOK V, LI M	1.731
The Literature Review of Chinese Medicine on the Treatment of Fatty Liver, *Hong Kong J. Tradit. Chin. Med. (Chin.)*, 2014, 9(4): 75-78.	ZHANG XB, WANG L, LI M	--

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
\# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
The loss of cellular junctions in epithelial lung cells induced by cigarette smoke is attenuated by corilagin. *Oxid Med Cell Longev*. 2015;2015:631758.	MURESAN XM, CERVELLATI F, STICOZZI C, BELMONTE G, CHUI CH, LAMPRONTI I, BORGATTI M, GAMBARI R, VALACCHI G	3.516
The melanogenesis-inhibitory effect and the percutaneous formulation of ginsenoside Rb1. *AAPS PharmSciTech*. 2014 Oct;15(5):1252-62.	WANG L, LU AP, YU ZL, WONG RN, BIAN ZX, KWOK HH, YUE PY, ZHOU LM, CHEN H, XU M, YANG Z	1.641
The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo. *Int J Mol Sci*. 2014 Dec 24;16(1):230-55.	NG HL, LU A, LIN G, QIN L, YANG Z	2.862
The shared crosstalk of multiple pathways involved in the inflammation between rheumatoid arthritis and coronary artery disease based on a digital gene expression profile. *PLoS One*. 2014 Dec 16;9(12):e113659.	NIU X, LU C, XIAO C, ZHANG Z, JIANG M, HE D, BIAN Y, ZHANG G, BIAN Z, LU A	3.234
The survival motor neuron gene smn-1 interacts with the U2AF large subunit gene uaf-1 to regulate Caenorhabditis elegans lifespan and motor functions. *RNA Biology*. 2014;11(9):1148-60.	GAO XY, TENG YL, LUO JT, HUANG LG, LI M, ZHANG ZH, MA YC, MA L	4.974
Tianma Gouteng Yin, a Traditional Chinese Medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinson's disease, *Sci. Rep.*, 2015, 18;5:16862.	LIU LF, SONG JX, LU JH, HUANG YY, CHEN LL, DURIARAJAN SSK, HAN QB, LI M	5.578
Time and dose relationships between schisandrin B- and schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice. *Drug Des Devel Ther*. 2014 Sep 19;8:1429-39.	ZHANG Y, PAN SY, ZHOU SF, WANG XY, SUN N, ZHU PL, CHU ZS, YU ZL, KO KM	3.028
Tissue-specific metabolites profiling and quantitative analyses of flavonoids in the rhizome of Belamcanda chinensis by combining laser-microdissection with UHPLC-Q/TOF-MS and UHPLC-QqQ-MS. *Talanta*. 2014 Dec;130:585-97.	CHEN YJ, LIANG ZT, ZHU Y, XIE GY, TIAN M, ZHAO ZZ, QIN MJ	3.545
Traditional Chinese medicine formulas for irritable bowel syndrome: from ancient wisdoms to scientific understandings. *Am J Chin Med*. 2015;43(1):1-23.	XIAO HT, ZHONG L, TSANG SW, LIN ZS, BIAN ZX	2.755
Traditional medicines in the world: where to go next? *Evid Based Complement Alternat Med*. 2014;2014:739895.	PAN SY, LITSCHER G, CHAN K, YU ZL, CHEN HQ, KO KM	1.880
Translational research in complementary and alternative medicine 2014. *Evid Based Complement Alternat Med*. 2015;2015:427508.	JIA W, LU A, CHAN K, GUSTAFSSON MG, LIU P	1.880
Tumor grafting induces changes of gut microbiota in athymic nude mice in the presence and absence of medicinal Gynostemma saponins. *PLoS One*. 2015 May 20;10(5):e0126807.	CHEN L, TAI WC, BRAR MS, LEUNG FC, HSIAO WL	3.234
Unconjugated bilirubin mediates heme oxygenase-1-induced vascular benefits in diabetic mice. *Diabetes*. 2015 May;64(5):1564-75.	LIU J, WANG L, TIAN XY, LIU L, WONG WT, ZHANG Y, HAN QB, HO HM, WANG N, WONG SL, CHEN ZY, YU J, NG CF, YAO X, HUANG Y	8.095
Unusual apocrine carcinoma with neuroendocrine differentiation: a cutaneous neoplasm may be analogous to neuroendocrine carcinoma with apocrine differentiation of breast. *Diagn Pathol*. 2015 Jun 10;10:64.	LI Y, CHEN LL, LI B, TIAN XY, LI Z	2.597
UPLC-QTOF-MS identification of metabolites in rat biosamples after oral administration of Dioscorea saponins: a comparative study. *J Ethnopharmacol*. 2015 May 13;165:127-40.	TANG YN, PANG YX, HE XC, ZHANG YZ, ZHANG JY, ZHAO ZZ, YI T, CHEN HB	2.998
Whole transverse section and specific-tissue analysis of secondary metabolites in seven different grades of root of Paeonia lactiflora using laser microdissection and liquid chromatography-quadrupole/time of flight-mass spectrometry. *J Pharm Biomed Anal*. 2014 Nov 6;103C:7-16.	WANG Q, LIANG Z, PENG Y, HOU JL, WEI SL, ZHAO ZZ, WANG WQ	2.979

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Chinese Books		
《腎病治療與中醫調養》，商務印書館 (香港) 有限公司。	徐大基	--
〈港澳台地區篇——香港區〉，載《中國中醫藥年鑒 (行政卷)》，《中國中醫藥年鑒（學術卷）》編輯委員會， 上海 : 中國中醫藥出版社。	鍾麗丹	--
《中國民間生草藥原色圖譜（上册）》，廣東科技出版社。	潘超美 , 陳虎彪（参编）	--
《南藥與大南藥》，中國醫藥科技出版社。	繆劍華 , 彭勇 , 肖培根 , 陳虎彪 （審稿）	--
《食素——合理素食才健康》，萬里機構・飲食天地出版社。	党毅 , 陳虎彪	--
《酒療：怎樣飲酒益健康》，萬里機構・萬里書店。	党毅 , 陳虎彪	--
《參療：對症吃參更健康》，萬里機構・得利書局。	党毅 , 陳虎彪	--
《粥療：祛病延年粥為補》，萬里機構・得利書局。	党毅 , 陳虎彪	--
《湯療——湯的健康小百科》，萬里機構・得利書局。	党毅 , 陳虎彪	--
《當代中醫藥領域傑出人物案例研究》，科學出版社。	呂愛平	--
《膝骨關節炎中醫治療與生活調養》，萬里機構・得利書局。	朱恩	--
《婦科調經良方》，萬里機構・得利書局。	梁浩榮	--
《常見皮膚病治療與中醫調養》，商務印書館 (香港) 有限公司。	黃霏莉	--
《ISO 中醫藥國際標準制定指南》，中國中醫藥出版社。	呂愛平 (與王燕平 , 韓學傑)	--
《濕疹》，萬里機構・得利書局。	梁惠梅	--
《百寶藥箱》，萬里機構・萬里書店。	趙中振	--
《拔罐療法》，萬里機構・得利書局。	倫新	--

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
2013-2014		
Research Paper		
A bioactivity-guided study on the anti-diarrheal activity of Polygonum chinense Linn, *Journal of Ethnopharmacolog*, 2013 Sep 16;149(2):499-505.	XIAO H, TSANG SW, QIN HY, CHOI FK, YANG ZJ, HAN QB, CHEN HB, XU HX, SHEN H, LU AP, BIAN ZX	2.998
A comparative study on the traditional Indian Shodhana and Chinese processing methods for aconite roots by characterisation and determination of the major components, *Chemistry Central Journal*, 2013 Oct 25;7(1):169.	JAISWAL Y, LIANG Z, PENG Y, CHEN H, ZHAO Z	2.187
A herbal formula consisting of Rosae Multiflorae Fructus and Lonicerae Japonicae Flos inhibits inflammatory mediators in LPS-stimulated RAW 264.7 macrophages, *Journal of Ethnopharmacology*,2014 May 14;153(3):922-7.	CHENG C, MA X, KWAN H, TSE KW, CAO H, SU T, SHU X, WU Z, YU Z	2.998
A Label-Free Luminescent Switch-On Assay for ATP Using a G-Quadruplex-Selective Iridium(III) Complex, *PLoS One*, 2013 Oct 25;8(10):e77021.	LEUNG KH, LU L, WANG M, MAK TY, CHAN DS, TANG FK, LEUNG CH, KWAN HY, YU ZL, MA DL	3.234
A Mixed Microscopic Method for Differentiating Seven Species of "Bixie"-Related Chinese Materia Medica, *Microscopy Research And Technique*, 2014 Jan;77(1):57-70.	TANG Y, HE XC, CHEN QL, FAN LL, ZHANG JY, ZHAO ZZ, DONG LS, LIANG ZT, YI T, CHEN HB	1.154
A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells, *Int J Med Sci.*, 2013 Apr 23;10(6):782-9	SHENG H, RUI XF, SHENG CJ, LI WJ, CHENG XY, JHUMMON NP, YU YC, QU S, ZHANG G, QIN L	2.003
A systems-pharmacology analysis of herbal medicines used in health improvement treatment: predicting potential new drugs and targets, *Evid Based Complement Alternat Med. 2013*;2013:938764. Epub 2013 Nov 28.	LIU J, PEI M, ZHENG C, LIU Y, WANG Y, YANG L , LU A	1.880
Acupuncture and moxibustion for lateral elbow pain: a systematic review of randomized controlled trials, *BMC Complementary & Alternative Medicine*, 2014 Apr 12;14:136.	GADAU M, YEUNG WF, LIU H, ZASLAWSKI C, TAN YS, WANG FC, BANGRAZI S, CHUNG KF, BIAN ZX, ZHANG SP	2.020
Acupuncture for the protracted withdrawal syndrome of heroin addiction: a review of randomized controlled clinical trials, *Hong Kong Chinese Medical Journal*, 2014;9(2):73-77.	XU W, XU Y, XU M, CHEN XL, TIAN XY, CHOW YL, WU YC, DING N	--
An Integrated Strategy Based on UPLC-DAD-QTOF-MS for Metabolism and Pharmacokinetic Studies of Herbal Medicines: Tibetan “Snow Lotus” Herb (Saussurea laniceps), a Case Study, *Journal of Ethnopharmacology*, 2014 May 14;153(3):701-13.	YI T, ZHU L, TANG Y, ZHANG JY, LIANG ZT, XU J, ZHAO ZZ, YU ZL, BIAN ZX, YANG ZJ, CHEN HB	2.998
Anti-fibrotic effects of curcumin: a review of Clinical study, *Hong Kong Chinese Medical Journal*, 2014;9(1):85-87.	CHOW YL, XU M, XU W, XU YP, CHEN, LJ, ZHOU ZY, CHI ZJ, SHU P	--
Anti-tumour and pharmacokinetics study of 2-Formyl-8-hydroxy-quinolinium chloride as Galipea longiflora alkaloid analogue, *Phytomedicine*, 2014 May 15;21(6):877-82.	LAM KH, LEE KH, GAMBARI R, KOK HL, KOK TW, CHAN SC, BIAN ZX, WONG WY, WONG SM, LAU FY, TONG SW, CHAN KW, CHENG CH, CHUI CH, TANG CO	3.126
Apoptosis Sensitization by Euphorbia Factor L1 in ABCB1-Mediated Multidrug Resistant K562/ADR Cells, *Molecules*, 2013 Oct 16;18(10):12793-808.	ZHANG J, LIN M, YI T, TANG Y, FAN L, HE X, ZHAO Z, CHEN H	2.416
Beta-glucan extraction from Qingke (Hull-less barley) grown in Qinghai-Tibet Plateau by applying accelerated solvent extraction technique combined with response surface methodology, *Journal of Cereal Science*, 2013 Jan; 59(1):95-100.	DU B, ZHU FM, XU BJ	2.094
Bioactive Compounds from Vitex leptobotrys, *Journal of Natural Products*, 2014 Mar 28;77(3):663-7.	PAN W, LIU KL, GUAN YF, TAN GT, NGUYEN VH, NGUYEN MC, SOEJARTO DD, PEZZUTO JM, FONG HS, ZHANG HJ	3.798
Case-control study on the associations between lifestyle-behavioral risk factors and phlegm-wetness constitution, *J Tradit Chin Med*, 2014 June15;34(3):286-292.	ZHU Y, WANG Q, DAI Z, ORIGASA H, DI J, WANG Y, LIN L, FAN C	0.716
Catechins and Procyanidins of Ginkgo biloba Show Potent Activities towards the Inhibition of β-Amyloid Peptide Aggregation and Destabilization of Preformed Fibrils, *Molecules*, 2014 Apr 22;19(4):5119-34.	XIE H, WANG JR, YAU LF, LIU Y, LIU L, HAN QB, ZHAO Z, JIANG ZH	2.416

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Cellular sources of cyclooxygenase-1 and -2 up-regulation in the spinal dorsal born after spinal nerve ligation, *Neuropathology & Applied Neurobiology*, 2014 Jun;40(4):452-63.	LAU YM, WONG SC, TSANG SW, LAU WK, LU AP, ZHANG HQ	3.927
Characterization of flavonoids in the ethomedicine Fordiae Cauliflora Radix and its adulterant Millettiae Pulchra Radix by HPLC-DAD-ESI-IT-TOF-MSn, *Molecules*, 2013 Dec 9;18(12):15134-52.	FAN L, YI T, XU F, ZHANG Y, ZHANG J, LI D, XIE Y, QIN S, CHEN H	2.416
Characterization of secondary metabolites from the raphides of calcium oxalate contained in three Araceae family plants using laser microdissection and ultrahigh performance liquid chromatographyquadrupole/ time of flight-mass spectrometry, *European Journal of Mass Spectrometry*, 2013;19(3):195-210.	LIANG Z, ZHANG J, WONG L, YI T, CHEN H, ZHAO Z	1.000
Chemical comparison of two dosage forms of Hemp Seed Pills by UHPLC-Q-ToF-MS/MS and multivariate statistical techniques, *Journal of Pharmaceutical and Biomedical Analysis*, 2013 Oct;84:59-68.	ZHOU WJ, SONG JZ, FU WW, TAN HS, XU HX, BIAN ZX	2.979
Chemical Profile Analysis and Comparison of Two Versions of the Classic TCM Formula Danggui Buxue Tang by HPLC-DAD-ESI-IT-TOF-MSn, *Molecules*, 2014 Apr 30;19(5):5650-73.	ZHANG Y, XU F, YI T, ZHANG J, XU J, TANG Y, HE X, LIU J, CHEN H	2.416
Chemical quantification and antioxidant assay of four active components in Ficus hirta root using UPLC-PAD-MS fingerprinting combined with cluster analysis, *Chemistry Central Journal*, 2013 Jul 8;7(1):115.	YI T, CHEN Q, HE X, SO S, LO Y, FAN L, XU J, TANG Y, ZHANG J, ZHAO Z, CHEN H	2.187
Chemistry, bioactivity and quality control of Dendrobium, a commonly used tonic herb in traditional Chinese medicine, *Phytochemistry Reviews*, 2013 12(2):341-367.	XU J, HAN QB, LI SL, CHEN X, WANG XN, ZHAO ZZ, CHEN HB	2.407
Chinese herbal medicine (Ma Zi Ren Wan) for functional constipation: study protocol for a prospective, double-blinded, double-dummy, randomized controlled trial, *Trials*, 2013 Nov 4;14:366.	ZHONG LD, CHENG CW, CHAN YW, CHAN KH, LAM TW, CHEN XR, WONG CT, WU CY, BIAN ZX	1.731
Chinese herbal medicine for functional constipation: a randomised controlled trial, *Hong Kong Medical Journal*, 2013 Dec;19 Suppl 9:44-6.	BIAN ZX, CHENG CW	0.872
Chinese manipulative therapies in the treatment of knee osteoarthritis: an evidence-based assessment, *World Journal of Manipulative Medicine*, 2013;9:96-99.	WEI J, XU W, ZHOU HH, CHOW YL, XIAO TT, XU M	--
Combined therapeutic effects of vinblastine and Astragalus saponins in human colon cancer cells and tumor xenograft via inhibition of tumor growth and proangiogenic factors, *Nutirion and Cancer*, 2014;66(4):662-74.	AU YEUNG KW, LAW P, KO KS	2.322
Comparative authentication of three “Snow Lotus” herbs by macroscopic and microscopic features, *Microscopy Research and Technique*, 2014 Aug;77(8):631-41.	CHEN Q, YI T, TANG Y, WONG L, HUANG X, ZHAO Z, CHEN H	1.154
Comparison of Effectiveness of Acupuncture thrust - debonding and three Acupoints in Patients shoulder with Subacromial impingement syndrome : A randomized Clinical Trial, *Shanghai Journal of Acupuncture and Moxibustion*.	TU F	--
Complementary and Alternative Medicine for Diseases and Disorders in Digestive Tract: Basic to Clinics, *Evidence-based Complementary and Alternative Medicine*, 2013;2013:565279.	SON CG, BIAN ZX, WANG JH, RAGHAVENDRAN HB	1.880
Complementary and alternative medicine for respiratory tract infectious disease: prevention and treatments, *Evidence-based Complementary and Alternative Medicine*, 2014 (2014) : 913095.	WU TX, BIAN ZX, ABUDU M, ADAMS D, KO SG	1.880
Corynoxine, a Natural Autophagy Enhancer, Promotes the Clearance of Alpha-synuclein via Akt/mTOR Pathway, J. Neuroimmune. *Pharma.*, 2014 Jun;9(3):380-7.	CHEN L, SONG J, LU J, YUAN Z, LIU L, DURAIRAJAN SSK, LI M	4.110
Corynoxine isomers decrease levels of amyloid-β peptide and amyloid-β precursor protein by promoting autophagy and lysosome biogenesis, Mol. Neurodegener, 2013 Sep 13;8(Suppl 1):P16.	DURAIRAJAN SSK, HUANG YY, CHEN LL, SONG JX, LI M	6.563
Current research and future directions in pattern identification: results of an international symposium, *Chinese Journal of Integrative Medicine*, 2014 Jun 18.	LEE MS, LEE JA, ALRAEK T, BIAN ZX, BIRCH S, GOTO H, JUNG J, KAO ST, MOON SK, PARK B, PARK KM, YOU S, YUN KJ, ZASLAWSKI C	1.217
Determination of five flavonoids in different parts of Fordia cauliflora by ultra performance liquid chromatography/triple-quadrupole mass spectrometry and chemical comparison with the root of Millettia pulchra var. laxior, *Chemistry Central Journal*, 2013 Jul 19;7(1):126.	FAN L, ZHANG Y, HUANG R, QIN S, YI T, XU F, TANG Y, QU X, CHEN H, MIAO J	2.187

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Development of ruthenium(II) complexes as topical antibiotics against methicillin resistant Staphylococcus aureus, *Dalton Transactions*, 2014 Mar 14;43(10):3949-57.	LAM PL, LU GL, HON KM, LEE KW, HO CL, WANG X, TANG CO, LAM KH, WONG SM, KOK SH, BIAN ZX, LI H, LEE KKH, GAMBARI R, CHUI CH, WONG WY	4.197
D-glucose as a modifying agent in gelatin/collagen matrix and reservoir nanoparticles for Calendula officinalis delivery, *Colloids and Surfaces B: Biointerfaces*, 2014 May 1;117:277-83.	LAM PL, KOK HL, BIAN ZX, LAM KH, TANG CO, LEE KH, GAMBARI R, CHUI CH	4.152
Dietary pulp from Fructus Schisandra Chinensis supplementation reduces serum hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt diet, *Lipids in Health and Disease*, 2014 Mar 12;13:46 .	SUN N, PAN SY, ZHANG Y, WANG XY, ZHU PL, CHU ZS, YU Z, ZHOU SF, KO KM	2.219
Disrupting the Indian hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis progression in Col2a1-CreERT2, Ihhfl/fl mice, *Arthritis Res Ther.*, 2014 Jan 15;16(1):R11.	ZHOU J, CHEN Q, LANSKE B, FLEMING BC, TEREK R, WEI X, ZHANG G, WANG S, LI K, WEI L	3.753
Dual using peanut as medicine and food, *Hong Kong Chinese Medical Journal*, 2013;8(4):73-76.	SUN Y, DANG Y, XU M	--
Effect of liposomes on the absorption of water-soluble active pharmaceutical ingredients via oral administration, *Current Pharmaceutical Design*, 2013; 19(37): 6647-54.	YANG Z, LU A, WONG CK, CHEN X, BIAN ZX, ZHAO Z, HUANG W, ZHANG G, CHEN H, XU M	3.452
Effectiveness guidance document (EGD) for Chinese medicine trials: a consensus document, *Trials,* 2014 May 13;15:169.	WITT CM, AICKIN M, CHERKIN D, CHE CT, ELDER C, FLOWER A, HAMMERSCHLAG R, LIU JP, LAO LX, PHURROUGH S, RITENBAUGH C, RUBIN LH, SCHNYER R, WAYNE PM, WITHERS SR, BIAN ZX, YOUNG J, BERMAN BM, COLLABORATORS	1.731
Effects of Chinese herbal medicine in the treatment of ketamine-associated urinary tract dysfunction: a report of 12 cases, *Hong Kong Chinese Medical Journal*, 2013;8(4):40-41.	XU M, XU W, XIAO TT, CHOW YL, TIAN XY	--
Effects of Huanglian-Jie-Du-Tang and Its Modified Formula on the Modulation of Amyloid-beta Precursor Protein Processing in Alzheimer's Disease Models, *PLoS ONE*, 2014 Mar 26;9(3):e92954.	DURAIRAJAN SSK, HUANG Y, YUEN P, CHEN L, KWOK K, LIU L, SONG J, HAN Q, XUE L, CHUNG S, HUANG J, BAUM L, SENAPATI S, LI M	3.234
Efficacy of classic Chinese medicine formula Ditan Decoction for Alzheimer's disease, *Chin. J. Integr. Med.*, 2014 Apr 22. [Epub ahead of print]	CHUA KK, CHEN LL, LIU LF, DURAIRAJAN SSK, LU JH, LI M	1.217
EGFL7 is expressed in bone microenvironment and promotes angiogenesis via ERK, STAT3, and integrin signaling cascades, *Journal of Cellular Physiology*, 2015 Jan;230(1):82-94.	CHIM SM, KUEK V, CHOW ST, LIM BS, TICKNER J, ZHAO J, CHUNG R, SU YW, ZHANG G, ERBER W, XIAN CJ, ROSEN V, XU J	3.839
Evidence-Based ZHENG: A Traditional Chinese Medicine Syndrome 2013, *Evid Based Complement Alternat Med.*, 2014;2014:484201.	SU SB, JIA W, LU A, LI S	1.880
GAP: From Sound Design to Practical Implementation in Clinical Trials for Traditional Chinese Medicine, *Evidence-Based Complementary and Alternative Medicine*, 2014;2014:560838.	SHANG HC, ZHANG BL, BIAN ZX, LI YP, CLARKE M, ROBINSON N	1.880
Genomics, proteomics and metabolomics in the assessment of herbal nephrotoxicity, *Hong Kong Chinese Medical Journal*, 2014;9(3):75-77.	XU W, XU M, CHOW YL	--
Ginseng extracts restore high-glucose induced vascular dysfunctions by altering triglyceride metabolism and downregulation of atherosclerosis-related genes, Evidence-Based Complementary and Alternative Medicine, *Hindawi Publishing Corporation*, 2013;2013:797310.	CHAN GH, LAW BY, CHU JM, YUE KM, JIANG Z, LAU CW, HUANG Y, CHAN SW, YUE PY, WONG R	1.880
Ginsenoside compound K induces apoptosis in nasopharyngeal carcinoma cells via activation of apoptosis-inducing factor, *Chinese Medicine*, 2014 Apr 2;9(1):11.	LAW CK, KWOK H, POON P, LAU C, JIANG Z, TAI CS, HSIAO W, MAK N, YUE P, WONG R	1.490
Ginsenosides attenuate methylglyoxal-induced impairment of insulin signaling and subsequent apoptosis in primary astrocytes, *Neuropharmacology*, 2014 Oct;85:215-23.	CHU JM, LEE DK, WONG DP, WONG RN, YUNG KK, CHENG CH, YUE KM	5.106
Global and targeted metabolomics reveal that Bupleurotoxin, a toxic type of polyacetylene, induces cerebral lesion by inhibiting GABA receptor in mice, *J Proteome Res.*, 2014 Feb 7;13(2):925-33.	ZHANG Z, LU C, LIU X, SU J, DAI W, YAN S, LU A, ZHANG W	4.245
Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources, Evidence-based Complementary and Alternative Medicine, 2014;2014:525340.	PAN SY, LITSCHER G, GAO SH, ZHOU SF, YU ZL, CHEN HQ, ZHANG SF, TANG MK, SUN JN, KO KM	1.880

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
HMGB1 is involved in autophagy inhibition caused by alpha-synuclein overexpression: a process modulated by the natural autophagy inducer Corynoxine B, *Autophagy*, 2014 Jan;10(1):144-54.	SONG J, LU J, LIU L, CHEN LL, DURAIRAJAN SSK, YUE Z, ZHANG H, LI M	11.753
HPLC-ELSD fingerprint analysis of saponins in the fruits of Momordica charantia L, *Chinese Journal of Pharmaceutical Analysis*, 2014;34(5):889-895.	LI QY, WANG JL, WANG B, CHEN HB, ZHANG QL, LIANG H, ZHAO YY	--
Identification of daqingye and banlangen including crude drugs and decoction drugs from three plant species by normal light and fluorescence microscopy, *Microscopy Research and Technique*, 2013 Aug;76(8):774-82.	WAN X, LIANG Z, CHEN H, ZHAO Z, LI P	1.154
Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis, *Arthritis Rheumatol.Wiley Online Library*, 2014 Jul;66(7):1843-53 .	WANG S, WEI X, ZHOU J, ZHANG J, LI K, CHEN Q, TEREK R, FLEMING BC, GOLDRING MB, EHRLICH MG, ZHANG G, WEI L	--#
Impact of Treatment-related Dyskinesias and Non-motor Symptoms on Quality of Life in Chinese Patients with Idiopathic Parkinson's disease, *Inter. J. Integra. Med.*, 2013 Sep 13.	CHUA KK, GAO J, KUM WF, LI M	--
Indomethacin Sensitizes TRAIL-Resistant Melanoma cells to TRAIL-induced Apoptosis through ROS-mediated Up-regulation of Death Receptor 5 and Downregulation of Survivin, *Journal of Investigative Dermatology*, 2014 May;134(5):1397-407.	TSE KW, CAO HH, CHENG CY, KWAN HY, YU H, FONG WF, YU ZL	7.216
Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy, *Current Pharmaceutical Design*, 2014;20(7):1082-96.	KO KS, AU YEUNG KW	3.452
Inhibition of DNA-dependent protein kinase reduced palmitate and oleate-induced lipid accumulation in HepG2 cells, *European Journal of Nutrition*, 2013 Sep;52(6):1621-30.	KWAN HY, FONG WF, YANG Z, YU ZL, HSIAO WL	3.467
Inhibitory effect of the gallotannin corilagin on dextran sulfate sodium-induced murine ulcerative colitis, *Journal of Natural Products*, 2013 Nov 22;76(11):2120-5.	XIAO H, LIN CY, HO DH, PENG J, CHEN Y, TSANG SW, WONG M, ZHANG XJ, ZHANG M, BIAN ZX	3.798
Insights of Chinese medicine syndrome study: from current to future prospects, *Chinese Journal of Integrative Medicine*, 2014 May;20(5):326-31.	BIAN ZX, XU H, LU AP, LEE MS, CHENG CW	1.217
Isolation of anticancer constituents from flos genkwa (Daphne genkwa Sieb.et Zucc.) through bioassay-guided procedures, *Chemistry Central Journal*, 2013 Sep 23;7(1):159.	LI S, CHOU G, HSEU Y, YANG H, KWAN HY, YU ZL	2.187
Literature Review of the Treatment of Chinese Medicine on Motor Symptoms and Non-Symptoms of Parkinson's disease, *Hong Kong J. Tradit. Chin. Med. (Chin.)*. 2013; 8(4): 27-29.	SI YW, CHUA KK, LI M	--
Japane se Medaka : A Non-Mammalian Vertebrate Model for Studying Sex and Age-Related Bone Metabolism In Vivo, *PLoS One*, 2014 Feb 11;9(2):e88165.	SHANTHANAGOUDA AH, GUO B, YE R, LIANG C, CHIANG MW, SINGARAM G, CHEUNG N, ZHANG G, AU D	3.234
Long-term efficacy of electroacupuncture for chronic neck pain: a randomised controlled trial, *Hong Kong Medical Journal*, 2013 Dec;19 Suppl 9:36-9.	ZHANG SP, CHIU TTW, CHIU SN	0.872
Magnolol inhibits colonic motility through down-regulation of voltage-sensitive L-type Ca2+ channels of colonic smooth muscle cells in rats, *Phytomedicine*, 2013 Nov 15;20(14):1272-9.	ZHANG M, ZANG KH, LUO JL, LEUNG FP, HUANG Y, LIN CY, YANG ZJ, LU AP, TANG XD, SUNG JY, BIAN ZX	3.126
Metabolic profiling reveals therapeutic biomarkers of processed Aconitum carmichaeli Debx in treating hydrocortisone induced kidney-yang deficiency syndrome rats, *J Ethnopharmacol.*, 2014 Mar 28;152(3):585-93.	TAN Y, LIU X, LU C, HE X, LI J, XIAO C, JIANG M, YANG J, ZHOU K, ZHANG Z, ZHANG W, LU A	2.998
Microencapsulation-protected L-ascorbic acid for the application of human epithelial HaCaT cell prolieration, *Journal of Microencapsulation*, 2014;31(8):754-8.	LAM PL, KOK SH, BIAN ZX, GAMBAR R, LEE KH , CHUI CH	1.585
Microscopic research on a multi-source traditional Chinese medicine: Asdragli Radix, *Journal of Natural Medicines*, 2014 Apr;68(2):340-50.	YU K, LIU J, GUO B, ZHAO Z, HONG H, CHEN H, CAI S	1.593
Modulation of endoplasmic reticulum chaperone GRP78 by high glucose in hippocampus of streptozotocin-induced diabetic mice and C6 astrocytic cells, *Neurochem Int.*, 2013 Nov;63(6):551-60.	WONG DP, CHU JM, HUNG VK, LEE DK, CHENG CH, YUNG KK, YUE KM	3.092

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Molecular network and chemical fragment-based characteristics of medicinal herbs with cold and hot properties from Chinese medicine, *J Ethnopharmacol*, 2013 Jul 30;148(3):770-9.	LIANG F, LI L, WANG M, NIU X, ZHANG J, HE X, YU C, JIANG M, LU A	2.998
Network pharmacology in traditional chinese medicine, *Evid Based Complement Alternat Med*, 2014;2014:138460.	LI S, FAN TP, JIA W, LU A	1.880
NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity, *Nat. Commun.*, 2014;5:3920.	LU J, HE LQ, BEHRENDS C, ARAKI M, ARAKI K, WANG QJ, CATANZARO JM, FRIEDMAN SL, ZONG WX, FIEL MI, LI M, YUE ZY	11.470
Oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) of β-glucans from different sources with various molecular weight, *Bioactive Carbohydrates and Dietary Fibre*, 2014 Jan ; 3(1):11-16.	DU B, XU BJ	--
Physiological effects of microgravity on bone cells, *Calcif Tissue Int.*, 2014 Jun;94(6):569-79.	ARFAT Y, XIAO WZ, IFTIKHAR S, ZHAO F, LI DJ, SUN YL, ZHANG G, SHANG P, QIAN AR	3.272
Preliminary Study of Establishing and Assessing IBS-D Model Rats of Gan Stagnation and Pi Deficiency Syndrome, *Chinese Journal of Integrated Traditional and Western Medicine*,2013;33(11);1507-14.	ZHAO YP, TANG XD, BIAN ZX, WANG FY, YANG JQ, SU M, WANG W	--
Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus, *Bioorganic & Medicinal Chemistry Letters*, 2014 Jan 1;24(1):367-70.	LAM KH, GAMBARI R, LEE KH, CHEN YX, KOK SH, WONG SM, LAU FY, CHENG CH, WONG WY, BIAN ZX, CHAN SC, TANG CO, CHUI CH	2.420
Proteomic and functional analyses demonstrate the involvement of oxidative stress in the anticancer activities of oridonin in HepG2 cells, *Oncology Reports*, 2014 May;31(5):2165-72.	WANG H, YE Y, YU Z	2.301
Quality evaluation of commercial Huang-Lian-Jie-Du-Tang based on simultaneous determination of fourteen major chemical constituents using high performance liquid chromatography, *Journal of Pharmaceutical and Biomedical Analysis*, 2013 Nov;85:239-44.	KWOK KY, XU J, HO HM, CHEN HB, LI M, LIANG Y, HAN QB	2.979
Quantitative Analysis of the Flavonoid Glycosides and Terpene Trilactones in the Extract of Ginkgo biloba and Evaluation of Their Inhibitory Activity towards Fibril Formation of β-Amyloid Peptide, *Molecules*, 2014 Apr 10;19(4):4466-78.	XIE H, WANG JR, YAU LF, LIU Y, LIU L, HAN QB, ZHAO Z, JIANG ZH	2.416
Quantitative Comparison of Multiple Components in Dioscorea nipponica and D. panthaica by Ultra-High Performance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry, *Phytochemical Analysis*, 2013 Jul-Aug;24(4):413-22.	TANG Y, YI T, CHEN HM, ZHAO ZZ, LIANG ZT, CHEN HB	2.341
Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling, *Biochemical Pharmacology*, 2014 Feb 1;87(3):424-34.	CAO HH, TSE KW, KWAN HY, YU H, CHENG CY, SU T, FONG WF, YU ZL	5.009
Rabdosia japonica var. glaucocalyx Flavonoids Fraction Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice, *Evidence-Based Complementary and Alternative Medicine*, 2014; 2014: 894515.	CHU C, XU N, LI X, XIA L, ZHANG JY, LIANG Z, ZHAO Z, CHEN D	1.880
Randomized Clinical Trial Evaluating Effects of Traditional Chinese Medicine (JiaWeiLiuJunZiTang) for Non-motor Symptoms in Parkinson's Disease (PD), Poster Presentations. *Movement Disorders*, 2014; 29: S1-S571.	MOK V, CHUA KK, CHAN KW, CHAN KH, LAU YK, TSE KP, CHEN LL MAN SC, WONG A, CHAN A, BIAN ZX, WU J, LI M	5.680
Resources and utilization of Taoist Medicinal Plants Distributed in Wudang Mountain, *Journal of Chinese Pharmaceutical Sciences*, 2014;23(6):412-420.	YANG G, CHEN H, ZHAO Z, YI T, CHEN J	--
Rhein, A Natural Anthraquinone Derivative, Attenuates The Activation of Pancreatic Stellate Cells And Ameliorates Pancreatic Fibrosis In Mice With Experimental Chronic Pancratitis, *Plos One*, 2013; 8(12): e82201.	TSANG S, ZHANG H, LIN C, XIAO H, WONG M, SHANG H, YANG Z, LU A, YUNG K, BIAN Z	3.234
Salvianolic acid A, a matrix metalloproteinase-9 inhibitor of Salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein E-deficient micee, *Phytomedicine*, 2014 Sep 15;21(10):1137-45. Epub: 2014 Jun 7.	ZHANG T, XU J, LI D, CHEN J, SHEN X, XU F, TENG F, DENG Y, MA H, ZHANG L, ZHANG G, ZHANG Z, WU W, LIU X, YANG M, JIANG B, GUO D	3.126
Salvianolic acid B promotes human chondrocyte growth and up-regulating the expression of β-catenin and CYTL-1, *Acta Scientiarum Naturalium Universitatis Sunyatseni 2013*, 2013;52(4):110-115.	LIU S, YANG X, CUI S, LIANG P, TAN J, ZHANG J, SHEN W, XU M	--

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Sensitization of Hep3B hepatoma cells to cisplatin and doxorubicin by corilagin, *Phytotherapy Research*, 2014 May;28(5):781-3.	GAMBARI R, HAU KP, WONG WY, CHUI CH	2.660
Serum metabolic signatures of four types of human arthritis, *J Proteome Res*., 2013;12(8):3769–3779.	JIANG M, CHEN T, FENG H, ZHANG Y, LI L, ZHAO A, NIU X, LIANG F, WANG M, ZHANG J, LU C, HE X, XIAO L, JIA W, LU A	4.245
Steroid-associated hip joint collapse in bipedal emus, *PLoS One*, 2013; 8(10):e76797.	ZHENG LZ, LIU Z, LEI M, PENG J, HE YX, XIE XH, MAN CW, HUANG L, WANG XL, FONG DT, XIAO DM, WANG DP, CHEN Y, FENG JQ, LIU Y, ZHANG G, QIN L	3.234
Strategies for combination of aptamer and targeted drug delivery, *J Nanosci Nanotechnol*, 2014 Jan;14(1):501-12.	WANG C, LIU B, LU J, ZHANG G, LU AP	1.556
Structural diversity requires individual optimization of ethanol concentration in polysaccharide precipitation, *International Journal of Biological Macromolecules*, 2014 Jun;67:205-9.	XU J, YUE R, LIU J, HO H, YI T, CHEN H, HAN Q	2.858
Study on essential oils from four species of Zhishi with gas chromatography-mass spectrometry, *Chem Cent J.*, 2014;3;8(1):22..	LIU Y, LIU Z, WANG C, ZHA Q, LU C, SONG Z, NING Z, ZHAO S, LU X, LU A	2.187
Supplementation with the extract of Schisandrae Fructus pulp, seed or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic diet, *Evid Based Complement Alternat Med*., 2014; 2014: 472638.	WANG XY, YU Z, PAN SY, ZHANG Y, SUN N, ZHU PL, ZHOU SF, KO KM	1.880
Target dIsease-Guided placEbo-contRolled (TIGER) design: a novel method for clinical trials of acupuncture, *Trials*, 2013; 14: 359.	ZHENG WK, WANG H, ZHANG L, BIAN ZX, SHANG HC	1.731
TCM Zheng Classification and Clinical Trials, *Evidence-Based Complementary and Alternative Medicine*, 2013: 723659.	LU AP, BENSOUSSAN A, LIU JP, BIAN ZX, CHO CS	1.880
The chemotaxonomic classification of Rhodiola plants and its correlation with morphological characteristics and genetic taxonomy, *Chem Cent J*., 2013; 7: 118.	LIU Z, LIU Y, LIU C, SONG Z, LI Q, ZHA Q, LU C, WANG C, NING Z, ZHANG Y, LU A	2.187
The evaluation on embryotoxicity of Dipsaci Radix with mice and embryonic stem cells, *Journal of Ethnopharmacology*, 2014;151(1):114-22.	XIAO TT, XU M, YANG XH, LOK L, CHOW YL, ZHAO Z, LEUNG SY, YANG Z, TIAN XY, LI Z, XING MY, XU W	2.998
The Herbal Compound Cryptotanshinone Restores Sensitivity in Cancer Cells That Are Resistant to the Tumor Necrosis Factor-related Apoptosis-inducing Ligand, *Journal of Biological Chemistry*, 2013 Oct 11; 288(41): 29923–29933.	TSE A, CHOW K, CAO H, CHENG C, KWAN H, YU H, ZHU G, WU Y, FONG W, YU Z	4.573
The Melanogenesis-inhibitory Effect and the Percutaneous Formulation of Ginsenoside Rb1, *AAPS PharmSciTech*, 2014 Oct; 15(5): 1252–1262. Epub : 2014 Jun 4.	WANG L, LU AP, YU Z, WONG NS, BIAN ZX, KWOK HH, YUE YK, ZHOU LM, CHEN HB, XU M, YANG ZJ	1.641
Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation, *Bone*, 2014 Feb;59:76-88.	GUO B, ZHANG B, ZHENG L, TANG T, LIU J, WU H, YANG Z, PENG S, HE X, ZHANG H, YUE KM, HE F, ZHANG L, QIN L, BIAN Z, TAN W, LIANG Z, LU A, ZHANG G	3.973
Tissue Specific Metabolite Profiling of Cyperus rotundus L. Rhizomes and (+)-Nootkatone Quantitation by Laser microdissection, Ultra-High-Performance Liquid Chromatography- Quadrupole Time-of-Flight Mass Spectrometry, and Gas Chromatography-Mass Spectrometry, *Journal of Agricultural and Food Chemistry*, 2014 Jul 23;62(29):7302-16.	JAISWAL YS, LIANG Z, GUO P, HO H, CHEN H, ZHAO Z	2.912
TMOT decoction combined with calcium channel blocker in the treatment of primary hypertension: a meta-analysis, *Hong Kong Chinese Medical Journal*, 2014;9(1):66-68.	CHEN XL, MO CW, XIA Q, XU M	--
Translational research in complementary and alternative medicine, *Evid Based Complement Alternat Med*, 2013;2013:296817.	JIA W, KOHLMEIER M, LU A, ZENG R	1.880
Triptolide downregulates Treg cells and the level of IL-10, TGF-β, and VEGF in melanoma-bearing mice, *Planta Me*d, 2013 Oct;79(15):1401-7.	LIU B, ZHANG HQ, LI J, LU C, CHEN G, ZHANG G, LU A, HE X	2.152
UHPLC UHD Q-TOF MS/MS analysis of the impact of sulfur fumigation on the chemical profile of Codonopsis Radix (Dangshen), *Analyst*, 2014 Jan 21;139(2):505-16.	MA XQ, LEUNG KM, CHAN CL, SU T, LI WD, LI SM, FONG WF, YU Z	4.107

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
Ultrahigh Resolution Mass Spectrometry-based Metabolic Characterization Reveals Cerebellum as a Disturbed Region in Two Animal Models, *Talanta*., 2014 Jan;118:45-53.	LIN SH, KANAWATI B, LIU LF, WITTING M, LI M, HUANG JD, SCHMITT-KOPPLIN P, CAI ZW	3.545
Wen Luo Yin inhibits angiogenesis in collagen-induced arthritis rat model and in vitro, *J Ethnopharmacol*., 2013 Sep 16;149(2):478-89.	LIU C, KONG X, LI X, GUO W, ZHANG C, SUN Y, SU X, LIU X, LU A, LIN N	2.998
Why Angelicae Sinensis Radix and Chuanxiong Rhizoma are different? An explanation from a chemical perspective, *Food Research International*, 2013; 54(1):439-447.	XU J, CHEN HB, LIU J, KWOK KY, YUE RQ, YI T, HO HM, ZHAO ZZ, HAN QB	2.818
*〈骶髂關節損傷的檢查〉，載《香港骨傷》。	涂豐	--
English / Chinese Books		
An insight into anti-diabetic effects of mushrooms, Grégoire Pesti, *Mushrooms: Cultivation, Antioxidant Properties and Health Benefits*, Nova Science Publishers, Inc., 141-155. ISBN: 978-1-63117-522-0.	DU B, XU BJ	--
Chinese Medicinal Identification: An Illustrated Approach, PING G and BRAND E (editor); ZHAO Z.Z. and CHEN H.B. (author), Paradigm Publications, Brookline, Mass and Taos, New Mexico, 560.	GUO P, BRAND E	--
Establishment of Chinese Medicinal Material Images Database, *Studies on Teaching and Learning (Volume 3)*, Pearson Education Asia Limited, 11-20.	CHEN H, SONG , LI YO	--
《百病食療》，萬里機構。	卞兆祥，趙中振	--
〈第一部 內科醫案 第七章肢體關節病〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港 : 靈蘭閣中醫藥文化有限公司，133-138。	董子林	--
〈第一部 內科醫案 第五章 腎病〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏， 香港 : 靈蘭閣中醫藥文化有限公司，74-106。	徐大基	--
〈第一部 內科醫案 第六章 脾胃病〉，載《我們在香港做中醫醫案輯》，徐大基 , 楊志敏， 香港 : 靈蘭閣中醫藥文化有限公司， 115-118。	張學斌	--
〈第七部 腫瘤科病案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司， 531-533。	毛小玲	--
〈第七部 腫瘤科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司， 501-505。	劉宇龍	--
〈第二部 婦科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港： 靈蘭閣中醫藥文化有限公司，179-187。	李晓光	--
〈第二部 婦科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司，207-212。	王玉荣	--
〈第五部 針灸科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港 : 靈蘭閣中醫藥文化有限公司，364-369。	彭增福	--
〈第六部 骨科、推拿科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司，418-422。	孫鋒	--
〈第六部 骨科、推拿科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司，440-445。	張建國	--
〈第六部 骨科、推拿科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港：靈蘭閣中醫藥文化有限公司，446-452。	朱恩	--
〈第四部 皮膚科、外科醫案〉，載《我們在香港做中醫醫案輯》，徐大基，楊志敏，香港 : 靈蘭閣中醫藥文化有限公司，252-262。	黃霏莉	--
《中草藥野外識別圖譜》，福建科學技術出版社，共 444 頁。	陳虎彪，楊全	--
《中國中藥材及原植 (動) 物彩色圖譜》，廣東科技出版社，共 650 頁。	郝近大，黃璐琦 ; 陳虎彪 (參編)	--
《五穀養生指南》，上海科學技術出版社，共 156 頁。	党毅，陳虎彪	--
《本草的世界——行天下探岐黃》，萬里書店，共 291 頁。	趙中振	--

Title / Brief Description	Author (s)	Impact Factor 2014 (IF)
《本草的世界——讀本草說中藥》，萬里書店，共 305 頁。	趙中振	--
《我們在香港做中醫醫案輯》，靈蘭閣中醫藥文化有限公司，共 626 頁。	徐大基，楊志敏	--
《豆療——小豆食出大健康》，萬里機構，共 144 頁。	党毅，陳虎彪	--
《俗語裏的健康智慧》，萬里機構，共 208 頁。	余寶珠	--
《柏金遜症：中醫治療與生活調養》，萬里機構，共 176 頁。	李敏	--
《高血壓病中醫治療與生活調養》，萬里機構，共 224 頁。	倫新	--
《婦科病：中醫治療與生活調養》，萬里機構．得利書局，共 240 頁。	郭岳峰，譚淵之	--
《糖尿病治療與中醫調養》，商務印書館 (香港) 有限公司，共 312 頁。	徐大基	--
《頸椎病中醫治療與生活調養》，萬里機構，共 160 頁。	涂豐，劉以正	--
《轉化醫學與類風濕關節炎中西醫結合研究》，科學出版社，共 176 頁。	張戈，呂愛平	--
《茶療良方》，萬里機構 · 得利書局，共 208 頁。	梁浩榮	--

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
\# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2013 (IF)
2012-2013		
Research Paper		
1,25-Dihydroxyvitamin D3 Suppresses Telomerase Expression and Human Cancer Growth through MicroRNA-498, *Journal of Biological Chemistry*, 2012 Nov 30;287(49):41297-309.	KASIAPPAN R, SHEN Z, TSE KW, JINWAL U, TANG J, LUNGCHUKIET P, SUN Y, KRUK P, NICOSIA SV, ZHANG X, BAI W	4.600
A Metabolomics Profiling Study in Hand-Foot-and-Mouth Disease and Modulated Pathways of Clinical Intervention Using Liquid Chromatography / Quadrupole Time-of-flight Mass Spectrometry, *Evid Based Complement Alternat Med*, 2013;2013:647452.	LIU C, LIU X, DING X, CHEN X, FAN H, LIU Y, XIE N, TAN Y, KO J, ZHANG W, LU A	2.175
A New Application of an Aqueous Diphase Solvent System in One-step Preparation of Polysaccharide from the Crude Water Extract of Radix Astragali by High-speed Counter-current Chromatography, *J. Chromatogr A.*, 2012 Nov 2;1262:92-7.	YIN JY, JIANG ZH, YU H, XIE MY, HSIAO WL, LU A, HAN QB	4.258
Adoption in China of Clinical Practice Guidelines for Hypertension Using Traditional Chinese Medical Approaches: A Literature Review Based on Clinical Studies., *J Altern Complement Med*, 2013 Jan;19(1):1-8.	SHI N, HAN X, YU W, WANG L, LU A	1.518
Alkyl and phenolic glycosides from Saussurea stella, *Fitoterapia*, 2013 Jul;88:38-43.	WANG T, WANG R, CHEN H, SHANG M, CAI S	2.216
Alkylphenols from the Roots of Ardisia brevicaulis Induce G1 Arrest and Apoptosis through Endoplasmic Reticulum Stress Pathway in Human Non-small-cell Lung Cancer Cells, *Chem Pharm Bull (Tokyo)*, 2012;60(8):1029-36.	ZHU G, WONG BC, LU A, BIAN ZX, ZHANG G, CHEN H, WONG YF, FONG W, YANG Z	1.375
An interesting two-phase solvent system and its use in preparative isolation of aconitines from aconite roots by counter-current chromatography, *Journal of Separation Science*, 2013 Apr;36(7):1304-10.	HAN QB, TANG W, DONG C, XU H, JIANG Z	2.594
Angiogenic factors in bone local environment, *Cytokin Growth Factor Rev.*, 2013 Jun;24(3):297-310.	CHIM SM, TICKNER J, CHOW ST, KUEK V, GUO B, ZHANG G, ROSEN V, ERBER W, XU J	6.537
Astragalus saponins downregulate hypoxia-induced VEGF induction in colon cancer cells, *BMC Complementary and Alternative Medicine*, 2012 Sep 19;12:160.	LAW P, AUYEUNG K, CHAN L, KO KS	1.877
Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway, *Arthritis Res Ther.*, 2012 Jul 31;14(4):R177.	WEI F, MOORE D, LI Y, ZHANG G, WEI X, LEE J, WEI L	4.117
Bridging the traditional Chinese medicine pattern classification and biomedical disease diagnosis with systems biology, *Chin J Integr Med*, 2012 Dec;18(12):883-90.	LU A, BIAN ZX, CHEN K	1.401
Characterization and determination of six flavonoids in the ethnomedicine “Dragon’s Blood” by UPLC-PAD-MS, *Chemistry Central Journal*, 2012 Oct 10;6(1):116.	YI T, TANG Y, ZHANG J, ZHAO Z, YANG Z, CHEN H	1.663
Characterization and simultaneous determination of immunosuppressive decalins in red yeast rice by ultra-high-performance liquid chromatography hyphenated with mass spectrometry, *Journal of Chromatography A*, 2013 Aug 16;1303:54-61.	ZHU L, HAN QB, HO A, HSIAO W, JIANG Z	4.258
Characterization of secondary metabolites from the raphides of calcium oxalate contained in three Araceae family plants using laser microdissection and ultra-high performance liquid chromatography-quadrupole/time of flight-mass spectrometry, *European Journal of Mass Spectrometry*, 2013;19(3):195-210.	LIANG Z, ZHANG J, WONG L, YI T, CHEN H, ZHAO Z	1.165
Chemical Differentiation of Two Taste Variants of Gynostemma pentaphyllum by Using UPLC-Q-TOF-MS and HPLC-ELSD, *Journal of Agricultural and Food Chemistry*, 2013 Jan 9;61(1):90-7.	LU JG, ZHU L, LO KY, LEUNG AK, HO AH, ZHANG HY, ZHAO ZZ, FONG WF, JIANG ZH	3.107
Chemical profiling and histochemical analysis of Bupleurum marginatum roots from different growing areas of Hubei province, *Acta Pharmaceutica Sinica B*, 2013 May; 3(3):193-204.	LIANG Z, ZHANG J, YANG G, ZHAO Z, CHEN H	--
Chemical quantification and antioxidant assay of four active components in Ficus hirta root using UPLC-PAD-MS fingerprinting combined with cluster analysis, *Chemistry Central Journal*, 2013 Jul 8;7(1):115.	YI T, CHEN Q, HE X, SO S, LO Y, FAN L, XU J, TANG Y, ZHANG J, ZHAO Z, CHEN H	1.663
Chemistry, bioactivity and quality control of Dendrobium, a commonly used tonic herb in traditional Chinese medicine., *Phytochemistry Reviews.*, 2013 June;12: 341-367.	XU J, HAN Q, LI S, CHEN X, WANG X, ZHAO Z, CHEN H	2.894

Title / Brief Description	Author (s)	Impact Factor 2013 (IF)
Chemotherapeutic activities of Carthami Flos and its reversal effect on multidrug resistance in cancer cells, *Afr J Tradit Complement Altern Med.*, 2013 May 16;10(4):36-40.	WU Y, YU Z, FONG W, SHI Y	0.560
Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study, *Evid Based Complement Alternat Med*, 2013;2013:327245.	ZHONG L, BIAN ZX, GU JH, ZHOU X, TIAN Y, MAO JC, CHEN XJ	2.175
Chronic cranberry juice consumption restores cholesterol profiles and improves endothelial function in ovariectomized rats., *Eur J Nutr*, 2013 Apr;52(3):1145-55.	YUNG LM, TIAN XY, WONG WT, LEUNG FP, YUNG LH, CHEN ZY, LAU CW, VANHOUTTE PM, YAO X, HUANG Y	3.840
Cloning and expression regulation of 1-deoxy-D-xylulose-5-phosphate reductoisomerase cDNA from Alpinia officinarum, *China Journal of Chinese Materia Medica*, 2012; 37(21):3208-3214.	ZHANG CR, YANG Q, CHEN HB, PANG YX, TANG XM, CHENG XX, WU WY,CHEN SM	--
Comparative chemical analysis of Radix Astragali and Radix Hedysari by HPLC, *Natural Product Research*, 2012;26(20):1935-8.	LIU Y, ZHANG X, ZHAO Y, CHEN H, WANG B, ZHANG Q	1.225
Comparison of the chemical composition and pharmacological effects of the aqueous and ethanolic extracts from a Tibetan "Snow Lotus" (Saussurea laniceps) herb, *Molecules*, 2012 Jun 12;17(6):7183-94.	YI T, LO H, ZHAO Z, YU Z, YANG Z, CHEN H	2.095
Considerations of Traditional Chinese Medicine as Adjunct Therapy in the Management of Ulcerative Colitis, *Clinical Reviews in Allergy & Immunology*, 2013 Jun;44(3):274-83.	ZHANG C, JIANG M, LU A	5.590
Content detemination of total tannin in Smilax glabra with reddish brown and off-white colored cross section, *China Journal of Chinese Materia Medica*, 2013,38(6):852-855.	ZHANG H, DONG LS, CHEN HB, HE XC, GE XQ, ZHANG XG, ZHOU YY	--
Corynoxine B, a Novel Autophagy Enhancer, Promotes the Clearance of Mutant Tau Aggregation in Vitro and in Vivo, *Neurodegen. Dis.*, 2013; Vol. 11, (Suppl.1): P120.	DURAIRAJAN SSK, CHEN LL, SONG JX, LIU LF, BAUM L, LI M	3.454
Deciphering the differential toxic responses of Radix Aconiti Lateralis Praeparata in Healthy and Hydrocortisone-pretreated rats based on Serum Metabolic Profiles, *J Proteome Res*, 2013 Jan 4;12(1):513-24.	TAN Y, LI J, LIU X, KO J, HE X, LU C, LIU Z, ZHAO H, XIAO C, NIU X, ZHA Q, YU Z, ZHANG W, LU A	5.001
Determination of five flavonoids in different parts of Fordia cauliflora by ultra performance liquid chromatography/triple-quadrupole mass spectrometry and chemical comparison with the root of Millettia pulchra var. laxior, *Chemistry Central Journal*, 2013 Jul 19;7(1):126.	FAN L, ZHANG Y, HUANG R, SHANDING Q, YI T, FENG X, TANG Y, QU X, CHEN H, MIAO J	1.663
Determination of the content of rosmarinic acid by HPLC and analytical comparison of volatile constituents by GC-MS in different parts of Perilla frutescens (L.) Britt., *Chemistry Central Journal*, 2013 Apr 1;7(1):61.	LIU J, WAN Y, CHEN H, ZHAO Z	1.663
Development of high-performance liquid chromatographic fingerprint for quality analysis of Hedysari Radix, *Natural Product Research*, 2013 Aug;27(15):1398-403.	LIU Y, ZHAO Y, CHEN H, LIANG H, ZHANG Q	1.225
Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity, *Lipids Health Dis.*, 2012 Sep 19;11:120.	PAN S, YU Q, ZHANG Y, WANG X, SUN N, YU Z, KO K	2.310
Effect of Combining Therapy with Traditional Chinese Medicine-based Psychotherapy and Herbal Medicines in Women with Menopausal Syndrome: A Randomized Controlled Clinical Trial, *Evid Based Complement Alternat Med*, 2012;2012:354145.	YANG H, YANG J, WEN Z, ZHA Q, NIE G, HUANG X, ZHANG C, LU A, JIANG M, WANG X	2.175
Effect of Liposomes on the Absorption of Water-soluble Active Pharmaceutical Ingredients via Oral Administration, *Curr Pharm Des*, 2013;19(37):6647-54.	YANG Z, LU A, WONG B C, CHEN X, BIAN Z, ZHAO Z, HUANG W, ZHANG G, CHEN H, XU M	3.288
Embryotoxicity of Psoralea corylifolia L.: In vivo and in vitro studies, *Birth Defects Research (Part B): Developmental and Reproductive Toxicology*, 2012 Dec;95(6):386-94.	XU M, TIAN X, LEUNG K, LEE K, CHOW T, DENG B, YIU C, CHOW C, ZHAO Z, YANG Z, FONG W, XIAO T, XU W, DENG P	1.168
Evidence-based ZHENG: A Traditional Chinese Medicine Syndrome, *Evid Based Complement Alternat Med.*, 2012;2012:246538.	SU SB, LU A, LI S, JIA W	2.175
Experimental and clinical research literature review of Tianma Gouteng Yin on the treatment of Parkinson's disease, *Hong Kong J. Tradit. Chin. Med. (Chin.)*, 2012;7(4):66-70.	CHUA K, CHAU C, LI M	--

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2013 (IF)
Expert Consensus on the Treatment of Hypertension with Chinese Patent Medicines, *Evid Based Complement Alternat Med*, 2013;2013:510146.	WANG LY, CHAN KW, YUWEN Y, SHI NN, HAN XJ, LU A	2.175
Expert Consensus on the Treatment of Rheumatoid Arthritis with Chinese Patent Medicines., *Evid Based Complement Alternat Med*, 2013 Feb;19(2):111-8.	ZHAO J, ZHA Q, JIANG M, CAO H, LU A	2.175
Extending the CONSORT Statement to moxibustion, *J Integr Med*, 2013 Jan;11(1):54-63.	CHENG C, FU S, ZHOU Q, WU T, SHANG H, TANG X, LIU Z, LIU J, LIN Z, LAO L, LU A, ZHANG B, LIU B, BIAN ZX	--
Feasibility Analysis of the Value of Q Method in the Classification and Understanding of Expert Experience, *Chin J Integr Med*., 2013 Nov;19(11):869-73. Epub 2012 Dec 3. [Epub ahead of print]	LIU MY, LI Y, LU A, HAN XJ	1.401
Fruits of the Popular European Medicinal Plant Vitex agnus-castus in Chemoprevention via NADP(H) : Quinone Oxidoreductase Type 1 Induction, *Evidence-Based Complementary and Alternative Medicine*, 2013;2013:432829.	LI S, QIU S, YAO P, SUN H, FONG H, ZHANG H	2.175
Hippocampal metabolomics using ultrahigh- resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice, *Anal Bioanal Chem*., 2013 Jun;405(15):5105-17.	LIN S, KANAWATI B, LIU L, LIU H, WITTING M, LI M, HUANG J, SCHMITT-KOPPLIN P, CAI Z	3.578
Identification of daqingye and banlangen including crude drugs and decoction dregs from three plant species by normal light and fluorescence microscopy, *Microscopy Research and Technique*, 2013 Aug;76(8):774-82.	WAN X, LIANG Z, CHEN H, ZHAO Z, LI P	1.170
Impact of Treatment-related Dyskinesias and Non-motor Symptoms on Quality of Life in Chinese Patients with Idiopathic Parkinson's Disease, *Inter. J. Integra. Med*, 2013, 1(31):1-7.	CHUA K, GAO J, KUM W, LI M	--
In vivo antitumour activity of amphiphilic sislcon(IV) phthalocyanine with axially ligated rhodamine B., *Bioorganic and Medicinal Chemistry Letters*, 2013 Apr 15;23(8):2373-6.	ZHAO Z, GAMBARI R, LEE K, KOK S, WONG R, LAU F, TANG J, LAM K, CHENG C, HAU D, CHUI C, WONG W, WONG W	2.331
In vivo study on the pharmacological interactions between a Chinese herbal formula ELP and anti-resorptive drugs to counteract osteoporosis, *Evidence-Based Complementary and Alternative Medicine*, 2012;2012:203732.	KO C, SIU W, WONG H, GAO S, SHUM W, LAU C, CHENG S, TAM C, HUNG L, FUNG K, LAU C, HAN Q, LEUNG P	2.175
Inhibition of DNA-dependent protein kinase reduced palmitate and oleate-induced lipid accumulation in HepG2 cells, *European Journal of Nutrition*, 2013 Sep;52(6):1621-30.	KWAN HY, FONG WF, YANG Z, YU Z, HSIAO WW	3.840
Insulin Resistance in In Vitro Astrocytic Cultures under Methylglyoxal Treatment, *Diabetes*, July 2013;62(S1):A154.	CHU M, YUNG KK, CHENG CH, YUE KM	3.840
Lipidomics identification of metabolic biomarkers in chemically induced hypertriglyceridemic mice, *Journal of Proteome Research*, 2013 Mar 1;12(3):1387-98.	KWAN HY, HU YM, CHAN CL, CAO HH, CHENG CY, PAN SY, TSE KW, WU YC, YU ZL, FONG WF	5.001
Literature Review and Data Analysis of Di-tan Decoction on Experimental and Clinical Study of Dementia, *Hong Kong J. Tradi. Chin. Med*., 2012;7(2): 72-75.	CHUA KK, LI M	--
Literature review of Chinese medicated diet for hypertension, *Hong Kong J. Tradit. Chin. Med. (Chin.)*, 2013;8(2): 66-69.	YUAN Y, LI M	--
miR-214 targets ATF4 to inhibit bone formation, *Nature Medicine*, 2013 Jan;19(1):93-100.	WANG X, GUO B, LI Q, PENG J, YANG Z, WANG A, LI D, HOU Z, LV K, KAN G, CAO H, WU H, SONG J, PAN X, SUN Q, LING S, LI Y, ZHU M, ZHANG P, PENG S, XIE X, TANG T, HONG A, BIAN ZX, BAI Y, LU AP, LI Y, HE F, ZHANG G, LI Y	28.054
Mushroom and Health, Curr Top Nutraceutical Res, 2012; 10: V-VI.	YU Z	0.190
New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics, *Evid Based Complement Alternat Med*., 2013;2013:627375.	PAN S, ZHOU S, GAO S, YU Z, ZHANG S, TANG M, SUN J, MA D, HAN Y, FONG W, KO K	2.175
Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft, *Oncology Reports*, 2012 Dec;28(6):2188-94.	AUYEUNG KW, LAW P, KO KS	2.191

Title / Brief Description	Author (s)	Impact Factor 2013 (IF)
Novel insights about the mechanism of visceral hypersensitivity in maternally separated rats, *Neurogastroenterol Motil*, 2012 Jul;24(7):593-6.	BIAN ZX	3.424
On difference between cold-attack disease and warm-heat disease, *Journal of Beijing University of Traditional Chinese Medicine*, 2013;5(36):p.297-300.	JIANG Y, ZHANG QL	--
Profiling of secondary metabolites in tissues from Rheum palmatum L. using laser microdissection and liquid chromatography mass spectrometry, *Analytical and Bioanalytical Chemistry*, 2013 May;405(12):4199-212.	LIANG Z, SHAM T, YANG G, YI L, CHEN HB, ZHAO ZZ	3.578
Quantitative comparison of multiple components in Dioscorea nipponica and D. panthaica by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry, *Phytochemical Analysis*, 2013 Jul-Aug;24(4):413-22.	TANG Y, YI T, CHEN H, ZHAO ZZ, LIANG Z, CHEN H	2.450
Quercetin induces apoptosis via mitochondrial pathway in KB and KBv200 cells, *Journal of Agricultural and Food Chemistry*, 2013 Mar 6;61(9):2188-95.	ZHANG J, YI T, LIU J, ZHAO Z, CHEN HB	3.107
Quercetin Induces Apoptosis, Suppresses Migration and Invasion in Human Melanoma Cells through Inhibiting the STAT3 Pathway, *Siriraj Med J*, 2012; 6(Suppl 2):101.	CAO H, YU ZL	--
Regulation of multiple transcription factors by reactive oxygen species and effects of pro-inflammatory cytokines released during myocardial infarction on cardiac differentiation of embryonic stem cells, *Int J Cardiol*, 2013 Oct 9;168(4):3458-72. Epub 2013 May 23.[Epub ahead of print]	LAW SK, LEUNG FP, LEUNG C, YAU KL, TSE CL, WONG CK, MASCHECK L, HUANG Y, SAUER H, TSANG SY	6.175
Role of Endoplasmic Reticulum Stress Proteins IRE-1, PERK and CHOP in Oridonin-treated HepG2 Cells, *Traditional Chinese Drug Research and Clinical Pharmacology*, 2012; 23:263-6.	WANG H, YE Y, YU ZL	--
Rubesanolides C-E: The abietane diterpenoids isolated from Isodon rubescens and evaluation of their anti-biofilm activity, *Organic & Biomolecular Chemistry*, 2012 Jul 14;10(26):5039-44.	ZOU J, PAN L, LI Q, PU J, YAO P, ZHU M, BANAS J, ZHANG H, SUN H	3.487
Skin Health Promotion Effects of Natural Beta-Glucan Derived from Cereals and Microorganisms: A Review, *Phytother Res*, 2014 Feb;28(2):159-66. Epub 2013 Mar 11. [Epub ahead of print]	DU B, BIAN ZX, XU B	2.397
Structural characterization and immuno-modulating activities of a polysaccharide from Ganoderma sinense, *International Journal of Biological Macromolecules*, 2012 Nov;51(4):597-603.	HAN X, CHAN B, YU H, YANG Y, HU S, KO C, DONG C, WONG C, SHAW P, FUNG K, LEUNG P, HSIAO WL, TU P, HAN Q	3.096
Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents, *American Chemical Society (ACS) Medicinal Chemistry Letters*, 2012 Dec 20;4(2):170-4.	CHAN S, CHUI C, CHAN S, KOK S, CHAN D, TSOI M, LEUNG P, LAM A, CHAN A, LAM K, TANG J	3.073
Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation, *Current Pharmaceutical Design*, 2013;19(1):48-66.	KO KS, AUYEUNG KW	3.288
The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells, *J Gastroenterol*, 2013 Feb;48(2):182-92.	KWAN HY, YANG ZJ, FONG W, HU Y, YU ZL, HSIAO W	4.020
The beneficial effect of Icaritin on osteoporotic bone is dependent on the treatment initiation timing in adult ovariectomized rats, *Bone*, 2013 Jul;55(1):230-40.	PENG S, ZHANG G, ZHANG B, GUO B, HE Y, BAKKER A, PAN X, ZHEN W, HUNG L, QIN L, LEUNG W	4.461
The commonly used ten Chinese medicines for the clinical treatment of dementia, *Hong Kong J. Tradit. Chin. Med. (Chin.)*, 2013;8(1): 55-58.	LI M	--
The Quest for Modernisation of Tradition Chinese Medicine, *BMC Complementary and Alternative Medicine*, 2013 Jun 13;13:132.	XU Q, BAUER R, HENDRY BM, FAN T, ZHAO ZZ, DUEZ P, SIMMONDS MSJ, WITT CM, LU AP, ROBINSON N, GUO D, HYLANDS PJ	1.877
The role of APP in Alzheimer's disease, *Advances in Alzheimer's Disease*, 2013;2(2):60-65.	PUNG L, WANG X, LI M, XUE L	--
Traditional Chinese medicine-based network pharmacology could lead to new multicompound drug discovery, *Evid Based Complement Alternat Med*, 2012;2012:149762.	LI J, LU C, JIANG M, NIU X, GUO H, LI L, BIAN ZX, LIN N, LU AP	2.175

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
\# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2013 (IF)
Triptolide Prevents Bone Destruction in the Collagen-induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway, *Evid Based Complement Alternat Med.*, 2013;2013:626038 .	LIU C, ZHANG Y, KONG X, ZHU L, PANG J, XU Y, CHEN W, ZHAN H, LU AP, LIN N	2.175
Understanding the Molecular Mechanism of Interventions in Treating Rheumatoid Arthritis Patients with Corresponding Traditional Chinese Meidicne Patterns Based on Bioinformatics Approach, *Evid Based Complement Alternat Med.*, 2012;2012:129452.	JIANG M, LU C, CHEN G, NIU X, ZHA Q, CHEN S, LU AP	2.175
Xiaoqinglong Granules as add-on Therapy for Asthma: Latent Class Analysis of Symoptom Predictors of Respons, *Evid Based Complement Alternat Med*, 2013;2013:759476.	ZHA Q, LIN S, ZHANG C, CHANG C, XUE H, LU C, JIANG M, LIU Y, XIAO Z, LIU W, SHANG Y, CHEN J, WEN M, LU AP	2.175
ZHENG-Omics Application in ZHENG Classification and Treatment: Chinese Personalized Medicine, *Evid Based Complement Alternat Med*, 2013;2013:235969.	DAI J, FANG J, SUN S, CHEN Q, CAO H, ZHENG N, ZHANG Y, LU AP	2.175
β-Ionone induces cell cycle arrest and apoptosis in human prostate tumor cells, *Nutr Cancer*, 2013;65(4):600-10.	JONES S, FERNANDES N, YEGANEHJOO H, KATURU R, QU H, YU ZL, MO H	2.635
Dynamic variation of total tannins content in the stems, leaf and fruit of Juglans mandshurica, *Chinese Traditional Patent Medicine*, 2012;34(8):1567-1569. (in Chinese)	WANG TM, XU SZ, ZHANG H, CHEN HB, KANG TG	--
Study on the dynamic variation of juglone content in the branches of Juglans mandshurica, *Chinese Journal of Hospital Pharmacy*, 2012;32(15):1166-1168. (in Chinese)	WANG TM, ZHAI YJ, XU SZ, CHEN HB, KANG TG	--
*〈益母草逆轉口腔癌細胞多藥耐藥作用〉，載《時珍國醫國藥 2012》，2012, 23(11):2900-2。	胡耀昌，方宏勳，禹志領，史亦謙	--
*〈欲求健康首護脊椎〉，載《現代中醫藥》，2:27-31。	涂豐	--
*〈槐米顯微特徵常數與化學成分相關性研究〉，載《中藥材》，2013;36(4):572-574。	梁鸝，趙中振，李娜，康廷國	--
*〈骶髂關節損傷的檢查運用〉，載《香港骨傷》，70-78 頁。	涂豐	--
Chinese Books		
《戰勝結腸炎——治療與飲食調理》，萬里機構・萬里書店。	郭岳峰 (與錢楊佩娟和王慶玲)	--
《痛風——治療與中醫調養》，商務 (香港) 印書館。	徐大基	--
《戰勝甲狀腺病——中醫治療調理與藥膳》，萬理機構 · 得利書局。	梁浩榮	--
《中藥材鑑定圖典 (日文版)》，日本：NTS。	趙中振，陳虎彪	--
《生藥鑑別圖鑑》，趙中振、陳虎彪著，楊智鈞監譯，日本科技出版社（NTS）。	趙中振，陳虎彪，楊智鈞	--
《中藥資源學（普通高等教育“十一五”國家級規劃教材）》，北京：中國中醫藥出版社（任編委）。	王文全，陳虎彪	--
《百草皆藥》，香港：萬里機構（參編）。	趙中振，郭平，洪雪榕，陳虎彪	--
《細說阿膠》，萬理機構 · 得利書局。	梁啟文，梁惠梅	--
《穀療》，萬理機構 · 得利書局。	党毅，陳虎彪	--
《福字阿膠》，萬理機構 · 得利書局。	陳虎彪	--
《中藥上市後臨床再評價設計方法與實施》，人民衛生出版社。	呂愛平	--
《基於循證醫學的中醫臨床實踐指南編制方法與範例》，中國中醫藥出版社。	呂愛平	--

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
2011-2012		
Research Paper		
20(S)-Protopanaxadiol, a metabolite of ginsenosides, induced cell apoptosis through 3 endoplasmic reticulum stress in human hepatocarcinoma HepG2 cells, *Eur J Pharmacol*., 2011 Oct 1;668(1-2):88-98.	ZHU G, LI Y, TSE A, HAU D, LEUNG C, YU Z, FONG W	2.592
3'-O,4'-O-aromatic acyl substituted 7,8-pyranocoumarins: a new class of P-glycoprotein modulators, *Journal of Pharmacy and Pharmacology*, 2012 Jan;64(1):90-100.	SHEN X, CHEN G, ZHU G, CAI J, WANG L, HU Y, FONG WF	2.033
A corss-sectional study of constipation and laxatives use in advanced cancer patients: insights for revision of current practice, *Supportive care in Cancer*, 2013 Jan;21(1):149-56. Epub 2012 Jun 1. [Epub ahead of print]	CHENG CW, KWOK AO, BIAN ZX, TSE DM	2.649
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy, *Nature Medicine*, 2012 Jan 29;18(2):307-14.	ZHANG G, GUO B, WU H, TANG T, ZHANG B, ZHENG L, HE Y, YANG Z, PAN X, CHOW HL, TO K, LI Y, LI D, WANG X, WANG Y, LEE K, HOU Z, DONG N, LI G, LEUNG K, HUNG L, HE F, ZHANG L, QIN L	24.302
A literature Review on the Treatment of Chinese Medicine in Neurodegenerative Diseases through Supplying Kidney Qi, Promote Blood Circulation and Dispel Phlegm, *Hong Kong Chin. Med. J. (Chin.)*, 2011;6(4): 35-40.	HUI M, CHUA K, LI M	--
Activation of p38 MAPK pathway contributes to the melanogenic property of apigenin in B16 cells, *Experimental Dermatology*, 2011 Sep;20(9):755-7.	YE Y, WANG H, CHU J, CHOU G, YU Z	3.578
Acylated protopanaxadiol-type ginsenosides from the root of Panax ginseng, *Chemistry & Biodiversity*, 2011 Oct;8(10):1853-63.	ZHU G, HAU D, JIANG Z, YU Z, FONG WF	1.808
Alkylphenols from the Roots of Ardisia brevicaulis Induce G1 Arrest and Apoptosis through Endoplasmic Reticulum Stress Pathway in Human Non-small-cell Lung Cancer Cells, *Chem Pharm Bull*., 2012;60(8):1029-36.	ZHU G, WONG B, LU A, BIAN Z, ZHANG G, CHEN H, WONG Y, FONG W, YANG Z	1.564
An ethnobotanical survey of medicinal plants of Laos toward the discovery of bioactive compounds as potential candidates for pharmaceutical development, *Pharmaceutical Biology*, 2012 Jan;50(1):42-60.	SOEJARTO D, GYLLENHAAL C, KADUSHIN M, SOUTHAVONG B, SYDARA K, BOUAMANIVONG S, XAIVEU M, ZHANG H, FRANZBLAU S, TAN G, PEZZUTO J, RILEY M, ELKINGTON B, WALLER D	1.206
An ethnobotanical survey of medicinal spices used in Chinese hotpot, *Food Research International*, 2012 August;48(1):226-232.	WU M, GUO P, CHEN H, ZHAO Z	3.005
Analysis on Volatile Components of "Huoluoyou" selled in Hong Kong Market by GC-MS, *Hong Kong Chinese Medicinal Journal*, 2011;6(4):28-29.	ZHUANG LL, YI T, ZHAO Z, CHEN H	--
Anti-inflammatory activities and mechanisms of action of the petroleum ether fraction of Rosa multiflora Thunb. hips., *J Ethnopharmacol*., 2011 Dec 8;138(3):717-22.	GUO D, XU L, CAO X, GUO Y, YE Y, CHAN C, MOK D, YU Z, CHEN S	2.755
Application and advantage of near infrared spectroscopy technology in authentication of Chinese materia medica, *China Journal of Chinese Materia Medica*, 2012;37(8):1062-1065□	ZHAO Z, LIANG Z	--
Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells, *Journal of Ethnopharmacology*, 2012 Jun 1;141(2):635-41.	AUYEUNG K, WOO P, LAW P, KO J	2.755
Authentication of Chinese Materia Medica decoction dregs. Part I: comparison of morphological and microscopic features of four Chinese Materia Medica before and after decoction, *Microscopy Research and Technique*, 2011 Apr;74(4):320-8.	WONG L, LIANG Z, CHEN H, ZHAO Z	1.593
Authentication of Chinese Materia Medica decoction dregs. Part II: comparison before and after decoction of four Chinese Materia Medica that mainly comprise storage tissue, *Microscopy Research and Technique*, 2012 Feb;75(2):164-75.	WONG L, LIANG Z, CHEN H, ZHAO Z	1.593

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.
* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
Authentication of the 31 species of toxic and potent Chinese materia medica (T/PCMM) by microscopic technique assisted by ICP-MS analysis, Part 4: four kinds of toxic and potent mineral arsenical CMMs, *Microscopy Research and Technique*, 2011 Jan;74(1):1-8.	LI Q, CHU C, WANG Y, CHEN H, LI P, ZHAO Z	1.593
Berberine Ameliorates Beta-amyloid Pathology, Gliosis and Cognitive Impairment in an Alzheimer's Disease Transgenic Mouse Model, *Neurobiol. Aging*, 2012 Dec;33(12):2903-19.	DURAIRAJAN S, LIU L, LU J, CHEN L, YUAN Q, CHUNG S, HUANG L, LI X, HUANG J, LI M	6.166
Bone morphogenic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38MAPK and JNK pathway, *J Mol Cell Cardiol*., 2012 Jan;52(1):237-44.	TIAN XY, YUNG LH, WONG WT, LIU J, LEUNG FP, LIU L, CHEN Y, KONG SK, KWAN KM, NG SM, LAI PB, YUNG LM, YAO X, HUANG Y	5.148
BYHW decoction in the treatment of angina pectoris: a systematic review and meta-analysis, *Hong Kong Chinese Medical Journal*, 2011;6(4):41-42.	XU M, CHEUNG CH, XIAO TT	--
Catalysis-based inhibitors of the calcium signaling function of CD38. *Biochemistry*, 2012 Jan 10;51(1):555-64.	KWONG AK, CHEN Z, ZHANG H, LEUNG FP, LAM CM, TING KY, ZHANG L, HAO Q, ZHANG LH, LEE HC	3.377
Chemical and DNA authentication of taste variants of Gynostemma pentaphyllum herbal tea, *Food Chemistry*, 2011 Sep 1;128(1):70-80.	WU PK, TAI WC, CHOI RC, TSIM KW, ZHOU H, LIU X, JIANG Z, HSIAO WL	3.334
Chinese herbal medicinal compound Cory B promotes the clearance of pathogenic protein aggregations associated with Parkinson's disease via inducing autophagy, *ACTA Biophysica Sinica (Suppl.1)*, 2012;28(7):21.	LU J, SONG J, DURAIRAJAN S, LIU L, LI M	--
Chinese herbs in treating and preventing abortion: a quantitative analysis of clinical data, *Hong Kong Chinese Medical Journal*, 2011;6(4):26-47.	TIAN X, XU M, DENG P, XIAO T, XU W, ZHANG D	--
Clinical application of Angelica sinensis and its formulae in the treatment of gynecological diseases, *Hong Kong Chinese Medical Journal*, 2012;7(2):29-32.	XIAO TT, XU M, DENG PX, WANG WQ	--
Combined effect of early life stress and acute stress on colonic sensory and motor responses through serotonin pathways: Differences between proximal and dista colon in rats, *Stress*, 2011 Jul;14(4):448-58.	BIAN ZX, QIN HY, TIAN SL, QI SD	3.252
Comparative study of wild and cultivated Astragali Radix in Daqingshan district in Wuchuan of Neimenggu, *China Journal of Chinese Materia Medica*, 2011;36(12):1577-1581.	LIU J, YANG H, ZHU X, ZHAO Z, CHEN H	--
Comparative study on decoction pieces of traditional Chinese crude drugs from Hong Kong and mainland of China, *Hong Kong Chinese Medicinal Journal*, 6(2):24-26.	ZHANG D, ZHAO Z, CHEN H	--
Comparison of the chemical composition and pharmacological effects of the aqueous and ethanolic extracts from a Tibetan "Snow Lotus" (Saussurea laniceps) herb, *Molecules*, 2012 Jun 12;17(6):7183-94.	YI T, LO H, ZHAO Z, YU Z, YANG Z, CHEN H	2.428
Comparison of the chemical profile and anti-platelet aggregation effects of two "Dragon's Blood" drugs used in traditional Chinese medicine, *Journal of Ethnopharmacology*, 2011 Jan 27;133(2):796-802.	YI T, CHEN H, ZHAO Z, YU Z, JIANG Z	2.755
Comprehensive chemical analysis of Venenum Bufonis by using liquid chromatography/electrospray ionization tandem mass spectrometry, *J Pharm Biomed Anal*., 2011 Sep 10;56(2):210-20.	HU Y, YU Z, YANG Z, ZHU G, FONG W	2.947
Cytotoxic dehydromonacolins from red yeast rice, *J. Agric. Food Chem*, 2012 Feb 1;60(4):934-9.	ZHU L, YAU LF, LU J, ZHU G, WANG J, HAN QB, HSIAO W, JIANG Z	2.906
Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model, *Osteoporosis International*, 2012 Jan;23(1):377-89.	HE Y, LIU Z, PAN X, TANG T, GUO B, ZHEN L, XIE X, WANG X, LEE K, LI G, CAO Y, WEI L, CHEN Y, YANG Z, HUNG L, QIN L, ZHANG G	4.039
Developing a library of authenticated traditional Chinese medicine (TCM) plants for systematic biological evaluation - rationale, methods and preliminary results from a sino-american collaboration, *Fitoterapia*, 2011 Jan;82(1):17-33.	EISENBERG D, HARRIS E, LITTLEFIELD B, CAO S, CRAYCROFT J, SCHOLTEN R, BAYLISS P, FU Y, WANG W, ZHAO Z, CHEN H, LIU Y, KAPTCHUK T, HAHN W, ROBERTS T, SHAMU C, CLARDY J	2.231
Developing new drugs from annals of Chinese medicine, *Acta Pharmaceutica Sinica B*, 2012 February 10;2(1): 1-7.	BIAN ZX, CHEN SL, CHENG CW, WANG J, XIAO H, QIN HY	--

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
Discovery of kuraridin, a nontoxic anti-bacterial agent against methicillin-resistant Staphylococcus aureus (MRSA), from Sophora flavescens by bioassay guided fractionation using high-speed counter-current chromatography, *Journal of Chromatography B*, 2012;880,157-62.	CHAN CL, IP M, YU H, WONG C, JOLIVALT C, LITAUDOR M, LAU BS, LUI SL, FUNG KP, LEUNG PC, HAN QB	2.487
Dual-direction effects of phytoestrogens, *Hong Kong Chinese Medical Journal*, 2011;6(3):27-28.	DENG PX, XU W, XU M	--
Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, *Toxicology & Applied Pharmacology*, 2012 Jul 1;262(1):80-90.	LI L, YUE GG, LAU CB, SUN H, FUNG K, LEUNG P, HAN QB, LEUNG PS	3.975
Estrogen controls embryonic stem cell proliferation via store-operated calcium entry and the nuclear factor of activated T-cells (NFAT) Estrogen controls embryonic stem cell proliferation via store-operated calcium entry and the nuclear factor of activate, *Journal of Cellular Physiology*, 2012 Jun;227(6):2519-30.	WONG CK, SO WY, LAW SK, LEUNG FP, YAU KL, YAO X, HUANG Y, LI X, TSANG SY	4.218
Ethnobotanical approach versus random approach in the search for new bioactive compounds: Support of a hypothesis, *Pharmaceutical Biology*, 2012 Jan;50(1):30-41.	GYLLENHAAL C, KADUSHIN M, SOUTHAVONG B, SYDARA K, BOUAMANIVONG S, XAIVEU M, XUAN L, HEIP N, LOC P, DAC L, BICH T, CUONG N, LY H, ZHANG H, FRANZBLAU S, XIE H, RILEY M, ELKINGTON B, NGUYEN H, WALLER D, MA C, TAMEZ P, TAN GT, PEZZUTO JM, SOEJARTO DD	1.206
Furanodienone induces cell cycle arrest and apoptosis b suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells, *Cancer Chemotherapy and Pharmacology*, 2011 Nov;68(5):1315-23.	LI Y, ZHU G, SHEN X, CHU J, YU Z, FONG WF	2.795
Gambogenic acid induces G1 arrest via GSK3 β-dependent Cyclin D1 degradation and triggers autophagy in lung cancer cells, *Cancer Letters*, 2012 Sep 28;322(2):185-94. Epub 2012 Mar 9. [Epub ahead of print]	YU X, HAN QB, WEN Z, MA L, GAO J, ZHOU G	4.258
Heavy metal and pesticide content in commonly prescribed individual raw Chinese Herbal Medicines, *Science of the Total Environment*, 2011 Sep 15;409(20):4297-305.	HARRIS E, CAO S, LITTLEFIELD B, CRAYCROFT J, SCHOLTEN R, KAPTCHUK T, FU Y, WANG W, LIU Y, CHEN H, ZHAO Z, CLARDY J, WOOLF A, EISENBERG D	3.258
Hippocampal metabolomics reveals 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity associated with ageing in Sprague-Dawley rats, *Talanta*, 2011 Aug 15;85(2):1007-12.	LIN S, YANG Z, ZHANG XJ, BIAN ZX, CAI ZW	3.498
Histochemical analysis of the root tuber of Polygonum multiflorum Thunb. (Fam. Polygonaceae), *Microscopy Research and Technique*, 2011 Jun;74(6):488-95.	LIANG Z, SHI Y, CHEN H, ZHAO Z	1.593
Identification and evaluation of apoptotic compounds from Garcinia oligantha, *Bioorganic & Medicinal Chemistry Letters*, 2012 Mar 15;22(6):2350-3.	GAO X, YU T, CUI J, PU J, DU X, HAN QB, HU Q, LIU T, LUO KQ, XU H	2.338
Identification of powdered Chinese herbal medicines by fluorescence microscope, Part 1: fluorescent characteristics of mechanical tissues, conducting tissues, and ergastic substances, *Microscopy Research and Technique*, 2011 Mar;74(3):269-80.	WANG Y, LIANG Z, LI Q, YANG H, CHEN H, ZHAO Z, LI P	1.593
Immunosuppressive decalin derivatives from Red Yeast Rice, *Journal of Natural Products*, 2012 Apr 27;75(4):567-71.	ZHU L, LU J, LI T, ZHU G, HAN QB, HSIAO W, LIU L, JIANG Z	3.285
Impacts on contents of juglonc in the stems of Juglans mandshurica Maxim. by different drying methods, *Chinese Journal of Hospital Pharmacy*, 2011;17:1461-1463.	WANG T, LIU L, DI X, XU L, KANG T, CHEN H	--
In Vitro Screening on Amyloid Precursor Protein Modulation of Plants used in Ayurvedic and Traditional Chinese Medicine for Memory Improvement, *J. Ethnopharmacol*, 2012 Jun 1;141(2):754-60.	LIU L, DURAIRAJAN S, LU J, KOO I, LI M	2.755
Inhibition of Janus kinase 2 by cylometalated rhodium complexes, *MedChemComm*, 2012 May;3(6):696.	LEUNG C, YANG H, MA V, CHAN D, ZHONG H, LAU W, LI Y, FONG WF, MA D	2.722
Inhibitory Effect of Astragalus Polysaccharides on Lipopolysaccharide-induced TNF-alpha and IL-1 beta production in THP-1 cells, *Molecules*, 2012 Mar 12;17(3):3155-64.	HE X, SHU J, XU L, LU C, LU A	2.428

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
Is Angelica sinensis a "wonderful herb" or "careful herb" for females?, *Hong Kong Chinese Medical Journal*, 2012;7(2):21-23.	DENG PX, XU M, XIAO TT, TIAN XY, XU W, WANG WQ	--
Isolation and Identification of Compounds Responsible for Antioxidant Capacity of Euryale ferox Seeds, *J. Agric. Food Chem.*, 2011 Feb 23;59(4):1199-204.	SONG C, WANG S, ZHOU L, HOU F, WANG K, HAN QB, LI N, CHENG Y	2.906
Isolation, structure characterization and immunomodulating activity of a hyperbranched polysaccharide from the fruiting bodies of Ganoderma sinense, *Journal of Agricultural & Food Chemistry*, 2012 May 2;60(17):4276-81.	HAN X, YU H, CHAN CL, DONG C, YANG Y, LUO K, KO C, CHEUNG DW, LEE K, YUE GG, CHEN D, WONG C, LAU CB, TU P, SHAW P, FUNG K, LEUNG P, HSIAO W, HAN QB	2.906
Isorhynchophylline, a Natural Alkaloid, Promotes the Degradation of Alpha-synuclein in Neuronal Cells via Inducing Autophagy, *Autophagy*, 2012 Jan;8(1):98-108.	LU J, TAN J, DURAIRAJAN S, LIU L, ZHANG Z, MA L, SHEN H, CHAN H, LI M	12.042
JCM-16021, a Chinese herbal formula, attenuated visceral hyperalgesia in TNBS-induced post-inflammatory irritable bowel syndrome rats through reducing colonic EC cell hyperplasia and serotonin availability, *Evid Based Complement Alternat Med*, 2012;2012:239638.	QIN HY, XIAO HT, LEUNG FP, YANG ZY, WU CY, SUNG JY, XU HX, TONG XD, BIAN ZX	1.722
Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, *World J Gastroenterol*, 2012 May 28;18(20):2481-92.	QIN HY, XIAO HT, WU CY, BERMAN BM, SUNG JY, BIAN ZX	2.547
Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery, *International Journal of Nanomedicine*, 2012;7:1139-1148.	CHEN XY, HUANG WH, WONG BC, YIN L, WONG YF, XU M, YANG ZJ	3.463
Literature Review and Data Analysis of Di-tan Decoction on Experimental and Clinical Study of Dementia, *Hong Kong Chin. Med. J. (Chin.)*, 2012;7(2):72-75.	CHUA K, LI M	--
Macroscopic identification of Chinese medicinal materials: Traditional experiences and modern understanding, *Journal of Ethnopharmacology*, 2011 Apr 12;134(3):556-64.	ZHAO Z, LIANG Z, GUO P	2.755
Maturation of murine bone marrow-derived dendritic cells induced by Radix Glycyrrhizae polysaccharide, *Molecules*, 2012 May 30;17(6):6557-68.	LI X, HE X, LIU B, XU L, LU C, ZHAO H, NIU X, CHEN S, LU A	2.428
Metabolite porfiling of plasma and urine from rats with TNBS-induced acute colitis using UPLC-ESI-QTOF-MS-based metabonomics, *FEBS J*, 2012 Jul;279(13):2322-38.	ZHANG XJ, CHOI FF, YAN Z, LEUNG FP, TAN S, LIN SH, XU HX, JIA W, SUNG JJ, CAI ZW, BIAN ZX	4.250
Metabonomic variations associated with AOM-induced precancerous colorectal lesions and resveratrol treatment, *J Proteome Res. 2012 Jun 1;11(6):3436-48*.	LAIO W, WEI H, WANG X, QIU Y, GUO X, ZHANG X, ZHOU M, WU J, KOU F, ZHANG Y, BIAN ZX, XIE G, JIA W	5.056
Mushroom and Health, *Curr. Top. Nutraceutical Res.*, 2012; 10:V-VI.	YU Z	0.262
NaHs relaxes rat cerebral artery in vitro via inhibition of L-type voltage-sensitive Ca2+ channel, *Pharmacological Research*, 2012 Feb;65(2):239-46.	TIAN XY, WONG WT, SAYED N, LUO JL, TSANG SY, BIAN ZX, LU Y, CHENG WS, YAO XQ, CHEN ZY, HUANG Y	4.346
Nerve growth factor-mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation-induced visceral hypersensitivity in rats, *European Journal of Pain*, 2012 Apr;16(4):463-72.	TSANG SW, ZHAO M, WU J, SUNG JJ, BIAN ZX	3.067
New bencaological studies of traditional Chinese medicine after name "Doukou", *China Journal of Chinese Materia Medica*, 2012;37(11):1686-1692◦	WU M, GUO P, CHEN H, ZHAO Z	--
New perspectives on complementary and alternative medicine: an overview and alternative therapy, *Altern Ther Health Med.*, 2012 Jul-Aug;18(4):20-36.	PAN S, GAO S, ZHOU S, TANG M, YU Z, KO K	1.088
Novel insights about the mechanism of visceral hypersensitivity in maternally separated rats, *Neurogastroent & Motil*, 2012 Jul;24(7):593-6.	BIAN ZX	2.935
Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats. *Antioxidants & Redox Signaling*, 2012 Feb 15;16(4):363-73.	TIAN XY, WONG WT, LEUNG FP, ZHANG Y, WANG YX, LEE HK, NG CF, CHEN ZY, YAO X, AU CL, LAU CW, VANHOUTTE PM, COOKE JP, HUANG Y	7.189

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
Proteome profiling of spinal cord and dorsal root ganglia in rats with trinitrobenzene sulfonic acid-induced colitis, *World J Gastroenterol*, 2012 Jun 21;18(23):2914-28.	ZHANG XJ, LEUNG FP, HSIAO WW, TAN S, LI S, XU HX, SUNG JJ, BIAN ZX	2.547
Quality evaluation of various commercial specifications of Polygoni Multiflori Radix and its dregs by determination of active compounds, *Chemistry Central Journal*, 2012 Jun 8;6(1):53.	LIANG ZT, LEUNG NN, CHEN HB, ZHAO ZZ	1.312
Raloxifene improves vascular reactivity in pressurized septal coronary arteries of ovariectomized hamsters fed cholesterol dietRaloxifene improves vascular reactivity in pressurized septal coronary arteries of ovariectomized hamsters fed cholesterol diet, *Pharmacological Research*, 2012 Feb;65(2):182-8.	CHAN YC, LEUNG FP, TIAN XY, YUNG LM, LAU CW, CHEN ZY, YAO X, LAHER I, HUANG Y	4.346
Rapid Analysis of Antioxidant Constituents from Taxillus delavayi, a Yi Ethnomedicinal Material, *Food Science*, 2012;33(1):16-19.	PIAO X, DENG Z, CHEN H, WANG J	--
Review of Astragali Radix, *Chinese Herbal Medicines*, 2011;3(2): 90-105.	LIU J, ZHAO Z, CHEN H	--
Role of Endoplasmie Reticulum Stress Proteins IRE-1, PERK and CHOP in Oridonin-treated HepG2 Cells, *Traditional Chinese Drug Research and Clinical Pharmacology*, 2012; 23:263-6.	WANG H, YE Y, YU Z	--
Selective G2/M arrest in a p53Val135-transformed cell line induced by lithium is mediated through an intricate network of MAPK and b-catenin signaling pathways, *Life Sciences*, 2012 Sep 24;91(9-10):312-21. Epub 2012 Aug 1. [Epub ahead of print]	TSUI MK, TAI CS, WONG WY, HSIAO WL	2.555
Separation, structure characterization, conformation and immunomodulating effect of a hyperbranched heteroglycan from Radix Astragali, *Carbohydrate Polymer*, 2012 January 4;87(1):667-75.	YIN J, CHAN BC, YU H, LAU IY, HAN X, CHENG S, WONG C, LAU CB, XIE M, FUNG K, LEUNG P, HAN QB	3.479
Sesquiterpenoid and Phenolic Glucoside Gallates from Lagerstroemia balansae, *Planta Medica*, 2011 Nov;77(17):1944-6.	ZHOU Y, CHEN HB, WANG B, LIANG H, ZHAO YY, ZHANG QY	2.348
Simple and convenient G-quadruplex-based turn-on fluorescence assay for 3' -> 5' exonuclease activity, *Analytical Chemistry*, 2011;83(2):463-6.	LEUNG C, CHAN D, MAN B, WANG C, LAM W, CHENG Y, FONG W, HSIAO WL, MA D	5.695
Simultaneous Determination of Eight Anthraquinones in Semen Cassiae by HPLC-DAD, *Phytochem Anal.*, 2011 Jan 15;83(2):463-6.	XU L, CHAN C, LAU C, YU Z, MOK D, CHEN S	2.480
Structural characterization and immuno-modulating activities of a polysaccharide from Ganoderma sinense, *Internat. J. Biol. Macromol*, 2012 Nov;51(4):597-603.	HAN X, CHAN BC, YU H, YANG Y, HU S, KO C, DONG C, WONG C, SHAW P, FUNG K, LEUNG P, HSIAO W, TU P, HAN QB	2.596
Studies on macroscopic and microscopic identification of Cordyceps sinensis and its counterfeits, *China Journal of Chinese Materia Medica*, 2011;36(9):1141-1144.	CHAN S, LIU B, ZHAO Z, LAM M, LAW K, CHEN H	--
Study of the relationship between genetics and geography in determining the quality of Astragali Radix, *Biological & Pharmaceutical Bulletin*, 2011;34(9):1404-1412.	LIU J, CHEN H, GUO B, ZHAO Z, LIANG Z, YI T	1.849
Study of the role of Hsp70.1 in oridonin-treated hepatocarcinoma cells, *Journal of Guangdong Pharmaceutical University*, 2011;27:243-6.	WANG H, YE Y, HUANG S, YU Z	--
Systematic Review on the Safety and Efficacy of Herbal Medicine for the Treatment of Vascular Dementia, *Evid Based Complement Alternat Med*, 2012;2012:426215.	MAN S, CHAN K, LU J, DURAIRAJAN S, LIU L, LI M	1.722
The abietane diterpenoids isolated from Isodon rubescens and evaluation of their anti-biofilm activity, *Organic & Biomolecular Chemistry*, 2012 Jul 14;10(26):5039-44.	ZOU J, PAN L, LI Q, YAO P, ZHU M, BANAS J, ZHANG H, SUN H	3.568
The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells, *J Gastroenterol*, 2013 Feb;48(2):182-92. Epub 2012 Jun 23. [Epub ahead of print]	KWAN H, YANG Z, FONG W, HU Y, YU Z, HSIAO W	3.788
The effects of Boehmeria nivea (L.) Gaud. on embryonic development: in vivo and in vitro studies, *Journal of Ethnopharmacology*, 2011 Mar 24;134(2):393-8.	TIAN X, XU M, DENG B, LEUNG K, CHENG K, ZHAO Z, ZHANG S, YANG Z, DENG P, XU D, XU X, KOO I, WONG M	2.755
The formation of daodi medicinal materials, *Journal of Ethnopharmacology*, 2012 Apr 10;140(3):476-81.	ZHAO Z, GUO P, BRAND E	2.755

HKBU SCM academic staff / student is first/co-first/corresponding/co-corresponding author of the publication.

* Only Chinese information is available.
\# SCI Paper, IF is not available yet.

Title / Brief Description	Author (s)	Impact Factor 2012 (IF)
The Important of Safety Issues in Traditional Chinese Medicine Marketing, *Progress in Nutrition*, 2012:13(3):175-183.	LEUNG KM, FONG WF	0.117
The quintessence of traditional Chinese medicine: Syndrome and its distribution among advanced cancer patients with constipation, *Evid Based Complement Alternat Med*, 2012;2012:739642.	CHENG CW, KWOK AO, BIAN ZX, TSE DM	1.722
The Rix1 (Ipi1p-2p-3p) complex is a critical determinant of DNA replication licensing independent of their roles in ribosome biogenesis, *Cell Cycle*, 2012 Apr 1;11(7):1325-39.	HUO L, WU R, YU Z, ZHAI Y, YANG X, CHAN T, YEUNG J, KAN J, LIANG C	5.321
Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies, *International Journal of Nanomedicine*, 2011;6:151-66.	NIE S, HSIAO WL, PAN W, YANG Z	3.463
Tissue-specific metabolite profiling of alkaloids in Sinomenii Caulis using laser microdissection and liquid chromatography-quadrupole/time of flight-mass spectrometry, *Journal of Chromatography A*, 2012 Jul 27;1248:93-103.	YI L, LIANG Z, PENG Y, YAO X, CHEN H, ZHAO Z	4.612
Traditional Chinese Medicine Syndrome Distribution in Chronic Hepatitis B Populations: A Systematic Review, *American Journal of Chinese Medicine*, 2011;39(6):1061-74.	ZENG XX, BIAN ZX, WU TX, FU SF, ZIEA E, WONG TAAM CW	2.281
Traditional Chinese Medicine Zheng in the Era of Evidence-based medicine: A Literature Anaylsis, *Evidence-based Complement Alternat Med*, 2012;2012:409568.	JIANG M, ZHANG C, ZHENG G, GUO H, LI L, YANG J, LU C, JIA W, LU A	1.722
Traditional medicine collection tracking system (TM-CTS): a database for ethnobotanically driven drug-discovery programs, *Journal of Ethnopharmacology*, 2011 May 17;135(2):590-3.	HARRIS E, ERICKSON S, TOLOPKO A, CAO S, CRAYCROFT J, SCHOLTEN R, FU Y, WANG W, LIU Y, ZHAO Z, CLARDY J, SHAMU C, EISENBERG D	2.755
*〈“雲療”初探〉，載《香港中醫雜誌》，2011; 6(4):60-61。	党毅，趙中振	--
*〈中醫綜合治療老年腰椎管狹窄之探討〉，載《香港中醫暨香港中醫學會成立二十二週年》。	涂豐	--
*〈日本藥都 —— 富山之旅〉，載《香港中醫雜誌》，2012;7(1):103-105。	趙中振	--
*〈再盼老樹發新葩 —— 葡國傳統醫藥記行〉，載《香港中醫雜誌》，2011;6(4):79-82。	趙中振	--
*〈印尼傳統醫藥初探〉，載《香港中醫雜誌》，2011;6(3):78-80。	趙中振	--
*〈香港花文化與“花療”〉，《中醫藥文化》，2011;6:28-30。	党毅，陳虎彪	--
*〈腰痛的分類及診斷思路〉，載《香港中醫骨傷》。	涂豐	--
English / Chinese Books		
Ethnobotany of Natural Products, in Natural Products, edited by Pezzuto, John and Kato, Massuo Jorge, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, Published online.	SOEJARTO D, GYLLENHAAL C, RILEY M, ZHANG H	--
Medicinal Plants of China', Genetic Resources, Chromosome Engineering, and Crop Improvement: Medicinal Plants, vol. 6, CRC Press, Boca Raton, FL, P123-162.	ZHAO Z, LIANG Z, GUO P, CHEN H	--
Plant Terpenes, in Natural Products, edited by Pezzuto, John and Kato, Massuo Jorge, in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, Online publication.	ZHANG H, QIU M, CHEN Y, CHEN J, WANG C, FONG H	--
《百藥西來》，萬里機構。	趙中振，郭平，洪雪榕	--
《百藥炮製（簡體版）》，人民衛生出版社。	趙中振	--
《茶療》，萬里機構。	党毅，陳虎彪	--
《細說花旗參》，萬里機構・萬里書店。	梁啟文，莊瑞寧	--
《細說培植蟲草》，萬里機構・得利書局。	梁啟文，梁惠梅	--
《葉天士用經方》，人民衛生出版社。	張文選	--

School of Chinese Medicine

Jockey Club School of Chinese Medicine Building,
7 Baptist University Road, Kowloon Tong, Hong Kong.

Tel (852) 3411 5387
Fax (852) 3411 2902
Email scm@hkbu.edu.hk
Website http://scm.hkbu.edu.hk